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Abstract (word count: 191/450) 
 
Background: In many randomized controlled trials, patients and doctors are more interested in the per-
protocol effect than in the intention-to-treat effect. However, valid estimation of per-protocol effect 
generally requires adjustment for prognostic factors associated with adherence. These adherence 
adjustments have been strongly questioned in the clinical trials community, especially after 1980 when 
the Coronary Drug Project (CDP) team found that adherers to placebo had lower 5-year mortality than 
non-adherers to placebo.  
Methods: We replicated the original CDP findings from 1980 and re-analyzed the CDP data using 
technical and conceptual developments that have become established since 1980. Specifically, we used 
logistic models for binary outcomes, decoupled the definition of adherence from loss to follow-up, 
adjusted for pre-randomization covariates via standardization and for post-randomization covariates via 
inverse probability weighting. 
Results: The original CDP analysis reported a difference in 5-year mortality between adherers and non-
adherers in the placebo arm of 9.4 percentage points. By using modern approaches, we found that this 
this difference was reduced to 2.5 (95% CI -2.1, 7.0). 
Conclusions: Valid estimation of per-protocol effects may be possible in randomized clinical trials when 
analysts use appropriate methods to adjust for post-randomization variables.  
 
Keywords  
Per-protocol effect, intention-to-treat effect, inverse probability weighting, Coronary Drug Project, 
adherence 
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 Clinical decision making relies heavily on the findings of randomized clinical trials. Because substantial 
societal resources are allocated to the conduct of these studies, it is surprising that randomized trial 
findings are often summarized by a single measure that provides incomplete clinical information: the 
intention-to-treat effect. In an intention-to-treat analysis individuals are assigned to the treatment arm 
they were randomized to, regardless of whether they actually took the treatment as intended in the 
study’s protocol. In placebo-controlled trials, patients assigned to treatment may stop taking it and 
those assigned to placebo may start taking treatment. As a result, the intention-to-treat effect will be 
closer to the null than the effect that would have been found if all patients had taken their assigned 
study treatment exactly as specified by the study protocol, i.e., the per-protocol effect, which is the 
effect under full adherence to the protocol.  
 
The intention-to-treat effect has well known advantages.
1
 However, patients and their doctors may be 
more interested in the per-protocol effect than in the intention-to-treat effect when making treatment 
decisions.
2
 In trials that try to detect harm, a closer-to-the-null-by-design intention-to-treat effect is 
misleading and generally discouraged. In the increasingly frequent pragmatic trials, the benefits of 
randomization may be overwhelmed by serious deviations from protocol, including lack of adherence to 
the assigned interventions and loss to follow-up. Therefore, in many randomized trials, intention-to-
treat analyses need to be complemented with properly conducted per-protocol analyses that adjust for 
incomplete adherence.
3
  
However, there is no universally accepted method to estimate per-protocol effects. The naïve approach 
commonly referred to as “per-protocol analysis” (that is, comparing only individuals who adhere to their 
assigned treatment while they adhere to it) is hardly a contender for a valid estimation of the per-
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protocol effect because this approach would only be valid if non-adherence occurred essentially at 
random.
2
 Adjustment for pre-randomization variables will generally help reduce bias in naïve per-
protocol analyses, but such adjustment is not common in practice. In fact, most clinical trial protocols 
devote little, if any, attention to the estimation of the per-protocol effect.  
Some of this lack of interest can be traced back to an influential article published in 1980 the New 
England Journal of Medicine 
4
 This article had a chilling effect on subsequent attempts to conduct per-
protocol analyses: investigators from the Coronary Drug Project (CDP) demonstrated that, among 
individuals assigned to placebo, the 5-year mortality risk was higher among those who did not adhere 
than among those who did adhere to the placebo pills. This finding is taught in courses around the world 
and often quoted as a reminder of the dangers of analyses that deviate from the intention-to-treat 
principle.  
Because placebo cannot affect mortality, the difference between compliers and noncompliers in the 
CDP clearly indicates that adherence is a marker of good prognosis and that a comparison of adherers 
and non-adherers is inherently biased. That statistical adjustment, using the best methods available at 
that time, could not eliminate the bias was interpreted as an indication that analyses to estimate the 
per-protocol effect were to be distrusted, if not outright discouraged. 
In the thirty-five years since the publication of the CDP paper, new statistical methods have been 
developed to adjust for protocol deviations.
5, 6
 These methods can validly incorporate pre- and post-
randomization variables; therefore they will generally result in less biased per-protocol effect estimates 
than those obtained from naïve per-protocol analyses. Randomized trials that, like the CDP, compare 
sustained interventions over long periods are the best candidates to benefit from these new methods, 
which estimate more robust per-protocol effect estimates, to complement the usual intention-to-treat 
analyses.  
Page 4 of 110
Here we (i) revisit the CDP findings in light of technical and conceptual developments that have become 
established since 1980, and (ii) review the options available for the estimation of per-protocol effects 
today. We start by summarizing the CDP and its findings.   
 
A brief summary of the CDP 
Design and conduct of the CDP 
The CDP was a 6-arm double-blind placebo-controlled randomized clinical trial designed to identify 
treatments that would reduce premature mortality in men with a history of myocardial infarction (MI).
7, 
8
 The study was funded by the National Heart, Lung, and Blood Institute of the U.S. National Institutes of 
Health. Enrollment occurred between March 1966 and October 1969, and follow-up continued until late 
1974 to early 1975. The trial compared five active treatments to placebo: clofibrate (ethyl 
chlorophenoxyisobutyrate, 1.8mg/day), low-dose equine estrogen (2.5mg/day), high-dose equine 
estrogen (5.0mg/day), dextrothyroxine (6mg/day), and nicotinic acid (3mg/day). Increased risk of 
adverse events was observed in the high- and low-dose estrogen arms and the dextrothyroxine arm; 
these arms were discontinued in 1970, 1973, and 1971, respectively.
9
 
Men were eligible to participate if they were between 30-64 years of age at the time of randomization, 
had an ECG with documented MI at least 3 months before entry, a New York Heart Association 
functional class I (no limitation of physical activity) or II (slight limitation), no previous surgery for 
coronary artery disease, no other life-limiting diseases or conditions that could affect long-term follow-
up, no contraindication for the study drugs, willingness to participate and to adhere to study drugs as 
assessed by a two-month control period, and no anti-coagulant therapy, lipid influencing drugs, or 
insulin use at baseline. Men were excluded if evidence suggested MI due to coronary artery embolism, 
aortic dissection, or prolonged arrhythmia.  
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Randomization was within each of 53 study centers and by risk group, with low risk defined as having 
had only one previous MI and no associated complications, and high risk as having had more than one 
MI or one MI with complications. Figure 1 displays an overview of the study timeline. Three initial 
monthly visits were conducted to determine eligibility and to estimate adherence to placebo; 
randomization occurred at the third visit, and dosage was adjusted at two additional monthly visits. 
Patients were prescribed three pills daily at randomization and dosage was increased by up to 3 pills per 
visit, on the basis of drug tolerance, to a final dose of nine daily pills by the fifth visit. Follow-up visits 
were planned to occur every four months until study completion, dropout, or death.
7
 Up to three close-
out visits were planned after study completion to assess any impact of drug withdrawal. Three of the 
study arms (both estrogen arms and the dextrothyroxine arm) were discontinued during follow-up 
because of adverse events.
10-12
 
 
Clofibrate versus placebo: Published results in 1980 
1103 patients were randomized to the clofibrate arm and 2789 to the placebo arm.
9
 Minimum follow-up 
duration for surviving participants was 54 months; 96% were followed for at least 5 years and 63% for at 
least 6 years.  As of August 31, 1974, 7.4% of survivors in the clofibrate arm and 8.0% of those in the 
placebo arm had stopped attending study visits and were classified as lost to follow-up. At 56-60 
months, 5.5% of the clofibrate arm and 4.2% of the placebo arm were receiving less than 20% of the 
prescribed dose (p-value= 0.28), and 11.5% of the clofibrate arm and 9.4% of the placebo arm were 
receiving less than 80% of the prescribed dose (p-value =0.20). Mean adherence to the maximum study 
dose was 77.1% in the clofibrate arm and 77.8% in the placebo arm; median adherence was 86.1% for 
clofibrate and 87.1% for placebo.
9
 The percentage of patients with adherence of less than 80% by the 
end of follow-up was 5.5% for the clofibrate arm and 9.4% in the placebo arm.
9
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The 5-year all-cause mortality was 20.0% for the clofibrate arm and 20.9% in the placebo arm (p-value = 
0.55). The five-year incidence for the secondary combined outcome of death due to coronary heart 
disease or occurrence of definite non-fatal MI was 23.8% for clofibrate and 26.2% for placebo (p-value = 
0.13). Adjustment for baseline characteristics did not materially alter the study results.
9
 The CDP 
Research Group concluded that there was no evidence that clofibrate reduced 5-year mortality.
9
  
 
How the Coronary Drug Project convinced us that adjustment for non-adherence is futile  
In 1980 the CDP investigators also compared the 5-year mortality risk between adherers and non-
adherers within each arm. To calculate adherence, the clinic staff computed the percentage of capsules 
prescribed that were actually taken by the patient during the previous four months. This assessment 
was made by questioning the patient and/or counting the capsules returned at each visit. Adherence 
was categorized into one of five levels: 80-100%, 60-79%, 40-59%, 20-39%, and less than 20% adherence 
to prescribed dosage. Adherence was standardized by prescribed dosage, and the cumulative adherence 
was computed from this value until death or the end of year 5. Finally, cumulative adherence was 
dichotomized at less than 80% versus greater than or equal to 80% over the follow-up.
4
 
In the placebo arm, 882 participants had a cumulative adherence of less than 80% (noncompliers) and 
1813 participants had a cumulative adherence of greater than or equal to 80% (compliers) until death or 
end of follow-up. Among noncompliers, 28% died within the first 5 years of follow-up, compared with 
only 15% of compliers; a difference of over 13%. After adjustment for 40 baseline characteristics, the 
difference in 5-year mortality risk was still about 10%. The authors concluded that compliers and non-
compliers must be different in ways not accounted for by the available data because a greater 
adherence to placebo is not expected to have a causal effect on the mortality risk. This inability to adjust 
for adherence in the placebo arm strongly suggests that any attempt at an adherence-adjusted analysis 
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of the entire trial data would be futile. By extension, if adherence adjustment cannot be done in the 
CDP, a large trial with extensive and detailed data collection at baseline and over time, why should we 
expect to do so in any other randomized trial?  
 
An early 21
st
 century update of the CDP placebo comparisons 
The approaches to data analysis that were standard in 1980 would not necessarily be the primary choice 
today. A modern comparison of compliers and noncompliers in the placebo arm of the CDP would differ 
from the 1980 analysis.  
We conducted a re-analysis of the placebo arm of the CDP to estimate the difference in 5-year mortality 
risk under adherence levels of <80% versus ≥80%. Because placebo should have no effect on the 5-year 
mortality risk, a non-null estimate would suggest that compliers and non-compliers are irreconcilably 
different. On the other hand, a null estimate would increase confidence in our ability to sufficiently 
adjust for the differences between compliers and noncompliers when estimating the per-protocol 
effect. 
Our re-analysis differs from the original 1980 analysis in three aspects: definition of adherence during 
missed visits, adjustment for baseline predictors of adherence, and adjustment for post-randomization 
predictors of adherence. We proposed four updates to the 1980 analysis.  
 
1. Definition of adherence 
When a participant missed a study visit, his adherence to the placebo pills was unknown and therefore 
needed to be imputed. The 1980 analysis set adherence to 0% at missed visits, even though individuals 
may have partly adhered to placebo during the period preceding the missed visit. Because individuals 
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were more likely to miss visits when they were about to die (mortality hazard ratio for those who did 
versus did not miss the previous visit was 1.8, 95% CI: 1.3 to 2.6), setting adherence to 0% may 
artificially increase the proportion of noncompliers among patients at high risk of death.  
We updated the analysis by decoupling the classification of an individual as a noncomplier from his risk 
of death in the near future. To do so, we used past adherence history as an indicator of expected 
adherence by setting adherence at missed visits equal to adherence at the most recently attended visit, 
which may better reflect an individual’s expected adherence. We censor individuals who miss more than 
three consecutive adherence measurements. See the Appendix for details.  
2. Adjustment for pre-randomization risk factors 
To adjust for baseline factors, the 1980 analysis used linear regression to model the 5-year mortality risk 
as a function of the baseline covariates, which were then evaluated at their average values in the study 
population. That was a typical choice. We updated the analysis to a logistic regression model followed 
by standardization by the baseline covariates.  
3. Adjustment for post-randomization risk factors 
Because adherence varies over time, an analysis adjusted for only baseline variables may miss important 
prognostic factors that impacted adherence during the follow-up but that were not present at the time 
of randomization. The use of this post-baseline information will generally improve adherence-adjusted 
analyses. Indeed not adjusting for post-randomization variables makes the extreme assumption that, 
conditional on the baseline variables, adherence after randomization is independent of all measured 
and unmeasured post-randomization variables. The 1980 analysis, however, could not adjust for any 
post-baseline, time-varying covariates because no methods had yet been developed for this purpose at 
the time. As a result, the CDP investigators could not take advantage of much of the data so carefully 
collected over the course of the study.  
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We updated the analysis by using inverse probability weighting
6
 to adjust for post-randomization risk 
factors. Because the weight assigned to an individual at time t is a function of the individual’s risk factor 
and adherence history through t, the analysis naturally adjusts for post-randomization variables that are 
joint determinants of adherence and the outcome. This analysis makes the less extreme assumption that 
adherence post-randomization is independent of the unmeasured but not the measured post-
randomization variables. If all such variables were correctly measured and modeled,
6, 13
 the inverse 
probability weighted analysis would allow us to validly estimate the 5-year mortality that would have 
been observed in this trial if everyone in the placebo arm had adhered at least 80% to placebo 
compared with if no one in the placebo arm had adhered at least 80%. See the Appendix for more 
details.  
4. Sensitivity analyses 
We performed a variety of sensitivity analyses for dealing with missing adherence, including setting 
adherence to the cumulative average adherence up to each missed visit, setting adherence to 0% or 80% 
for up to 2 missed visits and then censoring, and setting adherence to half of the most recent available 
adherence value, with and without censoring. We also varied the definition of adherence by including or 
ignoring information about prescribed dosage, and changing the cut-point for dichotomous adherence 
to 70% and 90%. Finally, we included weights for censoring due to dropout, and permuted the 
covariates to assess the potential for over-fitting. Full results of the sensitivity analyses are provided in 
the Appendix. 
Revisiting the CDP placebo comparisons 
The CDP data tapes in the NIH data repository were corrupted in the 1990s and the data were 
irretrievable. Fortunately, Dr. Paul Canner, principal statistician of the CDP, had preserved a version of 
the de-identified data sets, which we used for our analyses. In collaboration with Dr. Canner, we will 
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make the datasets user friendly. We will then submit the data sets and their documentation to the NIH 
data repository. 
Replication of the 1980 CDP findings 
As a check of the integrity of the data, we first replicated the main tables and results of the 1980 CDP 
article.
4
 To do so, we mimicked the methods described in the article as closely as possible (see Appendix 
for a detailed description).  
Of 2630 individuals with non-missing values of the baseline covariates, 68.8% had a cumulative average 
adherence to placebo of at least 80%.  We found a difference in 5-year mortality risk of 14.3 percentage 
points in the unadjusted analysis and of 10.9 after adjustment for baseline covariates. These estimates 
are within 1.5 percentage points of the estimates reported in the original 1980 analysis (unadjusted 
difference = 13.1%; adjusted difference = 9.4%). These small discrepancies are explained by the need to 
recalculate percent adherence and cumulative average adherence because of corruption in the original 
variables, and to correct some errors in coding for adherence at baseline and time of death.  A similar 
analysis conducted in the clofibrate arm also showed a slight increase in 5-year mortality in the non-
adherers compared to the original 1980 estimates (Table 1).  
 
A 2015 re-analysis of the CDP 
As described above, our updated analysis differs from the original CDP analysis in three aspects: (1) 
handling of adherence at missed visits, (2) type of regression model for adjustment using baseline 
predictors, and (3) adjustment for post-randomization predictors of adherence using inverse probability 
weighting. Changing the handling of adherence at missed visits reduced our sample size by 217 
individuals. These individuals missed more than three consecutive visits and were censored. 
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Adherence of less than 80% was associated with low prior adherence; acute coronary insufficiency, 
intermittent cerebral ischemic attack, congestive heart failure, and angina; recent use of diuretics and 
anti-arrhythmic agents; and smoking (Appendix Table 2).  The adherence weights, truncated at their 99
th
 
percentile to prevent undue influence of outliers, had a mean of 1.01 (SD = 0.51) and a range of 0.02 to 
3.94.  
Table 2 shows the estimated difference in 5-year mortality risk between noncompliers and compliers in 
the placebo arm of the CDP, both in our replication of the 1980 analysis and in our updated analysis. The 
unadjusted difference in 5-year mortality risk (95% CI) was 11.0 percentage points (6.5, 15.6). The 
difference in 5-year mortality risk was 7.0 percentage points (2.7, 11.2) after adjustment for baseline 
covariates.  Our handling of adherence and the use of logistic regression resulted in a 2.4 percentage 
point reduction compared with the CDP analysis that set missing adherence to 0 and used linear 
regression. The difference in 5-year mortality risk was 2.5 percentage points (-2.1, 7.0) after further 
adjustment for post-randomization covariates.   
That is, after adjustment, there was little survival difference between compliers and noncompliers in the 
placebo arm. This finding was robust to many possible variations of the analysis, which we explored in 
multiple sensitivity analyses (see Appendix). 
 
Where does this leave us when estimating per-protocol effects? 
The above shows that an analysis of the CDP that tries to adjust for adherence is not necessarily 
doomed. Our finding weakens the arguments against adherence-adjusted analyses of randomized trials 
for estimating the per-protocol effect.  The question remains of how to better estimate such effect. 
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The two broad approaches to the estimation of per-protocol effects---instrumental variable estimation 
and direct adjustment for measured covariates--- each have shortcomings. Adjustment for 
noncompliance via instrumental variable estimation
14
 is desirable because it removes the need to collect 
data on prognostic factors that predict compliance. For example, Holme et al.
15
 recently used 
instrumental variable estimation to estimate the per-protocol effect of once-only sigmoidoscopy on 
colon cancer and overall mortality rate in a large randomized trial conducted in Norway. However, 
instrumental variable estimation requires extreme assumptions in trials with interventions that, unlike a 
baseline sigmoidoscopy, need to be sustained during the follow-up. The use of instrumental variable 
estimations is even more questionable if the interventions are unmasked and potentially available to 
individuals in all arms (not a concern for the CDP). 
Direct adjustment for measured covariates is another approach for per-protocol analyses of randomized 
trials of sustained interventions. Typically, these analyses require adjustment for pre- and post-
randomization prognostic factors that predict adherence. Appropriate adjustment for post-
randomization factors requires methods specifically designed for that purpose. These methods, 
collectively referred as g-methods and developed by Robins and collaborators,
13, 16
 include inverse 
probability weighting, which we used in our updated analysis of the CDP. 
The key limitation of direct adjustment is the possibility of residual bias if the set of adjustment variables 
fails to include important joint predictors of adherence to the protocol and the outcome of interest. 
(Note that when the analysis fails to adjust for important joint predictors of both loss to follow-up and of 
the outcome of interest, then intention-to-treat effect estimates may also be biased because of 
informative censoring).
17
 In fact, there are examples, other than the CDP, in which adherers and non-
adherers are so different with respect to their risk of developing the outcome that the available data are 
insufficient for direct statistical adjustment. For example, Holme et al. demonstrated that the mortality 
rate was greater in participants who refused to undergo a sigmoidoscopy compared with those who did 
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undergo sigmoidoscopy, even after adjustment for multiple factors.
15
 However, the adjustment 
variables did not include cigarette smoking and other important prognostic factors, which, had they 
been available for inclusion might have explained the some of the observed difference in mortality rate. 
Many randomized trials collect only limited data after randomization, which prevents valid estimation of 
per-protocol effects when instrumental variable estimation is not possible.  Even in randomized trials 
that collect abundant baseline and post-randomization data, adjusted per-protocol effect estimates are 
not routinely presented along with intention-to-treat effect estimates. Appropriately adjusted per-
protocol effect estimates can provide better estimates of both the efficacy of a treatment and the harms 
associated with the treatment in randomized trials. The omission of appropriately adjusted per-protocol 
effect estimates is especially problematic in randomized trials that assess potential harm and in those in 
which little effort is made to encourage adherence to the protocol, such as pragmatic and large simple 
trials.
18
 The lack of established methodologic standards for adjusted per-protocol estimates contributes 
to the problem because it creates uncertainty among investigators and sponsors who need to justify 
their analytic choices to journal editors and regulators.
19
 
 
Conclusions 
Widely held beliefs about the impossibility of conducting adherence-adjusted analyses may be partly 
based on weak empirical evidence and out-of-date methodology. Per-protocol effects can be validly 
estimated in clinical trials when sufficient data are available and appropriate adjustment methods are 
used. Supplementing intention-to-treat analyses with per-protocol effect estimates can allow richer, 
more nuanced inference from clinical trials.  Clinical research would benefit from a concerted effort to 
establish clear guidelines for the definition and estimation of per-protocol effects.  
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Figure 1: Study timeline, Coronary Drug Project. Timing of study visits and variable measurement. Lt is 
the vector of post-randomization covariates measured at visit t and At is an indicator for adherence level 
for the period from t to just before t+1 measured at visit t+1. A0 is measured at follow-up visit 1 (FV1) or, 
for individuals who died or dropped out before FV1, at IV4 and IV5. 
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Table 1: Replication of the original results reported in reference 4, Coronary Drug Project 
 5-year mortality, % (95% CI) 
 Unadjusted Adjusted (linear regression with 
standardization to baseline 
covariates) 
 Cumulative 
Adherence < 80% 
Cumulative 
Adherence ≥80% 
Cumulative 
Adherence < 
80% 
Cumulative 
Adherence ≥80% 
Original 1980 
analysis, Placebo 
arm
4
 
28.2 (25.3, 31.1) 15.1 (13.5, 16.7) 25.8 (22.9, 28.7) 16.4 (14.8, 18.0) 
Replication of 
original 1980 
analysis, Placebo arm 
29.7 (26.6, 33.0) 15.5 (13.8, 17.2) 27.4 (24.5, 30.3) 16.5 (14.8, 18.2) 
Original 1980 
analysis, clofibrate 
arm
4
 
24.6 (20.1, 29.1) 15.0 (12.5, 17.5) 22.5 (18.0, 27.0) 15.7 (13.2, 18.2) 
Replication of 
original 1980 
analysis, clofibrate 
arm 
26.1 (21.5, 31.2) 15.3 (12.7, 18.2) 23.8 (19.7, 27.8) 16.4 (13.7, 19.2) 
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 Table 2. Comparison of original and updated estimates for the placebo arm, Coronary Drug Project 
 5-year mortality risk difference, % 
(95% CI) 
 Unadjusted 
 
Adjusted for 
baseline 
variables* via 
linear regression 
Adjusted for 
baseline 
variables* via 
logistic 
regression+ 
Further 
adjusted for 
post-
randomization 
variables** 
Replication of the original 
1980 analysis 
(N = 2630) 
 
14.3 (10.8, 17.8) 10.9 (7.5, 14.4) 10.6 (7.3, 14.0) N/A 
Updated 2015 analysis 
(N = 2401) 
11.0 (6.5, 15.6) 7.4 (3.0, 11.8) 7.0 (2.7, 11.2) 2.5 (-2.1, 7.0) 
*Adjusted for 39 baseline variables: age; race; risk group; number of prior myocardial infarctions; 
relative body weight; medical history; prescriptions of non-study medications; lab findings; blood 
pressure; cardiomegaly; ECG findings; cigarette smoking; and physical activity level (See Appendix Table 
1 for details). 
**Adjusted for the 39 baseline variables (age, race, risk group, prior MIs, and relative body weight were 
baseline only) and 34 post-randomization variables: medical history; prescriptions of non-study 
medications; lab findings; blood pressure; cardiomegaly; ECG findings; cigarette smoking; and physical 
activity level (See Appendix Table 1 for details). Comparing individuals with <80% versus ≥80% at each 
visit. 
+The original 1980 analysis did not include logistic regression; we include it here for comparison 
purposes 
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Appendix 
1. Compliers vs noncompliers in the placebo arm: Replication of the 1980 CDP results  
Individuals were followed from randomization until the end of follow-up, which was defined as the 
earliest of 60 months, end of study (August 31, 1974), or death. Individuals who stopped attending study 
visits were coded as dropouts but not censored; vital status on August 31, 1975 was known for all but 1 
dropout in the placebo arm and everyone in the clofibrate arm [1]. Of the 1103 individuals in the 
clofibrate arm, 311 died and 228 dropped out. Of the 2787 individuals in the placebo arm, 780 died and 
546 dropped out. Excluding 128 patients who started follow-up after August 31, 1969 and therefore 
were not followed for the full 5 years did not materially change the estimates below.  
Adherence 
CDP participants were assessed for adherence to placebo at dosage adjustment visits at month 1 and 2 
after randomization. Baseline adherence measure is taken as the average of percent adherence to 
placebo at these visits (IV4 and IV5). Adherence at each follow-up visit (IADH1-26) was classified as at 
least 80%, 60-79%, 40-59%, 20-39%, or less than 20% of the study dose over the previous 4-month 
period. Visits with missing adherence or prescription information because of missed visits, incomplete 
forms, or drop-out, and with no capsules prescribed, were assigned adherence equal to zero. Adherence 
was dose-adjusted by the percent of study dose prescribed during the previous 4-month period. 
Cumulative average adherence was then computed from percent adherence to prescription over the 
entire follow-up. Further details on the adherence measures can be found in the CDP documentation. 
 Covariates 
We used the 40 covariates included in the 1980 paper [2] (Table A1), except “time since most recent 
MI”, which was missing for nearly half the sample (1123/2787 placebo arm participants, 421/1103 
clofibrate arm participants) and had values less than 999 days for all others because of an error with 
missing indicator levels at some point in the past.  
The baseline covariates used in the 1980 analysis were selected from the full set of approximately 135 
baseline characteristics recorded at study entry by the CDP study team on the basis of their status as 
known or suspected risk factors for first MI [2, 3]. More information about these covariates and the 
selection process, as well as their relationships with recurrent MI among the CDP participants, was 
reported by the study team in 1974 [3]. 
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Of the 39 covariates, 5 were recorded at baseline only and 34 were measured at baseline and during 
follow-up. Of the 34, 20 were recorded at every follow-up visit, while 14 were only recorded at annual-
type visits which occurred at FV3, 6, 9, 12, and 15. Many additional variables were available in the CDP 
data both at baseline and during follow-up. We limited our analyses to the variables used in the original 
1980 paper for the sake of comparability between our and previous results. 
The 1980 paper did not specify whether the baseline covariates were dichotomized as in the main 
clofibrate analysis [1] or unchanged from the original coding as in interim analyses, in which the 40 
covariates were selected [3]. However, Dr. Canner recalls that the 1980 paper dichotomized all 
covariates so we did the same. 
Statistical Analysis 
To adjust for baseline variables, we fit the linear regression model E[Y|cumA] = β0 + β1cumA + β2V where 
Y is an indicator for death by the end of follow-up (1: yes, 0: no), cumA is an indicator for at least 80% 
cumulative average adherence to placebo by the end of follow-up (1: yes, 0: no), and V is a vector 
including the 39 dichotomized baseline covariates to the model. The predicted values of this model for 
cumA=1 and cumA=0, standardized for the baseline covariates in V, were our estimates of the 5-year 
mortality risks. We used standardization rather than conditioning on a particular combination of values 
of the covariates because the estimates were sensitive to the choice of values and it is not clear what 
values the 1980 paper used. The 95% confidence intervals were obtained via nonparametric bootstrap 
with 500 samples.  
 
2. Compliers vs noncompliers in the placebo arm: Re-Analysis of CDP 
Handling of adherence at missed visits  
Instead of setting adherence level to 0 at some visits like the 1980 analysis did, we carried forward 
adherence from the most recent attended visit for up to two consecutive missed visits. Individuals who 
missed three or more consecutive visits were censored at the third consecutive missed visit (Figure A1). 
Under this scheme, 217 individuals were censored from all analyses because of missing adherence data, 
and 3 additional individuals were censored from the post-randomization adjusted analysis because of 
missing covariate information (Table A3).  
Type of regression model for adjustment using baseline predictors  
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Instead of using linear regression for the outcome model adjusted for baseline variables, we used 
logistic regression because the outcome (death within 5 years) is binary. The model was 
logit(Pr[Y=1|cumA, V, C15=0]) = β0 + β1cumA + β2V, where Y, cumA, and V are defined as above, and C15 is 
an indicator of censoring (1: yes, 0: no) by the end of follow-up at visit 15. The predicted values of this 
model for cumA=1 and cumA=0, standardized the estimates over the baseline covariates V, were our 
estimates of the 5-year mortality risks. Nonstandardized estimates when covariates were set to their 
median value were similar (risk difference: 4.1, 95% CI: 1.1, 7.2). 
Adjustment for post-randomization predictors of adherence 
To adjust for post-randomization predictors of adherence we used inverse probability (IP) weighting [4] 
for adherence at time t and applied the weights to the same outcome model used for baseline covariate 
adjustment: logit(Pr[Y=1|cumA, V, C15=0]) = β0 + β1cumA + β2V. 
The weights were estimated as follows. Let t be an index for visit number, where t=0 is the baseline visit. 
Each uncensored subject contributing to the outcome model received a stabilized IP weight SW 
=  , where Mt is an indicator for 
measurement of adherence at visit t (1 if measured, 0 otherwise),  is the adherence level between 
visits t and t+1 (0: ≥80%, 1: <80%), is adherence history through t, V is a vector of baseline 
covariates,  is covariate history through t, and Ct =0 is an indicator for remaining in the study at visit t.  
To estimate the denominator of the weights, we fit models in two stages. First, we fit the logistic model 
logit(Pr[Mt=1| ]) = β0t + β1  + β2V + β3  + β4  to all person-visits. Second, 
we fit the logistic model logit(Pr[At=0| ,Mt=1]) = β0t +  β1  + β2V + β3  + β4   to 
all person-visits with measured adherence. Visits when adherence was not directly measured (Mt=0), 
but carried forward from the previous visit, the factor in the denominator of the adherence weight was 
1 for that visit.  
Similar models that did not include the time-varying covariates were fit to estimate the numerators of 
the weights. The final weight for each individual was the product of the measurement and adherence 
weights for that individual at each time point until censoring. As in previous studies[5, 6]we truncated 
the estimated IP weights at the 99
th
 percentile to avoid undue influence of outliers. In our application, 
truncation of the weights did not materially change the estimates.  For all analyses, 95% confidence 
intervals were obtained via nonparametric bootstrap with 500 samples. 
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 Adjustment for censoring due to dropout 
In a sensitivity analysis to adjust for potential bias from censoring due to dropout, we estimated 
stabilized IP censoring weights SW
C
 
=  by fitting the logistic 
regression model logit(Pr[Ct=0| ]) = β0t + β1  + β2V + β3  + β4  to visits 
when adherence had been missing for the previous two visits; at all other times the conditional 
probability of remaining in the study is 1 for all previously uncensored individuals.  
Similar models that did not include the time-varying covariates were fit to estimate the numerators of 
the stabilized censoring weights. The final weights for the censoring-adjusted models were the product 
of the censoring weights and the previously described adherence weights over all time points. To avoid 
undue influence of outliers, we again truncated the final weights at the 99
th
 percentile.  
Adding the inverse probability of censoring weights did not materially change the estimates; the 
estimated post-randomization-adjusted difference in 5-year mortality was 2.5% (-3.3, 8.8) after 
adjustment for censoring. The estimated censoring weights had a mean of 0.99 (SD = 0.06) and a range 
of 0.16 to 1.00. The combined adherence and censoring weights had a mean of 1.00 (SD = 0.50) and a 
range of 0.02 to 3.94. 
 
Sensitivity Analyses 
In our main analysis, we carried adherence forward from the previous visit for up to two consecutive 
missed visits and then censored individuals on their third consecutive missed visit. We also assessed 
other methods of dealing with missing adherence, which we present here and in Table A4. For all 
sensitivity analyses, 95% confidence intervals were obtained via bootstrap with 500 samples.  
We ran 6 sensitivity analyses for dealing with missing adherence, all but one of which resulted in a null 
effect of adherence in the post-randomization adjusted analyses. When adherence was carried forward 
for two missed visits and set to 0 only from the third missed visit, instead of censoring the individual, the 
estimated difference in mortality at 5-years was 0.2% (-3.7, 4.1) after adjustment for post-randomization 
variables. When adherence was carried forward for two missed visits and set to 80% from the third 
missed visit, the estimated post-randomization-adjusted difference was 0.9% (-3.2, 4.9). When 
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adherence was set to the cumulative average adherence reported prior to any missed visit, with no 
censoring, the estimated post-randomization-adjusted difference at 5 years was 1.1% (-3.4, 5.7).  
When missing adherence was set to half that at the last available measurement, the estimated post-
randomization adjusted difference was 1.4% (-2.6, 5.4) with no censoring, and 3.6% (-1.0, 8.1) with 
censoring at the third consecutive missed visit. When adherence was set to 0 for up to two missed visits 
and censored from the third consecutive missed visit (similar to 1980 analysis but with censoring after 3 
missed visits) the estimated difference was 3.2% (-1.2, 7.5). These last two approaches are less 
successful at breaking the link between missing adherence and mortality and thus give estimates further 
from the null. 
When adherence was set to 0 at all missed visits (the 1980 approach), the post-randomization-adjusted 
5-year mortality difference was 7.6% (2.0, 13.1). We assessed the effect of definition of adherence in 
two ways: by ignoring prescribed dosage when calculating adherence, and by varying the cut-point for 
adherent versus non-adherent. Ignoring prescribed dosage produced estimates that were further from 
the null than the main analyses, particularly in the analyses adjusted for post-randomization variables 
and censoring which resulted in a 5-year mortality risk difference of 6.3% (-2.7, 15.2). We also varied the 
cut-point for binary cumulative adherence to 70% and to 90% for the unadjusted and baseline adjusted 
analyses. We were unable to adjust the cut-point for binary adherence at each visit because of the way 
this data were collected, so we were not able to run the post-randomization adjusted model at these 
levels. When cumulative adherence was dichotomized at 70%, the 5-year mortality difference was 8.2 
percentage points (1.9, 14.4) in the baseline adjusted model. When cumulative adherence was 
dichotomized at 90% the 5-year mortality difference was -2.3 percentage points (-5.4, 0.8) in the 
baseline adjusted model. This latter finding may be explained because of the way the adherence data 
were coded by Canner with the midpoint of each category used for calculating cumulative adherence. 
Individuals with cumulative average adherence of 90% by the end of follow-up must have reported 
adherence in the 80-100% category at every visit while, and this was less common the longer an 
individual was under follow-up.   
Some individuals were randomized after Aug 31, 1969 and therefore were administratively censored 
before completing the full 5 years of follow-up; excluding these individuals did not appreciably change 
the estimated difference in 5-year mortality risk (2.7%, -4.0, 9.3).  
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Finally, to check for over-fitting of the post-randomization adjusted analyses due to the large number of 
covariates in the model, we permuted the values of all baseline and time-varying covariates, while 
maintaining the link between adherence and 5-year mortality. We permuted the data 500 times, re-
running the analyses on each, and obtained the mean, 2.5
th
 and 97.5
th
 percentiles of the distribution. In 
the permuted dataset, all covariates are independent of adherence and survival. As expected, analysis of 
this permuted dataset resulted in estimates similar in size to the unadjusted analysis. The mean baseline 
adjusted risk difference was 11.1 percentage points (2.5
th
, 97.5
th
 percentiles:  10.5, 11.8), and the mean 
post-randomization-adjusted risk difference was 11.3 percentage points (2.5
th
 and 97.5
th
 percentiles: 
10.1, 12.3). These results suggest little or no role of over-fitting of the post-randomization adjusted 
models in the findings. 
SAS code  
We have provided the SAS code used for the main analyses. SAS 9.4 was used for all analyses. The code 
appendix contains the following programs: 
1. Program 1: Data management 
This program reads in the CDP dataset and defines the variables for the original and updated 
analyses. It creates two datasets for the placebo arm. Changing the value of ITR to 3 produces 
the same datasets for the clofibrate arm.  
o Binary.sas7bdat for crude and baseline adjusted analyses 
o Censwt_ag.sas7bdat for post-randomization adjusted analyses 
2. Program 2: Replication of 1980 analysis 
This program estimates the crude and baseline adjustment using the original 1980 definition of 
adherence. The output gives the first 2 columns of row 1 of Table 2 when using the original 
adherence coding and the second column of row 2 when using the updated adherence coding. It 
also outputs the results for Table 1. 
3. Program 3: Updated analyses with baseline variables 
This program estimates the crude and baseline adjustment using updated definition of 
adherence and outputs columns 1 and 3 of row 2 of Table 2. Changing the adherence variable 
input allows estimation of the third column of row 1 in Table 2.  
4. Program 4: Updated analysis with post-randomization  covariates 
This program requires the restricted cubic spline macro developed by F.E. Harrell[7, 8] in order 
to run. It estimates the association between adherence and death using adjustment for post-
randomization covariates using inverse probability weighting and outputs final column for row 2 
of Table 2. 
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Figure A1: Censoring scheme for re-analyses of the Coronary Drug Project. Lt is the vector of covariates 
measured at visit t and At is an indicator for adherence level for the period from t to just before t+1. 
When an individual misses a study visit, the most recent covariate and adherence values are carried over 
from the previous inter-visit period. An individual is censored at the date of their third consecutive 
missed study visit. Covariates are therefore carried forward up to two consecutive missed visits, and 
adherence is carried forward up to three intervals between missed visits. 
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 Table A1: Covariates used for adjustment, Coronary Drug Project 
Covariate Variable Code 
Measured 
at: Levels when dichotomized 
Demographics:    
Age at entry (years) IAGE 
Baseline 
only ≥55 vs <55 
Race IRC 
Baseline 
only White vs not white 
Lifestyle characteristics:    
Cigarette smoking  ICG1-6 
Annual 
visits only Any/none 
Current habitual level of physical activity 
in leisure time IJOB34-39 
Annual 
visits only 
“Vigorous or Moderate” vs “Light or 
Sedentary” 
Medical history:    
Risk group IRK 
Baseline 
only 
“Low risk (1 previous MI with no 
complications)” vs “High risk (>1 previous 
MI or MI with complications)” 
Number of myocardial infarctions at 
baseline NMI 
Baseline 
only ≥2 vs <2 
Time since most recent myocardial 
infarction LMI 
Baseline 
only Dropped because of high missingness 
Relative body weight  RBW 
Baseline 
only ≥1.15 vs <1.15 
History of congestive heart failure  
(yes = suspect or definite) 
KLIN1; 
ICCL1-26 All visits 
Ever at Baseline: yes/no 
Since last visit: yes/no 
History of angina pectoris  
(yes = suspect or definite) 
KLIN2; 
ICCL27-52 All visits 
Ever at Baseline: yes/no 
Since last visit: yes/no 
History of acute coronary insufficiency 
(yes = suspect or definite) 
KLIN3; 
ICCL53-78 All visits 
Ever at Baseline: yes/no 
Since last visit: yes/no 
History of intermittent cerebral ischemic 
attack  
(yes = suspect or definite) 
KLIN5; 
ICCL157-182 All visits 
Ever at Baseline: yes/no 
Since last visit: yes/no 
History of intermittent claudication  
(yes = suspect or definite) 
KLIN7; 
ICCL235-260 All visits 
Ever at Baseline: yes/no 
Since last visit: yes/no 
Systolic blood pressure (mmHg) WTPB32-47 All visits ≥130 vs <130 
Diastolic blood pressure (mmHg) WTPB61-76 All visits ≥85 vs <85 
New York Heart Association functional 
class NIHA1-11 
Annual 
visits only “Any limitation” vs “no limitation” 
Cardiomegaly on chest X-ray 
(yes = probable or definite) IXRAY1-22 
Annual 
visits only Yes/no 
Prescription of non-study medications:    
Oral hypoglycemic agents IMDCT29-56 All visits 
Current at baseline: yes/no 
Since last visit yes/no 
Digitalis IMDCT57-84 All visits 
Current at baseline: yes/no 
Since last visit yes/no 
Antiarrhythmic agents IMDCT85-112 All visits 
Current at baseline: yes/no 
Since last visit yes/no 
Diuretics IMDCT113-140 All visits 
Current at baseline: yes/no 
Since last visit yes/no 
Antihypertensives other than diuretics IMDCT141-168 All visits 
Current at baseline: yes/no 
Since last visit yes/no 
Lab findings:     
Serum total bilirubin (mg/dl) 
ZLABB1;  
ZLAB4-18 All visits ≥0.5 vs <0.5 
Serum total cholesterol (mg/dl) 
ZLABB4;  
ZLAB91-105 All visits ≥250 vs <250 
Serum triglyceride (meq/L) ZLABB5;  All visits ≥5.0 vs <5.0 
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ZLAB120-134 
Serum uric acid (mg/dl) 
ZLABB6;  
ZLAB149-163 All visits ≥7.0 vs <7.0 
Serum alkaline phosphatase (K-A units) 
ZLABB7;  
ZLAB178-192 All visits ≥7.5 vs <7.5 
Plasma urea nitrogen (mg/dl) 
ZLABB8;  
ZLAB207-221 All visits ≥16 vs <16 
Plasma fasting glucose (mg/dl) 
ZLABB9;  
ZLAB236-250 All visits ≥100 vs <100 
Plasma one-hour glucose, after 75g oral 
load (mg/dl) 
ZLABB10;  
ZLAB265-279 All visits ≥180 vs <180 
White blood cell count (cells/mm3) WBC1-11 
Annual 
visits only ≥7500 vs <7500 
Absolute neutrophil count (cells/mm3) WBC12-22 
Annual 
visits only ≥4500 vs <4500 
Hematocrit (%) WBC23-33 
Annual 
visits only ≥46 vs <46 
ECG findings:    
Q/QS pattern on antero-lateral, postero-
inferior, or antero-septal recording IECG1-36 
Annual 
visits only Any/None 
ST segment depression on antero-lateral, 
postero-inferior, or antero-septal 
recording IECG37-72 
Annual 
visits only Any/None 
T-wave findings on antero-lateral, 
postero-inferior, or antero-septal 
recording IECG73-108 
Annual 
visits only Any/None 
ST segment elevation on antero-lateral, 
postero-inferior, or antero-septal 
recording IECG109-144 
Annual 
visits only Any/None 
Ventricular conduction defect IECG193-204 
Annual 
visits only Any/None 
Premature ventricular beats (frequent 
ventricular ectopic beats) 
(Note: any does not include premature 
atrial or nodal beats) IECG205-216 
Annual 
visits only Any/None 
Heart rate  
(beats per minute) IECG277-88 
Annual 
visits only ≥70 vs <70 
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Table A2: Predictors of low adherence (<80%), Coronary Drug Project 
Covariate OR (95% CI) 
Adherence history:  
Low adherence  
pre-baseline 
at baseline 
at most recent visit 
1.32 (1.11, 1.58) 
1.18 (1.01, 1.37) 
23.40 (21.12, 25.92) 
Demographics:  
Age ≥ 55 years at baseline 1.05 (0.94, 1.16) 
Race (not white) 0.96 (0.78, 1.17) 
Lifestyle characteristics:  
Cigarette smoking  
at baseline 
at most recent visit 
 
1.30 (1.11, 1.51) 
0.98 (0.84, 1.15) 
Current habitual level of physical activity in leisure time (light or sedentary) 
at baseline 
at most recent visit 
 
0.90 (0.81, 1.01) 
1.03 (0.92, 1.15) 
Medical history:  
Risk group (>1 previous MI or MI with complications) 0.96 (0.83, 1.11) 
Number of prior MIs (≥2) 0.96 (0.81, 1.14) 
Relative body weight  (≥1.15) 1.04 (0.94, 1.15) 
Congestive heart failure  
at baseline 
at most recent visit 
 
1.13 (0.96, 1.32) 
2.14 (1.73, 2.66) 
Angina pectoris  
at baseline 
at most recent visit 
 
0.98 (0.88, 1.11) 
1.22 (1.08, 1.36) 
Acute coronary insufficiency 
at baseline 
at most recent visit 
 
0.91 (0.799, 1.04) 
4.97 (3.96, 6.24) 
Intermittent cerebral ischemic attack  
at baseline 
at most recent visit 
 
1.18 (0.92, 1.52) 
2.31 (1.56. 3.42) 
Intermittent claudication  
at baseline 
at most recent visit 
 
1.06 (0.88, 1.27) 
1.03 (0.85, 1.26) 
Systolic blood pressure (≥130 mmHg) 
at baseline 
at most recent visit 
 
1.07 (0.95, 1.21) 
0.98 (0.87, 1.10) 
Diastolic blood pressure (≥85 mmHg) 
at baseline 
at most recent visit 
 
1.04 (0.92, 1.18) 
1.03 (0.91, 1.16) 
New York Heart Association functional class (any limitation) 
at baseline 
at most recent visit 
 
0.98 (0.87, 1.11) 
1.05 (0.93, 1.19) 
Cardiomegaly on chest X-ray 
at baseline 
at most recent visit 
 
0.96 (0.83, 1.12) 
1.04 (0.90, 1.20) 
Prescription of non-study medications:  
Oral hypoglycemic agents 
at baseline 
at most recent visit 
 
0.96 (0.69, 1.33) 
0.86 (0.64, 1.16) 
Digitalis 
at baseline 
at most recent visit 
 
0.73 (0.60, 0.90) 
1.34 (1.13, 1.61) 
Antiarrhythmic agents 
at baseline 
at most recent visit 
 
0.58 (0.42, 0.80) 
1.37 (1.11, 1.69) 
Diuretics  
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at baseline 
at most recent visit 
1.19 (1.00, 1.42) 
0.86 (0.74, 1.01) 
Antihypertensives other than diuretics 
at baseline 
at most recent visit 
 
1.17 (0.92, 1.48) 
0.89 (0.72, 1.10) 
Laboratory findings:  
Serum total bilirubin (≥0.5 mg/dl) 
at baseline 
at most recent visit 
 
1.02 (0.92, 1.14) 
0.93 (0.84, 1.03) 
Serum total cholesterol (≥250 mg/dl) 
at baseline 
at most recent visit 
 
0.88 (0.78, 0.99) 
1.03 (0.92, 1.16) 
Serum triglyceride (≥5.0 meq/L) 
at baseline 
at most recent visit 
 
1.11 (0.99, 1.25) 
0.91 (0.81, 1.02) 
Serum uric acid (≥7.0 mg/dl) 
at baseline 
at most recent visit 
 
0.93 (0.82, 1.04) 
1.13 (1.00, 1.28) 
Serum alkaline phosphatase (≥7.5 K-A units) 
at baseline 
at most recent visit 
 
1.13 (1.00, 1.27) 
0.93 (0.82, 1.05) 
Plasma urea nitrogen (≥16 mg/dl) 
at baseline 
at most recent visit 
 
0.94 (0.84, 1.05) 
1.01 (0.90, 1.12) 
Plasma fasting glucose (≥100 mg/dl) 
at baseline 
at most recent visit 
 
0.89 (0.79, 1.01) 
1.01 (0.90, 1.13) 
Plasma one-hour glucose, after 75g oral load (≥180 mg/dl) 
at baseline 
at most recent visit 
 
0.91 (0.80, 1.03) 
1.17 (1.04, 1.33) 
White blood cell count (≥7500 cells/mm3) 
at baseline 
at most recent visit 
 
0.99 (0.86, 1.14) 
1.05 (0.91, 1.21) 
Absolute neutrophil count (≥4500 cells/mm3) 
at baseline 
at most recent visit 
 
1.02 (0.89, 1.16) 
1.01 (0.87, 1.15) 
Hematocrit (≥46%) 
at baseline 
at most recent visit 
 
1.02 (0.91, 1.14) 
0.90 (0.81, 1.01) 
ECG findings:  
Q/QS pattern on antero-lateral, postero-inferior, or antero-septal recording 
at baseline 
at most recent visit 
 
0.85 (0.74, 0.97) 
1.07 (0.94, 1.22) 
ST segment depression on antero-lateral, postero-inferior, or antero-septal recording 
at baseline 
at most recent visit 
 
1.19 (1.02, 1.39) 
0.99 (0.86, 1.15) 
T-wave findings on antero-lateral, postero-inferior, or antero-septal recording 
at baseline 
at most recent visit 
 
1.03 (0.90, 1.19) 
1.04 (0.90, 1.20) 
ST segment elevation on antero-lateral, postero-inferior, or antero-septal recording 
at baseline 
at most recent visit 
 
0.60 (0.44, 0.82) 
1.33 (1.02, 1.73) 
Ventricular conduction defect 
at baseline 
at most recent visit 
 
0.82 (0.55, 1.23) 
0.90 (0.65, 1.25) 
Premature ventricular beats (frequent ventricular ectopic beats) 
at baseline 
at most recent visit 
 
1.41 (1.05, 1.90) 
1.41 (1.10, 1.80) 
Heart rate (≥70 beats per minute) 
at baseline 
at most recent visit 
 
0.85 (0.76, 0.96) 
1.13 (1.01, 1.27) 
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 Table A3. Outcome status and baseline characteristics for censored and uncensored individuals in the 
updated analyses, Coronary Drug Project. 
 
Covariate 
Prevalence among 
censored individuals,  
N = 217 (%) 
Prevalence among 
uncensored individuals, 
N = 2413 (%) 
Outcome status   
Death within 5 years 15.2 20.4  
Adherence history:   
Low adherence pre-baseline 11.5 6.0 
Demographics:   
Age ≥ 55 years at baseline 38.3 43.4 
Race (not white) 8.3 6.8 
Lifestyle characteristics:   
Cigarette smoking  52.1 36.1 
Current habitual level of physical activity in leisure time (light or 
sedentary) 
71.9 69.1 
Medical history:   
Risk group (>1 previous MI or MI with complications) 30.4 34.3 
Number of prior MIs (≥2) 19.4 19.3 
Relative body weight  (≥1.15) 44.7 46.0 
Congestive heart failure  12.9 15.9 
Angina pectoris  58.1 57.4 
Acute coronary insufficiency 18.4 15.8 
Intermittent cerebral ischemic attack  3.7 3.4 
Intermittent claudication  10.1 8.3 
Systolic blood pressure (≥130 mmHg) 56.7 50.4 
Diastolic blood pressure (≥85 mmHg) 46.5 35.4 
New York Heart Association functional class (any limitation) 56.2 53.1 
Cardiomegaly on chest X-ray 17.5 17.8 
Prescription of non-study medications:   
Oral hypoglycemic agents 5.5 5.1 
Digitalis 10.1 14.7 
Antiarrhythmic agents 2.8 3.5 
Diuretics 14.3 13.6 
Antihypertensives other than diuretics 8.3 6.7 
Laboratory findings:   
Serum total bilirubin (≥0.5 mg/dl) 52.5 51.6 
Serum total cholesterol (≥250 mg/dl) 50.7 45.9 
Serum triglyceride (≥5.0 meq/L) 50.2 49.4 
Serum uric acid (≥7.0 mg/dl) 43.3 43.8 
Serum alkaline phosphatase (≥7.5 K-A units) 46.1 47.8 
Plasma urea nitrogen (≥16 mg/dl) 47.5 53.1 
Plasma fasting glucose (≥100 mg/dl) 48.4 40.9 
Plasma one-hour glucose, after 75g oral load (≥180 mg/dl) 41.0 39.2 
White blood cell count (≥7500 cells/mm3) 48.4 44.2 
Absolute neutrophil count (≥4500 cells/mm3) 51.2 44.7 
Hematocrit (≥46%) 60.8 58.1 
ECG findings:   
Q/QS pattern on antero-lateral, postero-inferior, or antero-septal 
recording 
64.5 61.3 
ST segment depression on antero-lateral, postero-inferior, or antero-
septal recording 
22.6 24.7 
T-wave findings on antero-lateral, postero-inferior, or antero-septal 
recording 
53.0 48.5 
ST segment elevation on antero-lateral, postero-inferior, or antero-
septal recording 
6.0 3.8 
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Ventricular conduction defect 1.8 4.3 
Premature ventricular beats (frequent ventricular ectopic beats) 2.3 2.7 
Heart rate (≥70 beats per minute) 53.5 43.9 
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Table A4. Sensitivity analyses for the difference in 5-year mortality for <80% adherence minus ≥80% 
adherence among 2630 individuals with complete baseline data in the placebo arm, Coronary Drug 
Project 
 5-year mortality difference, % (95% CI) 
Sensitivity analysis N Unadjusted Adjusted for 
baseline variables 
Further adjusted 
for post-
randomization 
variables 
Method to assign % 
adherence at missed visits  
% adherence carried 
forward for 2 missed 
visits, set to 0 from 
third consecutive 
missed visit onwards 
2626 6.0  (2.3, 9.7) 3.1 (-0.3, 6.6) 0.2 (-3.7, 4.1) 
% adherence carried 
forward 2 missed visits, 
set to 80% from third 
consecutive missed visit 
onwards. 
2626 8.4 (4.4, 12.5) 4.9 (1.1, 8.6) 0.9 (-3.2, 4.9) 
% adherence set to 
cumulative % 
adherence through last 
available visit at all 
subsequent missed 
visits  
2623 8.6 (4.5, 12.7) 5.1 (1.3, 8.8) 1.1 (-3.4, 5.7) 
% adherence set to half 
the adherence at last 
available visit for all 
missed visits 
2623 7.9 (4.3, 11.5) 4.8 (1.4, 8.1) 1.4 (-2.6, 5.4) 
% adherence set to half 
the adherence at last 
available visit up to 2 
missed visits, censored 
from third consecutive 
missed visit onwards 
2413 12.5 (8.2, 16.9) 8.2 (4.3, 12.1) 3.6 (-1.0, 8.1) 
% adherence set to 0 
for 2 missed visits, 
censored from third 
consecutive missed 
visit onwards 
2413 11.7 (7.5, 15.8) 3.1 (-0.3, 6.6) 3.2 (-1.2, 7.5) 
Original 1980 analysis 
(missing adherence set 
to 0 at all visits) with 
2627 --- --- 7.6 (2.0, 13.1) 
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adjustment for post-
randomization 
covariates  
Ignore prescribed dosage 
when calculating 
adherence 
No adjustment for 
censoring 
 
 
2415 
 
 
11.6 (5.8, 17.4) 
 
 
 
7.6 (2.3, 13.0) 
 
 
 
5.8 (0.2, 11.5) 
 
Adjustment for 
censoring via IP 
weighting 
2385 12.0 (6.3, 17.8) 8.3 (3.1, 13.4) 
 
6.3 (-2.7, 15.2) 
Definition of adherence 
Binary adherence cut-
point at 70%  
2413 13.5 (6.9, 20.1) 8.2 (1.9, 14.4) --- 
Binary adherence cut-
point at 90%  
2413 -0.2 (-3.4, 3.0) -2.3 (-5.4, 0.8) --- 
Exclude individuals who 
started after Aug 30, 1969 
No adjustment for 
censoring 
 
 
2315 
 
 
11.0 (6.3, 15.6) 
 
 
6.7 (2.4, 11.0) 
 
 
2.5 (-2.1, 7.0) 
Adjustment for 
censoring via IP 
weighting 
2289 11.0 (6.3, 15.8) 7.0 (2.6, 11.4) 2.7 (-4.0, 9.3) 
Updated analysis, with 
adjustment for censoring 
via IP censoring weights 
2385 11.2 (6.5, 16.0) 7.3 (3.0, 11.6) 2.5 (-3.8, 8.8) 
Updated analysis, with 
covariates set to median 
values 
2410 --- 4.1 (1.1, 7.2) --- 
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SAS Appendix 
This package contains the SAS programs used for the main analyses to replicate the 1980 CDP findings 
and update these analyses using inverse probability weighting. SAS 9.4 was used for all analyses. The 
code appendix contains the following programs: 
1. Program 1: Data management 
This program reads in the CDP dataset and defines the variables for the original and updated 
analyses. It creates two datasets for the placebo arm. Changing the value of ITR to 3 produces 
the same datasets for the clofibrate arm.  
o Binary.sas7bdat for crude and baseline adjusted analyses 
o Censwt_ag.sas7bdat for post-randomization adjusted analyses 
2. Program 2: Replication of 1980 analysis 
This program estimates the crude and baseline adjustment using the original 1980 definition of 
adherence. The output gives the first 2 columns of row 1 of Table 2 when using the original 
adherence coding and the second column of row 2 when using the updated adherence coding. It 
also outputs the results for Table 1. 
3. Program 3: Updated analyses with baseline variables 
This program estimates the crude and baseline adjustment using updated definition of 
adherence and outputs columns 1 and 3 of row 2 of Table 2. Changing the adherence variable 
input allows estimation of the third column of row 1 in Table 2.  
4. Program 4: Updated analysis with post-randomization  covariates 
This program requires the restricted cubic spline macro developed by F.E. Harrell[7, 8] in order 
to run. It estimates the association between adherence and death using adjustment for post-
randomization covariates using inverse probability weighting and outputs final column for row 2 
of Table 2. 
The datasets for the Coronary Drug Project will be available through application to the National Heart, 
Lung, and Blood Institute. If you have any questions, comments, or discover an error, please contact 
Eleanor Murray at emurray@mail.harvard.edu. For the most updated versions of the SAS programs, 
please visit www.hsph.harvard.edu/causal/. 
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/*****************************************/ 
/**     Program 1 Data Management ********/ 
/**This program creates 2 data files for**/ 
/**analysis of CDP adherence data in******/ 
/**placebo arm. Creates: *****************/ 
/*****************************************/ 
/**Binary.sas7bdat: main dataset with: ***/ 
/**Old and new adherence definitions******/ 
/**dichotomized covariates.***************/ 
/*****************************************/ 
/*****************************************/ 
/**censwt_ag.sas7bdat: long-format ********/ 
/**dataset for analysis of time-varying***/ 
/**adherence******************************/ 
/*****************************************/ 
 
 
libname cdp "</path/>"; 
 
/*****************************************/ 
/***Main analysis dataset ****************/ 
 
 
data cdp.binary; 
set cdp.allcdp_new; 
where itr = 6;  /*ITR = 6 is placebo arm. */ 
 
/*For clofibrate arm, use ITR = 3*/ 
 
keep  
/*treatment group and administrative variables*/ 
ID ITR INV1--INV24 INV28 INVCV1-INVCV3 LVA LV5 LV6 LVSS ENTRYDATE ENDDATE DEATHDATE 
 
/*exposures*/ 
ICAP1--ICAP26 ICAPQ1 ICAPQ2 IADH1--IADH26 
ADHX15  ADH1--ADH52 CAPS1--CAPS26 JADH1-JADH2 
 
/*outcomes*/ 
DTH5 ISTAT ITS ITD INVDTH ITDX 
 
/*covariates from NEJM paper*/ 
IAGE IRC NMI LMI ZLABB1 ZLABB4  
ZLABB5 ZLABB6 ZLABB7 ZLABB8 ZLABB9  
ZLABB10 WTBP61 WTBP32 RBW WBC23  
WBC1 WBC12 IRK NIHA1  
KLIN1 KLIN2 KLIN3 KLIN5 KLIN7 
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IMDCT58 IMDCT114 IMDCT86 IMDCT142 IMDCT30  
IXRAY1 IXRAY12 ICG1 IJOB34 IECG2  
IECG14 IECG26 IECG38 IECG50 IECG62 
IECG74 IECG86 IECG98 IECG110 IECG122  
IECG134 IECG206 IECG194 IECG278 
 
ZLAB88 ZLAB89 ZLAB90 ZLAB91--ZLAB116  
 
/*Longitudinal variables for time-varying adherence analyses*/ 
NIHA1-NIHA6 ICG1-ICG6 WTBP32-WTBP47 WTBP61-WTBP76 
IJOB34-IJOB39 IXRAY1-IXRAY22 WBC1-WBC33 IMDCT30-IMDCT45  
IMDCT58-IMDCT73 IMDCT86-IMDCT101 IMDCT114-IMDCT129  
IMDCT142-IMDCT157 ICCL1-ICCL15 ZLAB4-ZLAB18 ZLAB91-ZLAB105  
ZLAB120-ZLAB134 ZLAB149-ZLAB163 ZLAB178-ZLAB192  
 
ZLAB207-ZLAB221 ZLAB236-ZLAB250 ZLAB265-ZLAB279 
IECG1-IECG283; 
 
 
/***Demographic & Baseline-Only Variables****/ 
age_bin = .; 
if iage ge 55 then age_bin = 1; 
else if .< iage <55 then age_bin = 0; 
 
age_cat = .; 
if .< iage <45 then age_cat =0; 
else if 45 le iage < 50 then age_cat = 1; 
else if 50 le iage < 55 then age_cat = 2; 
else if 55 le iage < 60 then age_cat = 3; 
else if 60 le iage  then age_cat = 4; 
 
nonwhite = .; 
if irc = 1 then nonwhite = 0; 
else if irc in (2,3) then nonwhite = 1; 
 
mi_bin = .; 
if NMI ge 2 then mi_bin = 1; 
else if .< NMI <2 then mi_bin = 0; 
 
rbw_bin = .; 
if RBW ge 1.15 then rbw_bin = 1; 
else if . < RBW < 1.15 then rbw_bin = 0; 
 
keep  age_cat age_bin nonwhite mi_bin rbw_bin; 
drop  irc nmi rbw; 
 
 
/***Time-varying Covariates*****************/ 
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 /*For annual variables, code assigns most recent annual visit to subsequent 2 non-annual follow-up 
visits*/ 
/*For any missing data, carry forward up to 2 consecutive missed visits - censor on third consecutive 
missed visit*/ 
/*Where necessary, set invalid response levels to missing*/ 
 
/*New York Heart Association Risk group: 1 v 2 at baseline; 1 v (2,3,4) over follow-up*/ 
array NIHA_FV(17) NIHA_FV1 - NIHA_FV17; 
array NIHA(6) NIHA1 - NIHA6; 
array NIHA_bin(6) NIHA_bin1 - NIHA_bin6; 
do i = 1 to 6; 
 if NIHA(i) = 1 then NIHA_bin(i) = 0; 
 else if NIHA(i) = 9 then do;  
  NIHA(i) = . ; 
  NIHA_bin(i) = .; 
  end; 
 else if NIHA(i) >1 then NIHA_bin(i) = 1; 
 end; 
NIHA_FV0 = NIHA_bin1; 
NIHA_FV1 = NIHA_bin1; 
NIHA_FV2 = NIHA_bin1; 
do i = 2 to 6; 
 if NIHA_bin(i) ne . then do; 
  NIHA_FV((i-1)*3) = NIHA_bin(i); 
  NIHA_FV((i-1)*3+1) = NIHA_bin(i); 
  NIHA_FV((i-1)*3+2) = NIHA_bin(i); 
  end; 
 else do; 
  NIHA_FV((i-1)*3) = .; 
  NIHA_FV((i-1)*3+1) = .; 
  NIHA_FV((i-1)*3+2) = .; 
  end; 
 end; 
 
keep NIHA_FV0-NIHA_FV15 NIHA_bin1; 
drop NIHA1-NIHA6 NIHA_FV16-NIHA_FV17; 
 
/*Clinical history variables: 0=no, 1=suspect or definite; baseline and follow-up*/ 
array KLIN1_FV(15) KLIN1_FV1-KLIN1_FV15; 
array KLIN2_FV(15) KLIN2_FV1-KLIN2_FV15; 
array KLIN3_FV(15) KLIN3_FV1-KLIN3_FV15; 
array KLIN5_FV(15) KLIN5_FV1-KLIN5_FV15; 
array KLIN7_FV(15) KLIN7_FV1-KLIN7_FV15; 
array ICCL(75)  ICCL1-ICCL15 
  ICCL27-ICCL41 
  ICCL53-ICCL67 
  ICCL157-ICCL171 
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  ICCL235-ICCL249; 
KLIN1_FV0 = KLIN1; 
KLIN2_FV0 = KLIN2; 
KLIN3_FV0 = KLIN3; 
KLIN5_FV0 = KLIN5; 
KLIN7_FV0 = KLIN7; 
do i=1 to 15; 
 if ICCL(i) ne .    then KLIN1_FV(i) = ICCL(i); 
 else if i = 1     then KLIN1_FV(i) = KLIN1_FV0; 
 else if i = 2 and ICCL(i-1) ne .  then KLIN1_FV(i) = KLIN1_FV1; 
 else if i >2 then do; 
  if ICCL(i-1) ne .   then KLIN1_FV(i) = KLIN1_FV(i-1); 
  else if ICCL(i-2) ne .   then KLIN1_FV(i) = KLIN1_FV(i-2); 
  else if ICCL(i-2) = .   then KLIN1_FV(i) = .; 
 end; 
end; 
do i=16 to 30; 
 if ICCL(i) ne .    then KLIN2_FV(i-15) = ICCL(i); 
 else if i =16     then KLIN2_FV(i-15) = KLIN2_FV0; 
 else if i =17 and ICCL(i-1) ne .  then KLIN2_FV(i-15) = KLIN2_FV1; 
 else if i >17 then do; 
  if ICCL(i-1) ne .   then KLIN2_FV(i-15) = KLIN2_FV(i-16); 
  else if ICCL(i-2) ne .  then KLIN2_FV(i-15) = KLIN2_FV(i-17); 
  else if ICCL(i-2) = .   then KLIN2_FV(i-15) = .; 
 end; 
end; 
do i=31 to 45; 
 if ICCL(i) ne .    then KLIN3_FV(i-30) = ICCL(i); 
 else if i =31     then KLIN3_FV(i-30) = KLIN3_FV0; 
 else if i =32 and ICCL(i-1) ne .  then KLIN3_FV(i-30) = KLIN3_FV1; 
 else if i >32 then do; 
  if ICCL(i-1) ne .   then KLIN3_FV(i-30) = KLIN3_FV(i-31); 
  else if ICCL(i-2) ne .   then KLIN3_FV(i-30) = KLIN3_FV(i-32); 
  else if ICCL(i-2) = .   then KLIN3_FV(i-30) = .; 
 end; 
end; 
do i=46 to 60; 
 if ICCL(i) ne .    then KLIN5_FV(i-45) = ICCL(i); 
 else if i =46     then KLIN5_FV(i-45) = KLIN5_FV0; 
 else if i =47 and ICCL(i-1) ne .  then KLIN5_FV(i-45) = KLIN5_FV1; 
 else if i >47 then do; 
  if ICCL(i-1) ne .   then KLIN5_FV(i-45) = KLIN5_FV(i-46); 
  else if ICCL(i-2) ne .  then KLIN5_FV(i-45) = KLIN5_FV(i-47); 
  else if ICCL(i-2) = .   then KLIN5_FV(i-45) = .; 
 end; 
end; 
do i=61 to 75; 
 if ICCL(i) ne .    then KLIN7_FV(i-60) = ICCL(i); 
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 else if i =61     then KLIN7_FV(i-60) = KLIN7_FV0; 
 else if i =62 and ICCL(i-1) ne .  then KLIN7_FV(i-60) = KLIN7_FV1; 
 else if i >62 then do; 
  if ICCL(i-1) ne .   then KLIN7_FV(i-60) = KLIN7_FV(i-61); 
  else if ICCL(i-2) ne .   then KLIN7_FV(i-60) = KLIN7_FV(i-62); 
  else if ICCL(i-2) = .   then KLIN7_FV(i-60) = .; 
 end; 
end; 
 
CHF = .; 
if KLIN1 = 2   then CHF = 0; 
if KLIN1 in (1,3) then CHF = 1; 
ACI =.; 
if KLIN3 = 2   then ACI = 0; 
if KLIN3 in (1, 3)  then ACI = 1; 
AP =.; 
if KLIN2 = 2   then AP = 0; 
if KLIN2 in (1,3)  then AP = 1; 
IC =.; 
if KLIN7 = 2   then IC = 0; 
if KLIN7 in (1,3) then IC = 1; 
ICIA=.; 
if KLIN5 = 2   then ICIA = 0; 
if KLIN5  in (1,3) then ICIA = 1; 
keep CHF ACI AP IC ICIA; 
 
array CHF_FV(15) CHF_FV1 - CHF_FV15; 
CHF_FV0 = CHF; 
do i = 1 to 15; 
 if KLIN1_FV(i) = 2 then CHF_FV(i) = 0; 
 if KLIN1_FV(i) in (1,3) then CHF_FV(i) = 1; 
 end; 
array ACI_FV(15) ACI_FV1 - ACI_FV15; 
ACI_FV0 = ACI; 
do i = 1 to 15; 
 if KLIN3_FV(i) = 2 then ACI_FV(i) = 0; 
 if KLIN3_FV(i) in (1,3) then ACI_FV(i) = 1; 
 end; 
array AP_FV(15) AP_FV1 - AP_FV15; 
AP_FV0 = AP; 
do i = 1 to 15; 
 if KLIN2_FV(i) = 2 then AP_FV(i) = 0; 
 if KLIN2_FV(i) in (1,3) then AP_FV(i) = 1; 
 end; 
array IC_FV(15) IC_FV1 - IC_FV15; 
IC_FV0 = IC; 
do i = 1 to 15; 
 if KLIN7_FV(i) = 2 then IC_FV(i) = 0; 
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 if KLIN7_FV(i) in (1,3) then IC_FV(i) = 1; 
 end; 
array ICIA_FV(15) ICIA_FV1 - ICIA_FV15; 
ICIA_FV0 = ICIA; 
do i = 1 to 15; 
 if KLIN5_FV(i) = 2 then ICIA_FV(i) = 0; 
 if KLIN5_FV(i) in (1,3) then ICIA_FV(i) = 1; 
 end; 
keep CHF_FV0-CHF_FV15 ACI_FV0-ACI_FV15 AP_FV0-AP_FV15 IC_FV0-IC_FV15 ICIA_FV0-ICIA_FV15; 
 
drop KLIN1_FV0-KLIN1_FV15 KLIN2_FV0-KLIN2_FV15 KLIN3_FV0-KLIN3_FV15 KLIN5_FV0-KLIN5_FV15  
KLIN7_FV0-KLIN7_FV15 
 ICCL1-ICCL15 ICCL27-ICCL41 ICCL53-ICCL67 ICCL157-ICCL171 ICCL235-ICCL249; 
 
/*Medication use variables: 0 = no, 1 = yes; baseline and follow-up*/ 
array IMDCT(80) IMDCT30-IMDCT45     
    IMDCT58-IMDCT73     
    IMDCT86-IMDCT101    
    IMDCT114-IMDCT129    
    IMDCT142-IMDCT157;  
array IMDCT30_FV(17) IMDCT30_FV1-IMDCT30_FV17; 
array IMDCT58_FV(17) IMDCT58_FV1-IMDCT58_FV17; 
array IMDCT86_FV(17) IMDCT86_FV1-IMDCT86_FV17; 
array IMDCT114_FV(17) IMDCT114_FV1-IMDCT114_FV17; 
array IMDCT142_FV(17) IMDCT142_FV1-IMDCT142_FV17; 
do i = 1 to 80; 
 if IMDCT(i) =0 then IMDCT(i)=.; 
 end; 
IMDCT30_FV0 = IMDCT30; 
IMDCT58_FV0 = IMDCT58; 
IMDCT86_FV0 = IMDCT86; 
IMDCT114_FV0 = IMDCT114; 
IMDCT142_FV0 = IMDCT142; 
do i=2 to 16; 
 if  IMDCT(i) ne .   then IMDCT30_FV(i-1) = IMDCT(i); 
 else if i = 2     then IMDCT30_FV(i-1) = IMDCT30_FV0; 
 else if i = 3 and IMDCT(i-1) ne .  then IMDCT30_FV(i-1) = IMDCT30_FV1; 
 else if i > 3 then do;  
  if IMDCT(i-1) ne .   then IMDCT30_FV(i-1) = IMDCT30_FV(i-2); 
  else if IMDCT(i-2) ne .  then IMDCT30_FV(i-1) = IMDCT30_FV(i-3); 
  else if IMDCT(i-2) = .   then IMDCT30_FV(i-1) = .; 
 end; 
end; 
do i=18 to 32; 
 if  IMDCT(i) ne .   then IMDCT58_FV(i-17) = IMDCT(i); 
 else if i = 18     then IMDCT58_FV(i-17) = IMDCT58_FV0; 
 else if i = 19 and IMDCT(i-1) ne .  then IMDCT58_FV(i-17) = IMDCT58_FV1; 
 else if i > 19 then do;  
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  if IMDCT(i-1) ne .   then IMDCT58_FV(i-17) = IMDCT58_FV(i-18); 
  else if IMDCT(i-2) ne .  then IMDCT58_FV(i-17) = IMDCT58_FV(i-19); 
  else if IMDCT(i-2) = .   then IMDCT58_FV(i-17) = .; 
 end; 
end; 
do i=34 to 48; 
 if  IMDCT(i) ne .   then IMDCT86_FV(i-33) = IMDCT(i); 
 else if i = 34     then IMDCT86_FV(i-33) = IMDCT86_FV0; 
 else if i = 35 and IMDCT(i-1) ne .  then IMDCT86_FV(i-33) = IMDCT86_FV1; 
 else if i > 35 then do;  
  if IMDCT(i-1) ne .   then IMDCT86_FV(i-33) = IMDCT86_FV(i-34); 
  else if IMDCT(i-2) ne .  then IMDCT86_FV(i-33) = IMDCT86_FV(i-35); 
  else if IMDCT(i-2) = .   then IMDCT86_FV(i-33) = .; 
 end; 
end; 
do i=50 to 64; 
 if  IMDCT(i) ne .   then IMDCT114_FV(i-49) = IMDCT(i); 
 else if i = 50     then IMDCT114_FV(i-49) = IMDCT114_FV0; 
 else if i = 51 and IMDCT(i-1) ne .  then IMDCT114_FV(i-49) = IMDCT114_FV1; 
 else if i > 51 then do;  
  if IMDCT(i-1) ne .   then IMDCT114_FV(i-49) = IMDCT114_FV(i-50); 
  else if IMDCT(i-2) ne .  then IMDCT114_FV(i-49) = IMDCT114_FV(i-51); 
  else if IMDCT(i-2) = .   then IMDCT114_FV(i-49) = .; 
 end; 
end; 
do i=66 to 80; 
 if  IMDCT(i) ne .   then IMDCT142_FV(i-65) = IMDCT(i); 
 else if i = 66     then IMDCT142_FV(i-65) = IMDCT142_FV0; 
 else if i = 67 and IMDCT(i-1) ne .  then IMDCT142_FV(i-65) = IMDCT142_FV1; 
 else if i > 67 then do;  
  if IMDCT(i-1) ne .   then IMDCT142_FV(i-65) = IMDCT142_FV(i-66); 
  else if IMDCT(i-2) ne .  then IMDCT142_FV(i-65) = IMDCT142_FV(i-67); 
  else if IMDCT(i-2) = .   then IMDCT142_FV(i-65) = .; 
 end; 
end; 
 
 
 
DIG =.; 
if IMDCT58 = 2 then DIG = 0; 
if IMDCT58 = 1 then DIG = 1; 
DIUR = .; 
if IMDCT114 = 2 then DIUR = 0; 
if IMDCT114 = 1 then DIUR = 1; 
AntiArr =.; 
if IMDCT86 = 2  then AntiArr = 0; 
if IMDCT86 = 1  then AntiArr = 1; 
AntiHyp =.; 
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if IMDCT142 = 2 then AntiHyp = 0; 
if IMDCT142 = 1 then AntiHyp = 1; 
OralHyp =.; 
if IMDCT30 = 2  then OralHyp = 0; 
if IMDCT30 = 1  then OralHyp = 1; 
Keep DIG DIUR AntiArr AntiHyp OralHyp; 
 
array DIG_FV(15) DIG_FV1 - DIG_FV15; 
DIG_FV0 = DIG; 
do i = 1 to 15; 
 if IMDCT58_FV(i) = 2 then DIG_FV(i) = 0; 
 if IMDCT58_FV(i) = 1 then DIG_FV(i) = 1; 
 end; 
array DIUR_FV(15) DIUR_FV1 - DIUR_FV15; 
DIUR_FV0 = DIUR; 
do i = 1 to 15; 
 if IMDCT114_FV(i) = 2 then DIUR_FV(i) = 0; 
 if IMDCT114_FV(i) = 1 then DIUR_FV(i) = 1; 
 end; 
array AntiArr_FV(15) AntiArr_FV1 - AntiArr_FV15; 
AntiArr_FV0 = AntiArr; 
do i = 1 to 15; 
 if IMDCT86_FV(i) = 2 then AntiArr_FV(i) = 0; 
 if IMDCT86_FV(i) = 1 then AntiArr_FV(i) = 1; 
 end; 
array AntiHyp_FV(15) AntiHyp_FV1 - AntiHyp_FV15; 
AntiHyp_FV0 = AntiHyp; 
do i = 1 to 15; 
 if IMDCT142_FV(i) = 2 then AntiHyp_FV(i) = 0; 
 if IMDCT142_FV(i) = 1 then AntiHyp_FV(i) = 1; 
 end; 
array OralHyp_FV(15) OralHyp_FV1 - OralHyp_FV15; 
OralHyp_FV0 = OralHyp; 
do i = 1 to 15; 
 if IMDCT30_FV(i) = 2 then OralHyp_FV(i) = 0; 
 if IMDCT30_FV(i) = 1 then OralHyp_FV(i) = 1; 
 end; 
keep DIG_FV0-DIG_FV15 DIUR_FV0-DIUR_FV15 AntiArr_FV0-AntiArr_FV15 
AntiHyp_FV0-AntiHyp_FV15 OralHyp_FV0-OralHyp_FV15; 
 
drop IMDCT30-IMDCT45     
    IMDCT58-IMDCT73     
    IMDCT86-IMDCT101    
    IMDCT114-IMDCT129    
    IMDCT142-IMDCT157; 
 
/*Cardiomegaly on x-ray: 0 = no, 1 = probable or definite; baseline and follow-up*/ 
array IXRAY1_FV(17) IXRAY1_FV1-IXRAY1_FV17; 
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array IXRAY2_FV(17) IXRAY2_FV1-IXRAY2_FV17; 
array IXRAY(22) IXRAY1 - IXRAY22; 
do i = 1 to 11; 
 if IXRAY(i) = 3 then IXRAY(i)=.; 
 end; 
IXRAY1_FV0 = IXRAY1; 
IXRAY1_FV1 = IXRAY1; 
IXRAY1_FV2 = IXRAY1; 
do i = 2 to 6; 
 if IXRAY(i) ne . then do; 
  IXRAY1_FV((i-1)*3) = IXRAY(i); 
  IXRAY1_FV((i-1)*3+1) = IXRAY(i); 
  IXRAY1_FV((i-1)*3+2) = IXRAY(i); 
  end; 
 else do; 
  IXRAY1_FV((i-1)*3) = .; 
  IXRAY1_FV((i-1)*3+1) = .; 
  IXRAY1_FV((i-1)*3+2) = .; 
  end; 
end; 
IXRAY2_FV0 = IXRAY12; 
IXRAY2_FV1 = IXRAY12; 
IXRAY2_FV2 = IXRAY12; 
do i = 13 to 17; 
 if IXRAY(i) ne . then do; 
  IXRAY2_FV((i-12)*3) = IXRAY(i); 
  IXRAY2_FV((i-12)*3+1) = IXRAY(i); 
  IXRAY2_FV((i-12)*3+2) = IXRAY(i); 
  end; 
 else do; 
  IXRAY2_FV((i-12)*3) = .; 
  IXRAY2_FV((i-12)*3+1) = .; 
  IXRAY2_FV((i-12)*3+2) = .; 
  end; 
end; 
 
CardioM =.; 
if IXRAY1 = 1 or IXRAY12 = 1 then CardioM = 0; 
if IXRAY12 in (2,3)     then CardioM = 1; 
keep CardioM; 
 
array CardioM_FV(15) CardioM_FV1 - CardioM_FV15; 
CardioM_FV0 = CardioM; 
do i = 1 to 15; 
 if IXRAY1_FV(i) = 1 or IXRAY2_FV(i) = 1 then CardioM_FV(i) = 0; 
 if IXRAY2_FV(i) in (2,3)     then CardioM_FV(i) = 1; 
 end; 
keep CardioM_FV0 - CardioM_FV15; 
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 drop IXRAY1 - IXRAY22; 
 
/*ECG findings: categorical; baseline and follow-up, scheduled ECGs only*/ 
array IECG(283) IECG1-IECG283; 
array IECG2_FV(17) IECG2_FV1 - IECG2_FV17; 
array IECG14_FV(17) IECG14_FV1 - IECG14_FV17; 
array IECG26_FV(17) IECG26_FV1 - IECG26_FV17; 
array IECG38_FV(17) IECG38_FV1 - IECG38_FV17; 
array IECG50_FV(17) IECG50_FV1 - IECG50_FV17; 
array IECG62_FV(17) IECG62_FV1 - IECG62_FV17; 
array IECG74_FV(17) IECG74_FV1 - IECG74_FV17; 
array IECG86_FV(17) IECG86_FV1 - IECG86_FV17; 
array IECG98_FV(17) IECG98_FV1 - IECG98_FV17; 
array IECG110_FV(17) IECG110_FV1 - IECG110_FV17; 
array IECG122_FV(17) IECG122_FV1 - IECG122_FV17; 
array IECG134_FV(17) IECG134_FV1 - IECG134_FV17; 
array IECG206_FV(17) IECG206_FV1 - IECG206_FV17; 
array IECG194_FV(17) IECG194_FV1 - IECG194_FV17; 
array IECG278_FV(17) IECG278_FV1 - IECG278_FV17; 
do i=1 to 36;  
 if IECG(i) in (1, 10, 20, 37, 99) then IECG(i) = .; 
 end; 
do i=37 to 72; 
 if IECG(i) in (5, 8, 9) then IECG(i) = .; 
 end; 
do i=73 to 108; 
 if IECG(i) in (6, 7, 9) then IECG(i) = .; 
 end; 
do i=109 to 144; 
 if IECG(i) in (3, 9) then IECG(i) = .; 
 end; 
do i=206 to 211; 
 if IECG(i) in (6, 9) then IECG(i) = .; 
 end; 
do i=194 to 199; 
 if IECG(i) = 9 then IECG(i) = .; 
 end; 
do i=278 to 283; 
 if IECG(i) in (490, 999) then IECG(i) = .; 
 end; 
IECG2_FV0 = IECG2; 
IECG14_FV0 = IECG14; 
IECG26_FV0 = IECG26; 
IECG38_FV0 = IECG38; 
IECG50_FV0 = IECG50; 
IECG62_FV0 = IECG62; 
IECG74_FV0 = IECG74; 
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IECG86_FV0 = IECG86; 
IECG98_FV0 = IECG98; 
IECG110_FV0 = IECG110; 
IECG122_FV0 = IECG122; 
IECG134_FV0 = IECG134; 
IECG206_FV0 = IECG206; 
IECG194_FV0 = IECG194; 
IECG278_FV0 = IECG278; 
IECG2_FV1 = IECG2; 
IECG14_FV1 = IECG14; 
IECG26_FV1 = IECG26; 
IECG38_FV1 = IECG38; 
IECG50_FV1 = IECG50; 
IECG62_FV1 = IECG62; 
IECG74_FV1 = IECG74; 
IECG86_FV1 = IECG86; 
IECG98_FV1 = IECG98; 
IECG110_FV1 = IECG110; 
IECG122_FV1 = IECG122; 
IECG134_FV1 = IECG134; 
IECG206_FV1 = IECG206; 
IECG194_FV1 = IECG194; 
IECG278_FV1 = IECG278; 
IECG2_FV2 = IECG2; 
IECG14_FV2 = IECG14; 
IECG26_FV2 = IECG26; 
IECG38_FV2 = IECG38; 
IECG50_FV2 = IECG50; 
IECG62_FV2 = IECG62; 
IECG74_FV2 = IECG74; 
IECG86_FV2 = IECG86; 
IECG98_FV2 = IECG98; 
IECG110_FV2 = IECG110; 
IECG122_FV2 = IECG122; 
IECG134_FV2 = IECG134; 
IECG206_FV2 = IECG206; 
IECG194_FV2 = IECG194; 
IECG278_FV2 = IECG278; 
 
do i = 3 to 7; 
 if IECG(i) ne . then do; 
  IECG2_FV((i-2)*3) = IECG(i); 
  IECG2_FV((i-2)*3+1) = IECG(i); 
  IECG2_FV((i-2)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG2_FV((i-2)*3) = .; 
  IECG2_FV((i-2)*3+1) = .; 
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  IECG2_FV((i-2)*3+2) = .; 
  end; 
end; 
 
do i = 15 to 19; 
 if IECG(i) ne . then do; 
  IECG14_FV((i-14)*3) = IECG(i); 
  IECG14_FV((i-14)*3+1) = IECG(i); 
  IECG14_FV((i-14)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG14_FV((i-14)*3) = .; 
  IECG14_FV((i-14)*3+1) = .; 
  IECG14_FV((i-14)*3+2) = .; 
  end; 
end; 
 
do i = 27 to 31; 
 if IECG(i) ne . then do; 
  IECG26_FV((i-26)*3) = IECG(i); 
  IECG26_FV((i-26)*3+1) = IECG(i); 
  IECG26_FV((i-26)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG26_FV((i-26)*3) = .; 
  IECG26_FV((i-26)*3+1) = .; 
  IECG26_FV((i-26)*3+2) = .; 
  end; 
end; 
 
do i = 39 to 43; 
 if IECG(i) ne . then do; 
  IECG38_FV((i-38)*3) = IECG(i); 
  IECG38_FV((i-38)*3+1) = IECG(i); 
  IECG38_FV((i-38)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG38_FV((i-38)*3) = .; 
  IECG38_FV((i-38)*3+1) = .; 
  IECG38_FV((i-38)*3+2) = .; 
  end; 
end; 
 
do i = 51 to 55; 
 if IECG(i) ne . then do; 
  IECG50_FV((i-50)*3) = IECG(i); 
  IECG50_FV((i-50)*3+1) = IECG(i); 
  IECG50_FV((i-50)*3+2) = IECG(i); 
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  end; 
 else do; 
  IECG50_FV((i-50)*3) = .; 
  IECG50_FV((i-50)*3+1) = .; 
  IECG50_FV((i-50)*3+2) = .; 
  end; 
end; 
 
do i = 63 to 67; 
 if IECG(i) ne . then do; 
  IECG62_FV((i-62)*3) = IECG(i); 
  IECG62_FV((i-62)*3+1) = IECG(i); 
  IECG62_FV((i-62)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG62_FV((i-62)*3) = .; 
  IECG62_FV((i-62)*3+1) = .; 
  IECG62_FV((i-62)*3+2) = .; 
  end; 
end; 
 
do i = 75 to 79; 
 if IECG(i) ne . then do; 
  IECG74_FV((i-74)*3) = IECG(i); 
  IECG74_FV((i-74)*3+1) = IECG(i); 
  IECG74_FV((i-74)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG74_FV((i-74)*3) = .; 
  IECG74_FV((i-74)*3+1) = .; 
  IECG74_FV((i-74)*3+2) = .; 
  end; 
end; 
 
do i = 87 to 91; 
 if IECG(i) ne . then do; 
  IECG86_FV((i-86)*3) = IECG(i); 
  IECG86_FV((i-86)*3+1) = IECG(i); 
  IECG86_FV((i-86)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG86_FV((i-86)*3) = .; 
  IECG86_FV((i-86)*3+1) = .; 
  IECG86_FV((i-86)*3+2) = .; 
  end; 
end; 
 
do i = 99 to 103; 
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 if IECG(i) ne . then do; 
  IECG98_FV((i-98)*3) = IECG(i); 
  IECG98_FV((i-98)*3+1) = IECG(i); 
  IECG98_FV((i-98)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG98_FV((i-98)*3) = .; 
  IECG98_FV((i-98)*3+1) = .; 
  IECG98_FV((i-98)*3+2) = .; 
  end; 
end; 
 
do i = 111 to 115; 
 if IECG(i) ne . then do; 
  IECG110_FV((i-110)*3) = IECG(i); 
  IECG110_FV((i-110)*3+1) = IECG(i); 
  IECG110_FV((i-110)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG110_FV((i-110)*3) = .; 
  IECG110_FV((i-110)*3+1) = .; 
  IECG110_FV((i-110)*3+2) = .; 
  end; 
end; 
 
do i = 123 to 127; 
 if IECG(i) ne . then do; 
  IECG122_FV((i-122)*3) = IECG(i); 
  IECG122_FV((i-122)*3+1) = IECG(i); 
  IECG122_FV((i-122)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG122_FV((i-122)*3) = .; 
  IECG122_FV((i-122)*3+1) = .; 
  IECG122_FV((i-122)*3+2) = .; 
  end; 
end; 
 
do i = 135 to 139; 
 if IECG(i) ne . then do; 
  IECG134_FV((i-134)*3) = IECG(i); 
  IECG134_FV((i-134)*3+1) = IECG(i); 
  IECG134_FV((i-134)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG134_FV((i-134)*3) = .; 
  IECG134_FV((i-134)*3+1) = .; 
  IECG134_FV((i-134)*3+2) = .; 
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  end; 
end; 
 
do i = 207 to 211; 
 if IECG(i) ne . then do; 
  IECG206_FV((i-206)*3) = IECG(i); 
  IECG206_FV((i-206)*3+1) = IECG(i); 
  IECG206_FV((i-206)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG206_FV((i-206)*3) = .; 
  IECG206_FV((i-206)*3+1) = .; 
  IECG206_FV((i-206)*3+2) = .; 
  end; 
end; 
 
do i = 195 to 199; 
 if IECG(i) ne . then do; 
  IECG194_FV((i-194)*3) = IECG(i); 
  IECG194_FV((i-194)*3+1) = IECG(i); 
  IECG194_FV((i-194)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG194_FV((i-194)*3) = .; 
  IECG194_FV((i-194)*3+1) = .; 
  IECG194_FV((i-194)*3+2) = .; 
  end; 
end; 
 
do i = 279 to 283; 
 if IECG(i) ne . then do; 
  IECG278_FV((i-278)*3) = IECG(i); 
  IECG278_FV((i-278)*3+1) = IECG(i); 
  IECG278_FV((i-278)*3+2) = IECG(i); 
  end; 
 else do; 
  IECG278_FV((i-278)*3) = .; 
  IECG278_FV((i-278)*3+1) = .; 
  IECG278_FV((i-278)*3+2) = .; 
  end; 
end; 
 
QQS = .; 
if IECG2 = 0 and IECG14 = 0 and IECG26 = 0      then QQS = 0; 
if IECG2 in (28,31,32,33,34,35,36) or IECG14 in (28,31,32,33,34,35,36)  
    or IECG26 in (28,31,32,33,34,35,36)   then QQS = 1; 
if IECG2 in (21,22,23,24,25,26,27) or IECG14 in (21,22,23,24,25,26,27)  
    or IECG26 in (21,22,23,24,25,26,27)   then QQS = 2; 
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if IECG2 in (11,12,13,14,15,16,17,18) or IECG14 in (11,12,13,14,15,16,17,18)  
    or IECG26 in (11,12,13,14,15,16,17,18)   then QQS = 3; 
array QQS_FV(15) QQS_FV1 - QQS_FV15; 
QQS_FV0 = QQS; 
do i = 1 to 15; 
 if IECG2_FV(i) = 0 and IECG14_FV(i) = 0 and IECG26_FV(i) = 0    then 
QQS_FV(i) = 0; 
 if IECG2_FV(i) in (28,31,32,33,34,35,36) or IECG14_FV(i) in (28,31,32,33,34,35,36)  
    or IECG26_FV(i) in (28,31,32,33,34,35,36)   then 
QQS_FV(i) = 1; 
 if IECG2_FV(i) in (21,22,23,24,25,26,27) or IECG14_FV(i) in (21,22,23,24,25,26,27)  
    or IECG26_FV(i) in (21,22,23,24,25,26,27)   then 
QQS_FV(i) = 2; 
 if IECG2_FV(i) in (11,12,13,14,15,16,17,18) or IECG14_FV(i) in (11,12,13,14,15,16,17,18)  
    or IECG26_FV(i) in (11,12,13,14,15,16,17,18)   then 
QQS_FV(i) = 3; 
  end; 
 
AnyQQS =.; 
if QQS ge 1 then AnyQQS = 1; 
if QQS = 0  then AnyQQS = 0; 
array AnyQQS_FV(15) AnyQQS_FV1 - AnyQQS_FV15; 
AnyQQS_FV0 = AnyQQS; 
do i=1 to 15; 
 if QQS_FV(i) ge 1  then AnyQQS_FV(i) = 1; 
 if QQS_FV(i) = 0  then AnyQQS_FV(i) = 0; 
 end; 
 
STDep = .; 
if IECG38 = 0 and IECG50 = 0 and IECG62 = 0   then STDep = 0; 
else if IECG38 = 4 or IECG50 = 4 or IECG62 = 4   then STDep = 1; 
else if IECG38 = 3 or IECG50 = 3 or IECG62 = 3  then STDep = 2; 
else if IECG38 = 2 or IECG50 = 2 or IECG62 = 2  then STDep = 3; 
else if IECG38 = 1 or IECG50 = 1 or IECG62 = 1  then STDep = 4; 
array STDep_FV(15) STDep_FV1 - STDep_FV15; 
STDep_FV0 = STDep; 
do i = 1 to 15; 
 if IECG38_FV(i) = 0 and IECG50_FV(i) = 0 and IECG62_FV(i) = 0   then STDep_FV(i) = 0; 
 else if IECG38_FV(i) = 4 or IECG50_FV(i) = 4 or IECG62_FV(i) = 4  then STDep_FV(i) = 1; 
 else if IECG38_FV(i) = 3 or IECG50_FV(i) = 3 or IECG62_FV(i) = 3 then STDep_FV(i) = 2; 
 else if IECG38_FV(i) = 2 or IECG50_FV(i) = 2 or IECG62_FV(i) = 2 then STDep_FV(i) = 3; 
 else if IECG38_FV(i) = 1 or IECG50_FV(i) = 1 or IECG62_FV(i) = 1 then STDep_FV(i) = 4; 
  end; 
 
AnySTDep=.; 
if STDep = 0  then AnySTDep = 0; 
if STDep >0  then AnySTDep = 1; 
array AnySTDep_FV(15) AnySTDep_FV1 - AnyStDep_FV15; 
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AnySTDep_FV0 = AnySTDep; 
do i=1 to 15; 
 if STDep_FV(i) = 0  then AnySTDep_FV(i) = 0; 
 if STDep_FV(i) >0  then AnySTDep_FV(i) = 1; 
 end; 
 
TWave =.; 
if IECG74 = 0 and IECG86 = 0 and IECG98 = 0   then TWave = 0; 
else if IECG74 = 4 or IECG86 = 4 or IECG98 = 4   then TWave = 1; 
else if IECG74 = 3 or IECG86 = 3 or IECG98 = 3  then TWave = 2; 
else if IECG74 = 2 or IECG86 = 2 or IECG98 = 2  then TWave = 3; 
else if IECG74 = 1 or IECG86 = 1 or IECG98 = 1  then TWave = 4; 
array TWave_FV(15)  TWave_FV1 - TWave_FV15; 
TWave_FV0 = TWave; 
do i = 1 to 15; 
 if IECG74_FV(i) = 0 and IECG86_FV(i) = 0 and IECG98_FV(i) = 0   then TWave_FV(i) = 0; 
 else if IECG74_FV(i) = 4 or IECG86_FV(i) = 4 or IECG98_FV(i) = 4  then TWave_FV(i) = 1; 
 else if IECG74_FV(i) = 3 or IECG86_FV(i) = 3 or IECG98_FV(i) = 3 then TWave_FV(i) = 2; 
 else if IECG74_FV(i) = 2 or IECG86_FV(i) = 2 or IECG98_FV(i) = 2 then TWave_FV(i) = 3; 
 else if IECG74_FV(i) = 1 or IECG86_FV(i) = 1 or IECG98_FV(i) = 1 then TWave_FV(i) = 4; 
  end; 
 
AnyTwave=.; 
if Twave = 0  then AnyTwave = 0; 
if Twave >0  then AnyTwave = 1; 
array AnyTwave_FV(15) AnyTwave_FV1 - AnyTwave_FV15; 
AnyTwave_FV0 = AnyTwave; 
do i=1 to 15; 
 if Twave_FV(i) = 0  then AnyTwave_FV(i) = 0; 
 if Twave_FV(i) >0  then AnyTwave_FV(i) = 1; 
 end; 
 
STElev = .; 
if IECG110 = 0 and IECG122 = 0 and IECG134 = 0  then STElev = 0; 
if IECG110 = 2 or IECG122 = 2 or IECG134 = 2 then STElev = 1; 
array STElev_FV(15)  STElev_FV1 - STElev_FV15; 
STElev_FV0 = STElev; 
do i = 1 to 15; 
 if IECG110_FV(i) = 0 and IECG122_FV(i) = 0 and IECG134_FV(i) = 0  then STElev_FV(i) = 0; 
 if IECG110_FV(i) = 2 or IECG122_FV(i) = 2 or IECG134_FV(i) = 2  then STElev_FV(i) = 1; 
 end; 
 
FVEB = .; 
if IECG206 in (0, 1, 3, 4) then FVEB = 0; 
if IECG206 = 2 then FVEB = 1; 
array FVEB_FV(15) FVEB_FV1 - FVEB_FV15; 
FVEB_FV0 = FVEB; 
do i = 1 to 15; 
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 if IECG206_FV(i) in (0, 1, 3, 4) then FVEB_FV(i) = 0; 
 if IECG206_FV(i) = 2     then FVEB_FV(i) = 1; 
  end; 
 
VCD = .; 
if IECG194 in (0,3,5) then VCD = 0; 
if IECG194 in (1,2,4) then VCD = 1; 
array VCD_FV(15) VCD_FV1 - VCD_FV15; 
VCD_FV0 = VCD; 
do i = 1 to 15; 
 if IECG194_FV(i) in (0,3,5) then VCD_FV(i) = 0; 
 if IECG194_FV(i) in (1,2,4) then VCD_FV(i) = 1; 
  end; 
 
HiHeart = .; 
if IECG278 ge 70  then HiHeart = 1; 
if IECG278 <70   then HiHeart = 0; 
array HiHeart_FV(15) HiHeart_FV1-HiHeart_FV15; 
HiHeart_FV0 = HiHeart; 
do i=1 to 15; 
 if IECG278_FV(i) ge 70  then HiHeart_FV(i) = 1; 
 if IECG278_FV(i) <70  then HiHeart_FV(i) = 0; 
 end; 
  
keep QQS QQS_FV0-QQS_FV15 AnyQQS AnyQQS_FV0-AnyQQS_FV15 
 STDep STDep_FV0-STDep_FV15 AnySTDep AnySTDep_FV0-AnySTDep_FV15 
 TWave TWave_FV0-TWave_FV15 AnyTWave AnyTWave_FV0-AnyTWave_FV15 
 STElev STElev_FV0-STElev_FV15  
 FVEB FVEB_FV0-FVEB_FV15 
 VCD VCD_FV0-VCD_FV15 
 HiHeart HiHeart_FV0-HiHeart_FV15; 
 
drop IECG1-IECG283; 
 
 
/* Blood pressure*/ 
array SysBP_FV(15) SysBP_FV1-SysBP_FV15; 
array DiasBP_FV(15) DiasBP_FV1-DiasBP_FV15; 
array WTBP(32) WTBP32 - WTBP47 WTBP61-WTBP76; 
SysBP_FV0 = WTBP32; 
do i=2 to 16; 
 if  WTBP(i) ne .    then SysBP_FV(i-1) = WTBP(i); 
 else if i = 2     then SysBP_FV(i-1) = SysBP_FV0; 
 else if i = 3 and WTBP(i-1) ne .  then SysBP_FV(i-1) = SysBP_FV1; 
 else if i > 3 then do;  
  if WTBP(i-1) ne .   then SysBP_FV(i-1) = SysBP_FV(i-2); 
  else if WTBP(i-2) ne .   then SysBP_FV(i-1) = SysBP_FV(i-3); 
  else if WTBP(i-2) = .   then SysBP_FV(i-1) = .; 
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 end; 
end; 
DiasBP_FV0 = WTBP61; 
do i=18 to 32; 
 if  WTBP(i) ne .    then DiasBP_FV(i-17) = WTBP(i); 
 else if i = 18     then DiasBP_FV(i-17) = DiasBP_FV0; 
 else if i = 19 and WTBP(i-1) ne .  then DiasBP_FV(i-17) = DiasBP_FV1; 
 else if i > 19 then do;  
  if WTBP(i-1) ne .   then DiasBP_FV(i-17) = DiasBP_FV(i-18); 
  else if WTBP(i-2) ne .   then DiasBP_FV(i-17) = DiasBP_FV(i-19); 
  else if WTBP(i-2) = .   then DiasBP_FV(i-17) = .; 
 end; 
end; 
 
 
array HiSysBP_a(15) HiSysBP_FV1 - HiSysBP_FV15; 
array HiDiasBP_a(15) HiDiasBP_FV1 - HiDiasBP_FV15; 
if . < SysBP_FV0 < 130 then do; 
 HiSysBP = 0; 
 HiSysBP_FV0 = 0; 
 end; 
 else if SysBP_FV0 ge 130 then do; 
 HiSysBP =1; 
 HiSysBP_FV0 = 1; 
 end; 
do i = 1 to 15; 
 if . < SysBP_FV(i) < 130 then HiSysBP_a(i) = 0; 
 else if SysBP_FV(i) ge 130 then HiSysBP_a(i) =1; 
 end; 
 
if . < DiasBP_FV0 < 85 then do;  
 HiDiasBP = 0; 
 HiDiasBP_FV0 = 0; 
 end; 
 else if DiasBP_FV0 ge 85 then do; 
 HiDiasBP =1; 
 HiDiasBP_FV0 = 1; 
 end; 
do i = 1 to 15; 
 if . < DiasBP_FV(i) < 85 then HiDiasBP_a(i) = 0; 
 else if DiasBP_FV(i) ge 85 then HiDiasBP_a(i) =1; 
 end; 
 
keep HiSysBP  HiSysBP_FV0 - HiSysBP_FV15 
 HiDiasBP HiDiasBP_FV0 - HiDiasBP_FV15; 
 
drop WTBP32 - WTBP47 WTBP61-WTBP76; 
 
Page 57 of 110
 /*blood work labs*/ 
array ZLABB1_FV(15) ZLABB1_FV1-ZLABB1_FV15; 
array ZLABB4_FV(15) ZLABB4_FV1-ZLABB4_FV15; 
array ZLABB5_FV(15) ZLABB5_FV1-ZLABB5_FV15; 
array ZLABB6_FV(15) ZLABB6_FV1-ZLABB6_FV15; 
array ZLABB7_FV(15) ZLABB7_FV1-ZLABB7_FV15; 
array ZLABB8_FV(15) ZLABB8_FV1-ZLABB8_FV15; 
array ZLABB9_FV(15) ZLABB9_FV1-ZLABB9_FV15; 
array ZLABB10_FV(15) ZLABB10_FV1-ZLABB10_FV15; 
array ZLAB(120) ZLAB4-ZLAB18  
    ZLAB91-ZLAB105  
    ZLAB120-ZLAB134 
    ZLAB149-ZLAB163  
    ZLAB178-ZLAB192  
    ZLAB207-ZLAB221 
    ZLAB236-ZLAB250  
    ZLAB265-ZLAB279; 
ZLABB1_FV0 = ZLABB1; 
ZLABB4_FV0 = ZLABB4; 
ZLABB5_FV0 = ZLABB5; 
ZLABB6_FV0 = ZLABB6; 
ZLABB7_FV0 = ZLABB7; 
ZLABB8_FV0 = ZLABB8; 
ZLABB9_FV0 = ZLABB9; 
ZLABB10_FV0 = ZLABB10; 
do i=1 to 15; 
 if   ZLAB(i) ne .    then ZLABB1_FV(i) = ZLAB(i); 
 else if i = 1     then ZLABB1_FV(i) = ZLABB1_FV0; 
 else if i = 2 and  ZLAB(i-1) ne .  then ZLABB1_FV(i) = ZLABB1_FV1; 
 else if i > 2 then do;  
  if  ZLAB(i-1) ne .   then ZLABB1_FV(i) = ZLABB1_FV(i-1); 
  else if ZLAB(i-2) ne .   then ZLABB1_FV(i) = ZLABB1_FV(i-2); 
  else if ZLAB(i-2) = .   then ZLABB1_FV(i) = .; 
 end; 
end; 
do i=16 to 30; 
 if   ZLAB(i) ne .    then ZLABB4_FV(i-15) = ZLAB(i); 
 else if i = 16     then ZLABB4_FV(i-15) = ZLABB4_FV0; 
 else if i = 17 and  ZLAB(i-1) ne .  then ZLABB4_FV(i-15) = ZLABB4_FV1; 
 else if i > 17 then do;  
  if  ZLAB(i-1) ne .   then ZLABB4_FV(i-15) = ZLABB4_FV(i-16); 
  else if ZLAB(i-2) ne .   then ZLABB4_FV(i-15) = ZLABB4_FV(i-17); 
  else if ZLAB(i-2) = .   then ZLABB4_FV(i-15) = .; 
 end; 
end; 
do i=31 to 45; 
 if   ZLAB(i) ne .    then ZLABB5_FV(i-30) = ZLAB(i); 
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 else if i = 31     then ZLABB5_FV(i-30) = ZLABB5_FV0; 
 else if i = 32 and  ZLAB(i-1) ne .  then ZLABB5_FV(i-30) = ZLABB5_FV1; 
 else if i > 32 then do;  
  if  ZLAB(i-1) ne .   then ZLABB5_FV(i-30) = ZLABB5_FV(i-31); 
  else if ZLAB(i-2) ne .   then ZLABB5_FV(i-30) = ZLABB5_FV(i-32); 
  else if ZLAB(i-2) = .   then ZLABB5_FV(i-30) = .; 
 end; 
end; 
do i=46 to 60; 
 if   ZLAB(i) ne .    then ZLABB6_FV(i-45) = ZLAB(i); 
 else if i = 46     then ZLABB6_FV(i-45) = ZLABB6_FV0; 
 else if i = 47 and  ZLAB(i-1) ne .  then ZLABB6_FV(i-45) = ZLABB6_FV1; 
 else if i > 47 then do;  
  if  ZLAB(i-1) ne .   then ZLABB6_FV(i-45) = ZLABB6_FV(i-46); 
  else if ZLAB(i-2) ne .   then ZLABB6_FV(i-45) = ZLABB6_FV(i-47); 
  else if ZLAB(i-2) = .   then ZLABB6_FV(i-45) = .; 
 end; 
end; 
do i=61 to 75; 
 if   ZLAB(i) ne .    then ZLABB7_FV(i-60) = ZLAB(i); 
 else if i = 61     then ZLABB7_FV(i-60) = ZLABB7_FV0; 
 else if i = 62 and  ZLAB(i-1) ne .  then ZLABB7_FV(i-60) = ZLABB7_FV1; 
 else if i > 62 then do;  
  if  ZLAB(i-1) ne .   then ZLABB7_FV(i-60) = ZLABB7_FV(i-61); 
  else if ZLAB(i-2) ne .   then ZLABB7_FV(i-60) = ZLABB7_FV(i-62); 
  else if ZLAB(i-2) = .   then ZLABB7_FV(i-60) = .; 
 end; 
end; 
do i=76 to 90; 
 if   ZLAB(i) ne .    then ZLABB8_FV(i-75) = ZLAB(i); 
 else if i = 76     then ZLABB8_FV(i-75) = ZLABB8_FV0; 
 else if i = 77 and  ZLAB(i-1) ne .  then ZLABB8_FV(i-75) = ZLABB8_FV1; 
 else if i > 77 then do;  
  if  ZLAB(i-1) ne .   then ZLABB8_FV(i-75) = ZLABB8_FV(i-76); 
  else if ZLAB(i-2) ne .   then ZLABB8_FV(i-75) = ZLABB8_FV(i-77); 
  else if ZLAB(i-2) = .   then ZLABB8_FV(i-75) = .; 
 end; 
end; 
do i=91 to 105; 
 if   ZLAB(i) ne .    then ZLABB9_FV(i-90) = ZLAB(i); 
 else if i = 91     then ZLABB9_FV(i-90) = ZLABB9_FV0; 
 else if i = 92 and  ZLAB(i-1) ne .  then ZLABB9_FV(i-90) = ZLABB9_FV1; 
 else if i > 92 then do;  
  if  ZLAB(i-1) ne .   then ZLABB9_FV(i-90) = ZLABB9_FV(i-91); 
  else if ZLAB(i-2) ne .   then ZLABB9_FV(i-90) = ZLABB9_FV(i-92); 
  else if ZLAB(i-2) = .   then ZLABB9_FV(i-90) = .; 
 end; 
end; 
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do i=106 to 120; 
 if   ZLAB(i) ne .    then ZLABB10_FV(i-105) = ZLAB(i); 
 else if i = 106    then ZLABB10_FV(i-105) = ZLABB10_FV0; 
 else if i = 107 and  ZLAB(i-1) ne .  then ZLABB10_FV(i-105) = ZLABB10_FV1; 
 else if i > 107 then do;  
  if  ZLAB(i-1) ne .   then ZLABB10_FV(i-105) = ZLABB10_FV(i-106); 
  else if ZLAB(i-2) ne .   then ZLABB10_FV(i-105) = ZLABB10_FV(i-107); 
  else if ZLAB(i-2) = .   then ZLABB10_FV(i-105) = .; 
 end; 
end; 
 
 
HiBili =.; 
if ZLABB1 ge 0.5  then HiBili = 1; 
if . < ZLABB1 <  0.5  then HiBili = 0; 
array HiBili_FV(15) HiBili_FV1-HiBili_FV15; 
HiBili_FV0 = HiBili; 
do i=1 to 15; 
 if ZLABB1_FV(i) ge 0.5   then HiBili_FV(i) = 1; 
 if . < ZLABB1_FV(i) <  0.5  then HiBili_FV(i) = 0; 
 end; 
 
HiSerChol = .; 
if ZLABB4 ge 250  then HiSerChol = 1; 
if . < ZLABB4 <  250  then HiSerChol = 0; 
array HiSerChol_FV(15) HiSerChol_FV1-HiSerChol_FV15; 
HiSerChol_FV0 = HiSerChol; 
do i=1 to 15; 
 if ZLABB4_FV(i) ge 250   then HiSerChol_FV(i) = 1; 
 if . < ZLABB4_FV(i) <  250  then HiSerChol_FV(i) = 0; 
 end; 
 
HiSerTrigly = .; 
if ZLABB5 ge 5.0  then HiSerTrigly =1; 
if . < ZLABB5 <  5.0  then HiSerTrigly = 0; 
array HiSerTrigly_FV(15) HiSerTrigly_FV1-HiSerTrigly_FV15; 
HiSerTrigly_FV0 = HiSerTrigly; 
do i=1 to 15;  
 if ZLABB5_FV(i) ge 5.0   then HiSerTrigly_FV(i) = 1; 
 if . < ZLABB5_FV(i) <  5.0  then HiSerTrigly_FV(i) = 0; 
 end; 
 
HiSerUric = .; 
if ZLABB6 ge 7.0  then HiSerUric = 1; 
if . < ZLABB6 <  7.0  then HiSerUric = 0; 
array HiSerUric_FV(15) HiSerUric_FV1-HiSerUric_FV15; 
HiSerUric_FV0 = HiSerUric; 
do i=1 to 15; 
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 if ZLABB6_FV(i) ge 7.0   then HiSerUric_FV(i) = 1; 
 if . < ZLABB6_FV(i) <  7.0  then HiSerUric_FV(i) = 0; 
 end; 
 
HiSerAlk = .; 
if ZLABB7 ge 7.5  then HiSerAlk = 1; 
if . < ZLABB7 <  7.5  then HiSerAlk = 0; 
array HiSerAlk_FV(15) HiSerAlk_FV1-HiSerAlk_FV15; 
HiSerAlk_FV0 = HiSerAlk; 
do i=1 to 15; 
 if ZLABB7_FV(i) ge 7.5   then HiSerAlk_FV(i) = 1; 
 if . < ZLABB7_FV(i) <  7.5  then HiSerAlk_FV(i) = 0; 
 end; 
 
HiPlasUrea = .; 
if ZLABB8 ge 16  then HiPlasUrea = 1; 
if . < ZLABB8 <  16  then HiPlasUrea = 0; 
array HiPlasUrea_FV(15) HiPlasUrea_FV1-HiPlasUrea_FV15; 
HiPlasUrea_FV0 = HiPlasUrea; 
do i=1 to 15; 
 if ZLABB8_FV(i) ge 16   then HiPlasUrea_FV(i) = 1; 
 if . < ZLABB8_FV(i) <  16  then HiPlasUrea_FV(i) = 0; 
 end; 
 
HiFastGluc = .; 
if ZLABB9 ge 100  then HiFastGluc = 1; 
if . < ZLABB9 <  100  then HiFastGluc = 0; 
array HiFastGluc_FV(15) HiFastGluc_FV1-HiFastGluc_FV15; 
HiFastGluc_FV0 = HiFastGluc; 
do i=1 to 15; 
 if ZLABB9_FV(i) ge 100   then HiFastGluc_FV(i) = 1; 
 if . < ZLABB9_FV(i) <  100  then HiFastGluc_FV(i) = 0; 
 end; 
 
HiOneGluc = .; 
if ZLABB10 ge 180  then HiOneGluc = 1; 
if . < ZLABB10 <  180  then HiOneGluc = 0; 
array HiOneGluc_FV(15) HiOneGluc_FV1-HiOneGluc_FV15; 
HiOneGluc_FV0 = HiOneGluc; 
do i=1 to 15; 
 if ZLABB10_FV(i) ge 180  then HiOneGluc_FV(i) = 1; 
 if . < ZLABB10_FV(i) <  180  then HiOneGluc_FV(i) = 0; 
 end; 
 
keep  HiBili   HiBili_FV0-HiBili_Fv15 
 HiSerChol  HiSerChol_FV0-HiSerChol_FV15 
 HiSerTrigly  HiSerTrigly_FV0-HiSerTrigly_FV15 
 HiSerUric  HiSerUric_FV0-HiSerUric_FV15 
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 HiSerAlk  HiSerAlk_FV0-HiSerAlk_FV15 
 HiPlasUrea HiPlasUrea_FV0-HiPlasUrea_FV15 
 HiFastGluc  HiFastGluc_FV0-HiFastGluc_FV15  
 HiOneGluc  HiOneGluc_FV0-HiOneGluc_FV15 
 ; 
 
drop  ZLAB4-ZLAB18  
    ZLAB91-ZLAB105  
    ZLAB120-ZLAB134 
    ZLAB149-ZLAB163  
    ZLAB178-ZLAB192  
    ZLAB207-ZLAB221 
    ZLAB236-ZLAB250  
    ZLAB265-ZLAB279; 
 
array WBC1_FV(17) WBC1_FV1 - WBC1_FV17; 
array WBC12_FV(17) WBC12_FV1 - WBC12_FV17; 
array WBC23_FV(17) WBC23_FV1 - WBC23_FV17; 
array WBC(33) WBC1-WBC33; 
WBC1_FV0 = WBC1; 
WBC1_FV1 = WBC1; 
WBC1_FV2 = WBC1; 
do i = 2 to 6; 
 if WBC(i) ne . then do; 
  WBC1_FV((i-1)*3) = WBC(i); 
  WBC1_FV((i-1)*3+1) = WBC(i); 
  WBC1_FV((i-1)*3+2) = WBC(i); 
  end; 
 else do; 
  WBC1_FV((i-1)*3) = .; 
  WBC1_FV((i-1)*3+1) = .; 
  WBC1_FV((i-1)*3+2) = .; 
  end; 
end; 
WBC12_FV0 = WBC12; 
WBC12_FV1 = WBC12; 
WBC12_FV2 = WBC12; 
do i = 13 to 17; 
 if WBC(i) ne . then do; 
  WBC12_FV((i-12)*3) = WBC(i); 
  WBC12_FV((i-12)*3+1) = WBC(i); 
  WBC12_FV((i-12)*3+2) = WBC(i); 
  end; 
 else do; 
  WBC12_FV((i-12)*3) = .; 
  WBC12_FV((i-12)*3+1) = .; 
  WBC12_FV((i-12)*3+2) = .; 
  end; 
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end; 
WBC23_FV0 = WBC23; 
WBC23_FV1 = WBC23; 
WBC23_FV2 = WBC23; 
do i = 24 to 28; 
 if WBC(i) ne . then do; 
  WBC23_FV((i-23)*3) = WBC(i); 
  WBC23_FV((i-23)*3+1) = WBC(i); 
  WBC23_FV((i-23)*3+2) = WBC(i); 
  end; 
 else do; 
  WBC23_FV((i-23)*3) = .; 
  WBC23_FV((i-23)*3+1) = .; 
  WBC23_FV((i-23)*3+2) = .; 
  end; 
end; 
 
 
HiWhiteCell = .; 
if WBC1 ge 7500   then HiWhiteCell = 1; 
if . <  WBC1 <  7500  then HiWhiteCell = 0; 
array HiWhiteCell_FV(15) HiWhiteCell_FV1-HiWhiteCell_FV15; 
HiWhiteCell_FV0 = HiWhiteCell; 
do i=1 to 15; 
 if WBC1_FV(i) ge 7500   then HiWhiteCell_FV(i) = 1; 
 if . < WBC1_FV(i) <  7500  then HiWhiteCell_FV(i) = 0; 
 end; 
 
HiNeut = .; 
if WBC12 ge 4500   then HiNeut = 1; 
if . <  WBC12 <  4500  then HiNeut = 0; 
array HiNeut_FV(15) HiNeut_FV1-HiNeut_FV15; 
HiNeut_FV0 = HiNeut; 
do i=1 to 15; 
 if WBC12_FV(i) ge 4500  then HiNeut_FV(i) = 1; 
 if . < WBC12_FV(i) <  4500  then HiNeut_FV(i) = 0; 
 end; 
 
HiHemat = .; 
if WBC23 ge 46    then HiHemat = 1; 
if . <  WBC23 <  46  then HiHemat = 0; 
array HiHemat_FV(15) HiHemat_FV1-HiHemat_FV15; 
HiHemat_FV0 = HiHemat; 
do i=1 to 15; 
 if WBC23_FV(i) ge 46   then HiHemat_FV(i) = 1; 
 if . < WBC23_FV(i) <  46  then HiHemat_FV(i) = 0; 
 end; 
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keep HiWhiteCell HiWhiteCell_FV0-HiWhiteCell_FV15 
 HiNeut  HiNeut_FV0-HiNeut_FV15 
 HiHemat  HiHemat_FV0-HiHemat_FV15 
 ; 
 
drop WBC1-WBC33; 
 
 
/*Other covariates*/ 
array ICG_FV(17) ICG_FV1 - ICG_FV17; 
array ICG(6) ICG1 - ICG6; 
ICG_FV0 = ICG1; 
ICG_FV1 = ICG1; 
ICG_FV2 = ICG1; 
do i = 2 to 6; 
 if ICG(i) ne . then do; 
  ICG_FV((i-1)*3) = ICG(i); 
  ICG_FV((i-1)*3+1) = ICG(i); 
  ICG_FV((i-1)*3+2) = ICG(i); 
  end; 
 else do; 
  ICG_FV((i-1)*3) = .; 
  ICG_FV((i-1)*3+1) = .; 
  ICG_FV((i-1)*3+2) = .; 
  end; 
end; 
 
CIG = .; 
if ICG1 = 1    then CIG = 0; 
if ICG1 in (2,3,4,5,6)  then CIG = 1; 
keep CIG; 
array CIG_FV(15) CIG_FV1 - CIG_FV15; 
CIG_FV0 = CIG; 
do i = 1 to 15; 
 if ICG_FV(i) = 1   then CIG_FV(i) = 0; 
 if ICG_FV(i) in (2,3,4,5,6) then CIG_FV(i) = 1; 
 end; 
keep CIG_FV0 - CIG_FV15; 
drop ICG1 - ICG6; 
 
 
 
array IJOB_FV(17) IJOB_FV1 - IJOB_FV17; 
array IJOB(6) IJOB34 - IJOB39; 
IJOB_FV0 = IJOB34; 
IJOB_FV1 = IJOB34; 
IJOB_FV2 = IJOB34; 
do i = 2 to 6; 
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 if IJOB(i) ne . then do; 
  IJOB_FV((i-1)*3) = IJOB(i); 
  IJOB_FV((i-1)*3+1) = IJOB(i); 
  IJOB_FV((i-1)*3+2) = IJOB(i); 
  end; 
 else do; 
  IJOB_FV((i-1)*3) = .; 
  IJOB_FV((i-1)*3+1) = .; 
  IJOB_FV((i-1)*3+2) = .; 
  end; 
end; 
 
 
INACT =.; 
if IJOB34 = 1 then INACT = 1; 
if IJOB34 = 2 then INACT = 0; 
if IJOB34 = 3 then INACT = 0; 
keep INACT; 
array INACT_FV(15) INACT_FV1 - INACT_FV15; 
INACT_FV0 = INACT; 
do i=1 to 15; 
 if IJOB_FV(i) = 1 then INACT_FV(i) = 1; 
 if IJOB_FV(i) = 2 then INACT_FV(i) = 0; 
 if IJOB_FV(i) = 3 then INACT_FV(i) = 0; 
 end; 
keep INACT_FV0-INACT_FV15; 
drop  IJOB34 - IJOB39; 
 
 
/*******Adherence measures************/ 
 
/*Notes on visit number: */ 
/*icap1-26 prescription made at FV1-26*/ 
/*caps1-26 prescription made for baseline, FV1-25*/ 
/*iadh1-26; adh1-26 adherence observed at baseline, fv1 - 25*/ 
array inv_a(*)  inv1 - inv24; 
array iadh(26)  iadh1-iadh26; 
array caps(26)  caps1-caps26; 
array capsFV(*) capsFV1 - capsFV26; 
array adh(52)   adh1-adh52; 
array adhFV(26) adhFV0 -adhFV25; 
 
/*clear adherence variable to recalculate*/ 
do i = 2 to 52; 
 adh(i) = .; 
end; 
 
/*Pre-baseline adherence: adherence to placebo assessed pre-randomization for all participants*/ 
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if JADH1 ne . and JADH2 ne . then adhpre0 = (JADH1 + JADH2)/2; 
else if JADH1 = . and JADH2 ne . then adhpre0 = JADH2; 
else if JADH1 ne . and JADH2 = . then adhpre0 = JADH1; 
else if JADH1 = . and JADH2 = .  then adhpre0 = .; 
 
adhpre0bin = .; 
if adhpre0 ge 80 then adhpre0bin  = 0; 
if .< adhpre0 <80 then adhpre0bin  = 1; 
 
/*Follow-up: calculate adherence at each time point*/ 
 
do i = 1 to 26; 
 capsFV(i) = caps(i); 
 if caps(i) = . then do; 
  if i = 2 then capsFV(i) = 9; 
  else if caps(i-1) ne . then capsFV(i) = caps(i-1); 
  else if caps(i-1) = . then do; 
   if i > 2 then capsFV(i) = caps(i-2); 
  end; 
 end; 
end; 
 
do i=2 to 26;  
 if invdth = 0 or i le invdth then do; 
  if . < iadh(i) < 6 then adh(i)=(capsFV(i)/9)*(110-iadh(i)*20); 
  else if iadh(i)= 6 then adh(i)=0;    /*if no prescription, then adh = 0%*/ 
 end; 
 else if i > invdth then adh(i) = .; 
end; 
 
/*carry forward adherence for a maximum of three consecutive missed visits (carry forward 3 times 
because occurs b/f visit when measured);*/ 
array indic(*) indic1-indic15; 
indic0 = 0; 
 
do i = 1 to 15; 
 if adh(i) ne .    then adhFV(i) = adh(i); 
 else if i = 1    then  adhFV(i) = .; 
 else if i = 2    then  adhFV(i) = adhFV(i-1); 
 else if i = 3   then do; 
  if adh(i-1) ne .  then adhFV(i) = adh(i-1); 
  else if adh(i-2) ne . then adhFV(i) = adh(i-2); 
     else adhFV(i) = .; 
 end; 
 else if i = 4  then do; 
  if adh(i-1) ne .  then adhFV(i) = adh(i-1); 
  else if adh(i-2) ne . then adhFV(i) = adh(i-2); 
Page 66 of 110
  else if adh(i-2) = .  then adhFV(i) =.;        /*special case of censoring at visit 4 
because Adh0 can be measured at IV4 or IV5*/ 
 end; 
 else if i > 4  then do;  
  if adh(i-1) ne .  then adhFV(i) = adh(i-1); 
  else if adh(i-2) ne . then adhFV(i) = adh(i-2); 
  else if adh(i-3) ne . then adhFV(i) = adh(i-3); 
  else if adh(i-3) = .  then adhFV(i) = .; 
 end; 
  
 if i in (1,2,3)        then indic(i) = 0;   
 else if adh(i) = . and adh(i-1) = . and adh(i-2) ne .  then indic(i) = 1;  
 else if adh(i) = . and adh(i-1) = . and adh(i-2) = .   then indic(i) = .; 
 else         indic(i) = 0; 
 
 
 if invdth ne 0 and i ge invdth then do; 
  indic(i) = .; 
  adhFV(i) = .; 
 end; 
end; 
 
keep  adhFV0 -adhFV25 indic0-indic15 ; 
 
/*censoring indicator - adherence*/ 
/*censvisit = visit # when adherence first is missing or end of 5-year follow-up*/ 
censvisit = .; 
do i = 1 to 15; /*adh15 is adherence measured at visit 15 for the intervisit period 14-15 (last adherence 
before 5 years)*/ 
 if censvisit ne . then censvisit = censvisit; 
 else if censvisit = . then do; 
  if adhFV(i) = . then censvisit = i-1; 
  else if i < 15 and adhFV(i) ne . then censvisit = .; 
  else if i = 15 and adhFV(i) ne . then censvisit = 15; 
  end; 
 end; 
keep censvisit; 
 
/*For i = 27-52: ADH(i) = cumulative adherence from baseline to FV(x), x = 1-15*/ 
adh27=adhFV0; 
 
do i=2 to 15; 
 if adhFV(i) ne . then adh(26+i)=(adh(26+i-1)*(i-1)+adhFV(i))/i;  
 else adh(26+i) = .; 
 end; 
 
array adhbin_array(*)   adhbin0-adhbin25 adhbin27-adhbin42;  /*binary time-varying 
adherence level*/ 
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if     . < adhFV0 < 80 then adhbin0 = 1; 
else if     adhFV0 >=80 then adhbin0 = 0; 
else if     adhFV0 = .  then adhbin0 = .; 
 
do i=2 to 15; 
        if       . < adh(i) < 80 then adhbin_array(i) = 1; 
       else if     adh(i) >=80 then adhbin_array(i) = 0; 
       else if     adh(i) = .  then adhbin_array(i) = .; 
end; 
adhbin27 = adhbin0; 
do i=28 to 42; 
        if      . < adh(i) < 80 then adhbin_array(i) = 1; 
       else if     adh(i) >=80 then adhbin_array(i) = 0; 
 else if     adh(i) = .  then adhbin_array(i) = .; 
end; 
keep adhbin0-adhbin15 adhbin27-adhbin42; 
 
if dth5 = 1 and invdth = 0 then invdth = ceil(min(itd,itdx)*3/365); 
 
/*New variable: ADHX15. Cumulative average adherence at last visit before death or 5 years, whichever 
is first*/ 
if dth5 = 1 and invdth = 1     then adhx15 = adh27; 
else if dth5 = 1 and invdth > 0    then adhx15 = adh(26+(invdth-1)); 
else if dth5 = 1 and invdth = 0 and 0 < inv28 le 15  then adhx15 = adh(26+(inv_a(inv28))); 
else if dth5 ne 1      then adhx15 = adh(26+15); 
 
Adhx15Bin = .; 
if Adhx15 ge 80 then Adhx15Bin = 0; 
if .<Adhx15 <80 then Adhx15Bin = 1; 
keep Adhx15Bin adhx15; 
 
 
keep adhpre0bin adh1-adh52  ; 
 
 
/****Code adherence to match original paper, where adherence = 0 on all missed visits*****/ 
array inv(*) inv1-inv27; 
array old_adh(52) old_adh1-old_adh52; 
 
old_adh1 = adh1; 
if adh1 = . then old_adh1 = 0;  /*set adherence to 0 when missing*/ 
 
ihigh=2; 
if invdth=0 and inv28>14 then ihigh=inv28; 
if (istat=3 or istat=6) and lvss>ihigh then ihigh=lvss; 
if invdth>2 then ihigh=invdth-1; 
 
old_adh27=old_adh1; 
Page 68 of 110
do i=2 to ihigh; 
 if iadh(i)=6 then old_adh(i)=0;   /*if no prescription, then adh =0%*/ 
 else if inv(i)=0 or inv(i)=2 or inv(i)=7 or inv(i)=8 then old_adh(i)=0; 
 else if capsFV(i) = . or iadh(i) = . then old_adh(i) = 0; 
 else old_adh(i)= adh(i); 
 if old_adh(i) = . then old_adh(i) = 0; 
end; 
do i=2 to ihigh; 
 old_adh(26+i)=(old_adh(26+i-1)*(i-1)+old_adh(i))/i; 
end; 
keep old_adh1-old_adh52; 
 
old_adhx=old_adh(26+ihigh); 
old_adhx15=old_adhx; 
if ihigh>15 then old_adhx15=old_adh41; 
 
old_Adhx15Bin = .; 
if old_Adhx15 ge 80 then old_Adhx15Bin = 0; 
if .<old_Adhx15 <80 then old_Adhx15Bin = 1; 
keep old_Adhx15Bin old_adhx old_adhx15; 
 
run; 
 
proc freq data = cdp.binary nlevels; 
tables ID /noprint; 
title 'Before exclusion of missing baseline vars'; 
run; 
 
data cdp.binary; 
set cdp.binary; 
where adhbin0 ne . and age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_FV0 ne . and  HiSysBP_FV0  ne . and  HiDiasBP_FV0 ne . and   
HiWhiteCell_FV0 ne . and   HiNeut_FV0 ne . and   HiHemat_FV0   ne . and   
   HiBili_FV0 ne . and   HiSerChol_FV0  ne . and  HiSerTrigly_FV0  ne . and  
HiSerUric_FV0  ne . and  HiSerAlk_FV0  ne . and  HiPlasUrea_FV0  ne . and   
   HiFastGluc_FV0  ne . and  HiOneGluc_FV0  ne . and  HiHeart_FV0 ne . and   
CHF_FV0 ne . and   ACI_FV0  ne . and  AP_FV0 ne . and   
   IC_FV0  ne . and  ICIA_FV0 ne . and   DIG_FV0  ne . and  DIUR_FV0  ne . and  
AntiArr_FV0 ne . and   AntiHyp_FV0 ne . and   OralHyp_FV0  ne . and   
   CardioM_FV0 ne . and   AnyQQS_FV0 ne . and   AnySTDep_FV0  ne . and  
AnyTWave_FV0 ne . and   
   STElev_FV0 ne . and   FVEB_FV0 ne . and   VCD_FV0 ne . and   CIG_FV0 ne . and   
INACT_FV0 ne .; 
run; 
 
proc freq data = cdp.binary nlevels; 
tables ID /noprint; 
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title 'After exclusion of missing baseline vars'; 
run; 
 
/***************************************************/ 
/**Long format dataset for analysis of**************/ 
/**Censoring-Weighted Cumulative Adherence**********/ 
/***************************************************/ 
 
/*Convert data into observations for each follow-up visit*/ 
/*For censoring due to change in missing adherence only*/ 
/*As with baseline-only analysis, individuals with missing*/ 
/*covariates over time not censored - covariates carried */ 
/*forward from last recorded value for censoring weights*/ 
 
data cdp.censwt_ag; 
set cdp.binary; 
 
array adhbin_a(*)   adhbin0 - adhbin15; 
array adh(*)      adh1-adh16; 
array indic(*)   indic0 - indic15; 
 
array NIHA_FV_a(*)   NIHA_FV0 - NIHA_FV15;  
array HiSysBP_FV_a(*)   HiSysBP_FV0-HiSysBP_FV15; 
array HiDiasBP_FV_a(*)   HiDiasBP_FV0-HiDiasBP_FV15 ; 
array HiWhiteCell_FV_a(*)  HiWhiteCell_FV0-HiWhiteCell_FV15; 
array HiNeut_FV_a(*)  HiNeut_FV0-HiNeut_FV15;  
array HiHemat_FV_a(*)  HiHemat_FV0-HiHemat_FV15; 
array HiBili_FV_a(*)  HiBili_FV0-HiBili_FV15;  
array HiSerChol_FV_a(*)  HiSerChol_FV0-HiSerChol_FV15; 
array HiSerTrigly_FV_a(*)  HiSerTrigly_FV0-HiSerTrigly_FV15; 
array HiSerUric_FV_a(*)  HiSerUric_FV0-HiSerUric_FV15; 
array HiSerAlk_FV_a(*)  HiSerAlk_FV0-HiSerAlk_FV15;  
array HiPlasUrea_FV_a(*) HiPlasUrea_FV0-HiPlasUrea_FV15; 
array HiFastGluc_FV_a(*) HiFastGluc_FV0-HiFastGluc_FV15; 
array HiOneGluc_FV_a(*)  HiOneGluc_FV0-HiOneGluc_FV15; 
array HiHeart_FV_a(*)   HiHeart_FV0-HiHeart_FV15; 
array CHF_FV_a(*)  CHF_FV0-CHF_FV15; 
array ACI_FV_a(*)  ACI_FV0-ACI_FV15; 
array AP_FV_a(*)  AP_FV0-AP_FV15; 
array IC_FV_a(*)  IC_FV0-IC_FV15; 
array ICIA_FV_a(*)  ICIA_FV0-ICIA_FV15; 
array DIG_FV_a(*)  DIG_FV0-DIG_FV15; 
array DIUR_FV_a(*)  DIUR_FV0-DIUR_FV15; 
array AntiArr_FV_a(*)   AntiArr_FV0-AntiArr_FV15; 
array AntiHyp_FV_a(*)   AntiHyp_FV0-AntiHyp_FV15; 
array OralHyp_FV_a(*)   OralHyp_FV0-OralHyp_FV15; 
array CardioM_FV_a(*)   CardioM_FV0 - CardioM_FV15; 
array AnyQQS_FV_a(*)  AnyQQS_FV0-AnyQQS_FV15;  
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array AnySTDep_FV_a(*)  AnySTDep_FV0-AnySTDep_FV15; 
array AnyTwave_FV_a(*)  AnyTwave_FV0-AnyTwave_FV15; 
array STElev_FV_a(*)  STElev_FV0-STElev_FV15; 
array FVEB_FV_a(*)  FVEB_FV0-FVEB_FV15; 
array VCD_FV_a(*)  VCD_FV0-VCD_FV15; 
array CIG_FV_a(*)  CIG_FV0 - CIG_FV15; 
array INACT_FV_a(*)  INACT_FV0-INACT_FV15; 
 
 
do i = 1 to 15; 
 
 ind = indic(i); 
 
 visit = i-1; /*visit number: 0 = baseline, 1 = FV1, etc*/ 
  
 if i < 4 then do; 
  if invdth = 0 then do; 
   cens = -1; 
   p_cens0 = 1; 
 
   adhr_t = adhbin_a(i); 
 
   death = 0; 
 
   if i ge 2 then adhr_t1 = adhbin_a(i-1); 
   if i ge 3 then adhr_t2 = adhbin_a(i-2); 
  end; 
 
  else if i > invdth then do; 
   cens = .;  
   p_cens0 = .; 
   adhr_t = .; 
   death = .; 
  end; 
  else if i le invdth then do; 
   cens = -1; 
   p_cens0 = 1;  
  
   adhr_t = adhbin_a(i); 
 
   if invdth = i then death = 1;  
   else if  invdth > i then death = 0; 
    
   if death in (0,1) then do; 
    if i ge 2 then adhr_t1 = adhbin_a(i-1); 
    if i ge 3 then adhr_t2 = adhbin_a(i-2); 
   end; 
  end; 
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 end; 
 
 else if i ge 4 then do; 
  if indic(i) = 0  then do;  
   cens = -1;  
   p_cens0 = 1;  
 
   if invdth = i then death = 1;  
   else if invdth = 0 or invdth > i then death = 0; 
  end; 
  else if indic(i) = 1  then do;  
   if adh(i) = .       then cens = 1;  
   else if adh(i) ne . then cens = 0; 
   p_cens0 = .;  
  end; 
  else if indic(i) = .  then do;  
   cens = .;  
   p_cens0 = .;  
   death = .; 
  end; 
   
  /*current and baseline adherence*/ 
  if death in (0,1) then do;   
   adhr_t  = adhbin_a(i); 
 
   adhr_t1 = adhbin_a(i-1); 
   adhr_t2 = adhbin_a(i-2); 
   adhr_t3 = adhbin_a(i-3);      
  end; 
  else if death = . then do; 
   adhr_t = .;  
    
   adhr_t1 = .; 
   adhr_t2 = .; 
   adhr_t3 = .; 
  end; 
 end; 
 
 /*if death = 1 and i > 1 then adhr_t = adhbin_a(i-1);*/ 
  
 if death in (0,1) then do;  
  if adhr_t = . then adh_measure = 0; 
  else if adhr_t ne . then adh_measure = 1; 
 end; 
 else if death = . then adh_measure = .; 
 
 /*Save covariates for visit i*/ 
 NIHA_bin0 = NIHA_FV0; 
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 NIHAFV = NIHA_FV_a(i); 
 if i > 1 then NIHAFV_t1 = NIHA_FV_a(i-1); else NIHAFV_t1 = NIHA_bin0; 
  if NIHAFV_t1 = . then NIHAFV_t1 = NIHA_FV_a(i-2); 
  if NIHAFV_t1 = . then NIHAFV_t1 = NIHA_FV_a(i-3); 
 
 
 CHF0 = CHF_FV0;  
 ACI0 = ACI_FV0; 
 AP0 = AP_FV0; 
 IC0 = IC_FV0; 
 ICIA0 = ICIA_FV0; 
  
 CHFFV = CHF_FV_a(i); 
 ACIFV = ACI_FV_a(i); 
 APFV = AP_FV_a(i); 
 ICFV = IC_FV_a(i); 
 ICIAFV = ICIA_FV_a(i); 
 
 if i > 1 then CHFFV_t1 = CHF_FV_a(i-1);  else CHFFV_t1 = CHF0; 
 if i > 1 then ACIFV_t1 = ACI_FV_a(i-1);  else ACIFV_t1 = ACI0; 
 if i > 1 then APFV_t1 = AP_FV_a(i-1);  else APFV_t1 = AP0; 
 if i > 1 then ICFV_t1 = IC_FV_a(i-1);  else ICFV_t1 = IC0; 
 if i > 1 then ICIAFV_t1 = ICIA_FV_a(i-1); else ICIAFV_t1 = ICIA0; 
 
  if CHFFV_t1 = . then CHFFV_t1 = CHF_FV_a(i-2); 
  if ACIFV_t1 = . then ACIFV_t1 = ACI_FV_a(i-2); 
  if APFV_t1  = . then APFV_t1 = AP_FV_a(i-2); 
  if ICFV_t1  = . then ICFV_t1 = IC_FV_a(i-2); 
  if ICIAFV_t1 = . then ICIAFV_t1 = ICIA_FV_a(i-2); 
 
 DIG0 = DIG_FV0; 
 DIUR0 = DIUR_FV0; 
 AntiArr0 = AntiARR_FV0; 
 AntiHyp0 = AntiHyp_FV0; 
 OralHyp0 = OralHyp_FV0; 
 
 
 DIGFV = DIG_FV_a(i); 
 DIURFV = DIUR_FV_a(i); 
 AntiArrFV = AntiARR_FV_a(i); 
 AntiHypFV = AntiHyp_FV_a(i); 
 OralHypFV = OralHyp_FV_a(i); 
 
 if i > 1 then DIGFV_t1 = DIG_FV_a(i-1);   else DigFV_t1 = DIG0; 
 if i > 1 then DIURFV_t1 = DIUR_FV_a(i-1);  else DiurFV_t1 = DIUR0; 
 if i > 1 then AntiArrFV_t1 = AntiARR_FV_a(i-1);  else AntiArrFV_t1 = AntiArr0; 
 if i > 1 then AntiHypFV_t1 = AntiHyp_FV_a(i-1);  else AntiHypFV_t1 = AntiHyp0; 
 if i > 1 then OralHypFV_t1 = OralHyp_FV_a(i-1);  else OralHypFV_t1 = OralHyp0;  
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   if DIGFV_t1 = . then DIGFV_t1 = DIG_FV_a(i-2); 
  if DIURFV_t1 = . then DIURFV_t1 = DIUR_FV_a(i-2); 
  if AntiArrFV_t1  = . then AntiArrFV_t1 = AntiARR_FV_a(i-2); 
  if AntiHypFV_t1  = . then AntiHypFV_t1 = AntiHyp_FV_a(i-2); 
  if OralHypFV_t1 = . then OralHypFV_t1 = OralHyp_FV_a(i-2); 
 
  
 
 CardioM0 = CardioM_FV0; 
 CardioMFV = CardioM_FV_a(i); 
 if i > 1 then CardioMFV_t1 = CardioM_FV_a(i-1);  else CardioMFV_t1 = CardioM0; 
  if CardioMFV_t1 = . then CardioMFV_t1 = CardioM_FV_a(i-2); 
   
 
 AnyQQS0 = AnyQQS_FV0; 
 AnySTDep0 = AnySTDep_FV0; 
 AnyTWave0 = AnyTWave_FV0; 
 STElev0 = STElev_FV0; 
 FVEB0 = FVEB_FV0; 
 VCD0 = VCD_FV0; 
 HiHeart0 = HiHeart_FV0; 
 
 AnyQQSFV = AnyQQS_FV_a(i); 
 AnySTDepFV = AnySTDep_FV_a(i); 
 AnyTWaveFV = AnyTWave_FV_a(i); 
 STElevFV = STElev_FV_a(i); 
 FVEBFV = FVEB_FV_a(i); 
 VCDFV = VCD_FV_a(i); 
 HiHeartFV = HiHeart_FV_a(i); 
 
 if i > 1 then AnyQQSFV_t1 = AnyQQS_FV_a(i-1);  else AnyQQSFV_t1 = AnyQQS0; 
 if i > 1 then AnySTDepFV_t1 = AnySTDep_FV_a(i-1); else AnyStDepFV_t1 = AnyStDep0; 
 if i > 1 then AnyTWaveFV_t1 = AnyTWave_FV_a(i-1); else AnyTWaveFV_t1 = AnyTWave0; 
 if i > 1 then STElevFV_t1 = STElev_FV_a(i-1);  else StElevFV_t1 = StElev0; 
 if i > 1 then FVEBFV_t1 = FVEB_FV_a(i-1);  else FVEBFV_t1 = FVEB0; 
 if i > 1 then VCDFV_t1 = VCD_FV_a(i-1);   else VCDFV_t1 = VCD0; 
 if i > 1 then HiHeartFV_t1 = HiHeart_FV_a(i-1);  else HiHeartFV_t1 = HiHeart0; 
 
  if AnyQQSFV_t1 = . then AnyQQSFV_t1 = AnyQQS_FV_a(i-2); 
  if AnySTDepFV_t1 = . then AnySTDepFV_t1 = AnySTDep_FV_a(i-2); 
  if AnyTWaveFV_t1 = . then AnyTWaveFV_t1 = AnyTWave_FV_a(i-2); 
  if STElevFV_t1  = . then STElevFV_t1 = STElev_FV_a(i-2); 
  if FVEBFV_t1  = . then  FVEBFV_t1 = FVEB_FV_a(i-2); 
  if VCDFV_t1 = . then  VCDFV_t1 = VCD_FV_a(i-2); 
  if HiHeartFV_t1 = . then  HiHeartFV_t1 = HiHeart_FV_a(i-2); 
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  HiBili0 = HiBili_FV0; 
 HiSerChol0 = HiSerChol_FV0; 
 HiSerTrigly0 = HiSerTrigly_FV0; 
 HiSerUric0 = HiSerUric_FV0;  
 HiSerAlk0 = HiSerAlk_FV0; 
 HiPlasUrea0 = HiPlasUrea_FV0; 
 HiFastGluc0 = HiFastGluc_FV0; 
 HiOneGluc0 = HiOneGluc_FV0; 
 
 HiBiliFV = HiBili_FV_a(i); 
 HiSerCholFV = HiSerChol_FV_a(i); 
 HiSerTriglyFV = HiSerTrigly_FV_a(i); 
 HiSerUricFV = HiSerUric_FV_a(i); 
 HiSerAlkFV = HiSerAlk_FV_a(i); 
 HiPlasUreaFV = HiPlasUrea_FV_a(i); 
 HiFastGlucFV = HiFastGluc_FV_a(i); 
 HiOneGlucFV = HiOneGluc_FV_a(i); 
 
 if i > 1 then HiBiliFV_t1 = HiBili_FV_a(i-1);  else HiBiliFV_t1 = HiBili0; 
 if i > 1 then HiSerCholFV_t1 = HiSerChol_FV_a(i-1); else HiSerCholFV_t1 = HiSerChol0; 
 if i > 1 then HiSerTriglyFV_t1 = HiSerTrigly_FV_a(i-1); else HiSerTriglyFV_t1 = HiSerTrigly0; 
 if i > 1 then HiSerUricFV_t1 = HiSerUric_FV_a(i-1); else HiSerUricFV_t1 = HiSerUric0; 
 if i > 1 then HiSerAlkFV_t1 = HiSerAlk_FV_a(i-1); else HiSerAlkFV_t1 = HiSerAlk0; 
 if i > 1 then HiPlasUreaFV_t1 = HiPlasUrea_FV_a(i-1); else HiPlasUreaFV_t1 = HiPlasUrea0; 
 if i > 1 then HiFastGlucFV_t1 = HiFastGluc_FV_a(i-1); else HiFastGlucFV_t1 = HiFastGluc0; 
 if i > 1 then HiOneGlucFV_t1 = HiOneGluc_FV_a(i-1); else HiOneGlucFV_t1 = HiOneGluc0; 
 
  if HiBiliFV_t1 = . then HiBiliFV_t1 = HiBili_FV_a(i-2); 
  if HiSerCholFV_t1 = . then HiSerCholFV_t1 = HiSerChol_FV_a(i-2); 
  if HiSerTriglyFV_t1 = . then HiSerTriglyFV_t1 = HiSerTrigly_FV_a(i-2); 
  if HiSerUricFV_t1 = . then HiSerUricFV_t1 = HiSerUric_FV_a(i-2); 
  if HiSerAlkFV_t1 = . then  HiSerAlkFV_t1 = HiSerAlk_FV_a(i-2); 
  if HiPlasUreaFV_t1 = . then  HiPlasUreaFV_t1 = HiPlasUrea_FV_a(i-2); 
  if HiFastGlucFV_t1 = . then  HiFastGlucFV_t1 = HiFastGluc_FV_a(i-2); 
  if HiOneGlucFV_t1 = . then  HiOneGlucFV_t1 = HiOneGluc_FV_a(i-2); 
 
 
 
 HiSysBP0 = HiSysBP_FV0; 
 HiDiasBP0 = HiDiasBP_FV0; 
 
 HiSysBPFV = HiSysBP_FV_a(i); 
 HiDiasBPFV = HiDiasBP_FV_a(i); 
 
 if i > 1 then HiSysBPFV_t1 = HiSysBP_FV_a(i-1);  else HiSysBPFV_t1 = HiSysBP0; 
 if i > 1 then HiDiasBPFV_t1 = HiDiasBP_FV_a(i-1); else HiDiasBPFV_t1 = HiDiasBP0; 
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  if HiSysBPFV_t1  = . then HiSysBPFV_t1 = HiSysBP_FV_a(i-2); 
  if HiDiasBPFV_t1 = . then  HiDiasBPFV_t1 = HiDiasBP_FV_a(i-2); 
 
 
 CIG0 = CIG_FV0; 
 INACT0 = INACT_FV0;  
 
 CIGFV = CIG_FV_a(i); 
 INACTFV = INACT_FV_a(i); 
 
 if i > 1 then CIGFV_t1 = CIG_FV_a(i-1);  else CIGFV_t1 = CIG0; 
 if i > 1 then INACTFV_t1 = INACT_FV_a(i-1);  else InactFV_t1 = Inact0; 
 
  if CIGFV_t1 = . then CIGFV_t1 = CIG_FV_a(i-2); 
  if INACTFV_t1 = . then INACTFV_t1 = INACT_FV_a(i-2); 
 
 
 
 
 HiWhiteCell0 = HiWhiteCell_FV0; 
 HiNeut0  = HiNeut_FV0; 
 HiHemat0  = HiHemat_FV0; 
 
 HiWhiteCellFV = HiWhiteCell_FV_a(i); 
 HiNeutFV  = HiNeut_FV_a(i); 
 HiHematFV = HiHemat_FV_a(i); 
 
 if i > 1 then HiWhiteCellFV_t1 = HiWhiteCell_FV_a(i-1); else HiWhiteCellFV_t1 = HiWhiteCell0; 
 if i > 1 then HiNeutFV_t1 = HiNeut_FV_a(i-1);   else HiNeutFV_t1 = HiNeut0; 
 if i > 1 then HiHematFV_t1 = HiHemat_FV_a(i-1);   else HiHematFV_t1 = 
HiHemat0; 
 
  if HiWhiteCellFV_t1 = . then HiWhiteCellFV_t1 = HiWhiteCell_FV_a(i-2); 
  if HiNeutFV_t1 = . then HiNeutFV_t1 = HiNeut_FV_a(i-2); 
  if HiHematFV_t1 = . then HiHematFV_t1 = HiHemat_FV_a(i-2); 
 
   
 
 keep ID istat visit dth5 invdth  
 Adhx15Bin itr entrydate death 
 
  adhbin0  adhr_t adhr_t1 adhr_t2 adhr_t3 cens p_cens0  adh_measure 
  
 adh1-adh16 adhbin0-adhbin15 indic0 - indic15 ind 
 
 
 adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin age_cat 
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   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 
   
   NIHAFV HiSysBPFV HiDiasBPFV HiWhiteCellFV HiNeutFV HiHematFV  
   HiBiliFV HiSerCholFV HiSerTriglyFV HiSerUricFV HiSerAlkFV 
   HiPlasUreaFV HiFastGlucFV HiOneGlucFV HiHeartFV  
   CHFFV ACIFV APFV ICFV ICIAFV DIGFV DIURFV AntiArrFV  
   AntiHypFV OralHypFV CardioMFV AnyQQSFV AnySTDepFV 
   AnyTWaveFV STElevFV FVEBFV VCDFV 
   CIGFV INACTFV  
 
   NIHAFV_t1 HiSysBPFV_t1 HiDiasBPFV_t1 HiWhiteCellFV_t1 HiNeutFV_t1 
HiHematFV_t1   
   HiBiliFV_t1 HiSerCholFV_t1 HiSerTriglyFV_t1 HiSerUricFV_t1 HiSerAlkFV_t1  
   HiPlasUreaFV_t1 HiFastGlucFV_t1 HiOneGlucFV_t1 HiHeartFV_t1  
   CHFFV_t1 ACIFV_t1 APFV_t1 ICFV_t1 ICIAFV_t1 DIGFV_t1 DIURFV_t1 
AntiArrFV_t1  
   AntiHypFV_t1 OralHypFV_t1 CardioMFV_t1 AnyQQSFV_t1 AnySTDepFV_t1  
   AnyTWaveFV_t1 STElevFV_t1 FVEBFV_t1 VCDFV_t1 
   CIGFV_t1 INACTFV_t1  ; 
 
 output; 
end; 
run; 
 
data cdp.censwt_ag; 
 set cdp.censwt_ag; 
 
 if death ne . then output; 
run; 
 
 
 
/****************************************************/ 
/**Program 2: Replicate Analysis of 1980 NEJM paper**/ 
/****************************************************/ 
/*Note: adherence = 0 for missed visits*************/ 
/*%difference and 95%CI based on 500 bootstraps*****/ 
/***************************************************/ 
 
libname cdp "</path/>"; 
 
/*A. Unadjusted 1980 analysis*/ 
%macro partA_unadjusted(outdest = , inset=, titlemain =, nboot = , lib = ); 
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 proc printto print = &outdest; 
run; 
 
%let rawdata = &lib..&inset; 
 
/******A.1. Unadjusted*********************/ 
/*Original coding for missing adherence (missed visits: adherence = 0)*/ 
 
title &titlemain; 
 
/*Tabulate Unadjusted Probabilities*/ 
 
proc freq data = &rawdata; 
 tables old_adhx15bin*dth5 / nopercent nocol cl binomial riskdiff; 
run; 
 
 
%mend partA_unadjusted; 
 
 
/*B. Adjusted via linear regression, baseline covariates only*/ 
%macro partA_adjusted(nboot = , outdest = , inset=, titlemain =, lib=, adhvar = ); 
 
proc printto print = &outdest; 
run; 
 
%let rawdata = &lib..&inset; 
 
/******b. Adjusted: linear regression*****/ 
title &titlemain; 
 
data onesample ;    
  set &rawdata end = _end_  ; 
   retain _id ; 
  if _n_ = 1 then _id = 0; 
  _id = _id + 1 ; 
  if _end_ then do ; 
     call symput("nids",trim(left(_id))); 
  end; 
  label adher= "Adherence";  
  adher = -1 ;    /* 1st copy: equal to original one */ 
   output ;  
  adher = 0 ;     /* 2nd copy: adherence set to 0, outcome to missing */ 
   &adhvar = 0 ; 
   dth5 = . ; 
   output ;   
  adher = 1 ;     /* 3rd copy: adherence set to 1, outcome to missing*/ 
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   &adhvar = 1 ; 
   dth5 = . ; 
   output ; 
run; 
 
 
data ids ; 
 do bsample = 1 to &nboot  ; 
         do _id = 1 to &nids ;         
           output ; 
  end; 
 end; 
run; 
 
proc surveyselect data= ids  
        method = urs 
        n= &nids 
        seed = 1232   
        out = _idsamples (keep = bsample _id  numberhits  )  
        outall  noprint  ; 
strata bsample ; 
run; 
 
%do bsample =  0 %to &nboot ;    
 
 %if %eval(&bsample) = 0 %then %do; 
  proc reg data = onesample plots=none outest = est0; 
   model dth5 = &adhvar  
   age_bin nonwhite IRK MI_bin NIHA_bin1 RBW_bin 
   CHF ACI AP IC ICIA DIG DIUR AntiArr AntiHyp OralHyp  
   CardioM AnyQQS AnySTDep AnyTWave STElev FVEB VCD  
   HiHeart HiDiasBP HiSySBP HiBili HiSerChol HiSerTrigly HiSerUric HiSerAlk  
   HiPlasUrea HiFastGluc HiOneGluc HiWhiteCell HiNeut HiHemat Cig Inact  ; 
     output out = predicted_mean0 (keep = id &adhvar adher meanY) p = meanY ; 
  run; 
  quit; 
 
  data params; 
   set est0 ; 
   bsample = 0 ; 
   keep &adhvar bsample; 
  run; 
 
  data predicted_mean; 
   set predicted_mean0 ; 
   bsample = 0 ; 
   numberhits = 1 ; 
  run; 
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  proc datasets library = work nolist; 
   delete est0 predicted_mean0; 
  run; 
 %end; 
 
 %else %do; 
 
  data bootsample; 
   merge onesample _idsamples (where= (bsample = &bsample ));   
   by _id; 
  run; 
   
  ods listing select none ; 
  proc reg data=bootsample plots = none outest = est1; 
        model dth5 = &adhvar  
   age_bin nonwhite IRK MI_bin NIHA_bin1 RBW_bin 
   CHF ACI AP IC ICIA DIG DIUR AntiArr AntiHyp OralHyp  
   CardioM AnyQQS AnySTDep AnyTWave STElev FVEB VCD  
   HiHeart HiDiasBP HiSySBP HiBili HiSerChol HiSerTrigly HiSerUric HiSerAlk  
   HiPlasUrea HiFastGluc HiOneGluc HiWhiteCell HiNeut HiHemat Cig Inact  ; 
       freq numberhits; 
       output out = predicted_mean1 (keep = bsample id &adhvar adher meanY 
numberhits) p = meanY;  
  run;   
  quit; 
  ods listing ; 
  
  data est1; 
   set est1; 
   bsample = %eval(&bsample); 
   keep &adhvar bsample; 
  run; 
  
  data params ; 
   set params est1; 
   by bsample ; 
  run; 
 
 
  data predicted_mean; 
   set predicted_mean predicted_mean1; 
   by bsample ; 
  run; 
  
  proc datasets library = work nolist; 
   delete est1 predicted_mean1 bootsample; 
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  run; 
 %end; 
 
%end; 
 
 
proc sort data = params; 
 by bsample &adhvar; 
run; 
 
proc sort data = predicted_mean ; 
 by bsample adher; 
run; 
 
 
/*Risk Difference and Confidence Intervals*/ 
data temp; 
 set params (where=(bsample = 0)); 
 call symput("rd",&adhvar); 
run; 
proc univariate data=params (where = (bsample > 0)) noprint; 
 var &adhvar; 
 output out = stderrs 
 std = rd_std; 
run; 
data temp; 
 set stderrs; 
 call symput("std",rd_std); 
run; 
data final_1980Bbin; 
 mean = &rd; 
 std = &std; 
 lb = mean - 1.96 * std ; 
 ub = mean + 1.96 * std ; 
 label lb="95% Lower bound" 
           ub="95% Upper bound" 
             std="Standard Error" 
      ; 
run; 
 
 
/*Standardized risks and confidence intervals*/ 
proc means data = predicted_mean mean noprint ;  
  var meanY;   
  by bsample adher; 
  freq numberhits ;  
  output out = results0 (keep = bsample adher mean ) mean = mean ; 
run; 
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 proc transpose data=results0 out=results1b prefix=Risk_; 
 by bsample; 
 id adher; 
 var mean; 
run; 
 
data results3; 
 set results1b; 
 rd = Risk_1 - Risk_0; 
run; 
 
 
data temp3; 
 set results3 (where=(bsample = 0)); 
 call symput("Ard",rd); 
 call symput("ARisk0", Risk_0); 
 call symput("ARisk1", Risk_1); 
run; 
proc univariate data=results3 (where = (bsample > 0)) noprint; 
 var Risk_0 Risk_1; 
 output out = stderrs3 
 std = Risk0_std Risk1_std; 
run; 
 
data temp3; 
 set stderrs3; 
 call symput("ARisk0std",risk0_std); 
 call symput("ARisk1std",risk1_std); 
 
run; 
data final_predB; 
 RDmean = &Ard; 
 HiAd = &ARisk0; 
 HiAdstd = &ARisk0std; 
 HiAdlb = HiAd - 1.96 * HiAdstd ; 
 HiAdub = HiAd + 1.96 * HiAdstd ; 
 LoAd = &ARisk1; 
 LoAdstd = &ARisk1std; 
 LoAdlb = LoAd - 1.96 * LoAdstd ; 
 LoAdub = LoAd + 1.96 * LoAdstd ; 
        label HiADlb="95% Lower bound >80% Adh" 
           HiADub="95% Upper bound >80% Adh" 
       LoADlb="95% Lower bound <80% Adh" 
           LoADub="95% Upper bound <80% Adh" 
 ; 
run; 
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 /*Print Results*/ 
proc printto print = &outdest; 
run; 
proc print data = final_1980Bbin label noobs ; 
title2 "Bootstrap results using &nboot samples" ; 
title3 "Linear Regression, Placebo Arm"; 
title4 "<80% Adherence vs >=80% Adherence"; 
 var mean std lb ub; 
run; 
 
proc print data = final_predB label noobs ; 
title2 "Bootstrap results using &nboot samples" ; 
title3 "Linear Regression, Placebo Arm"; 
title4 "<80% Adherence vs >=80% Adherence"; 
 var RDmean HiAd HiAdlb HiAdub LoAd LoAdlb LoAdub; 
run; 
 
proc datasets library=work nolist; 
 delete Ids Onesample  
  params predicted_mean 
 results0 results1b results3 
 stderrs temp test _idsamples 
 temp2 temp3 stderrs3 
 ;  
quit; 
 
 
 
proc printto; 
run; 
%let timenow2=%sysfunc(time(), time.); 
%let datenow2=%sysfunc(date(), date9.); 
%put Part A is Complete; 
%put End time is &datenow2 / &timenow2 ; 
%put ; 
 
 
%mend partA_adjusted; 
 
/*****RUN MACROS***/ 
%let nboot = 50; 
 
%partA_unadjusted( outdest = "PartA.Unadj.final.rtf", inset = binary, titlemain = "Unadjusted, 1980 
Replication, Missed Adherence = 0",  
  nboot = &nboot, lib = cdp); 
 
/*original 1980 adherence definition*/ 
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%partA_adjusted( outdest = "PartA.Adj.linear.final.rtf", inset = binary,  
 titlemain = 'Adjusted, 1980 Replication, Missed Adherence = 0',  nboot = &nboot, lib=cdp, 
adhvar = old_adhx15bin); 
 
 
/*updated adherence definition*/ 
%partA_adjusted( outdest = "PartB.Adj.linear.final.rtf", inset = binary,  
 titlemain = 'Adjusted, 1980 Replication, Missed Adherence = 0',  nboot = &nboot, lib=cdp, 
adhvar = adhx15bin); 
 
 
 
 
/*****************************************************/ 
/**Program 3: New Analyses: Baseline Covariates Only**/ 
/*****************************************************/ 
/*Note: adherence carried forward 2 missed visits****/ 
/*%difference and 95%CI based on 500 bootstraps******/ 
/*Crude and Standardized estimates*******************/ 
/****************************************************/ 
 
libname cdp "</path/>"; 
 
%macro partB_unadjusted(outdest = , inset = , titlemain = , nboot=, lib=); 
proc printto print = &outdest; 
run; 
%let rawdata = &lib..&inset; 
 
/******a. Unadjusted*********************/ 
title &titlemain; 
 
/*Tabulate Unadjusted Probabilities*/ 
 
proc freq data = &rawdata; 
 tables adhx15bin*dth5 / nopercent nocol cl binomial riskdiff; 
run; 
 
 
%mend partB_unadjusted; 
 
 
%macro partB_adjusted(outdest = , inset = , titlemain = , nboot=, lib=, adhvar = ); 
 
 
/******b. Adjusted*********************/ 
 
%let rawdata = &lib..&inset; 
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title &titlemain; 
 
proc format ; 
   value adher -1= "Observed" 
                0= "Adherence >=80%" 
   1= "Adherence <80%" 
    ;  
run; 
data onesample ; 
  set &rawdata  end = _end_  ; 
  label adher= "Adherence";  
 
 retain _id ; 
  if _n_ = 1 then _id = 0; 
  _id = _id + 1 ; 
  if _end_ then do ; 
     call symput("nids",trim(left(_id))); 
  end; 
  adher = -1 ;     
   output ;  
  adher = 0 ;      
   &adhvar = 0 ; 
   dth5 = . ; 
   output ;   
  adher = 1 ;     
   &adhvar = 1 ; 
   dth5 = . ; 
   output ;     
run; 
data ids ; 
   do bsample = 1 to &nboot; 
       do _id = 1 to &nids ; 
           output ; 
       end; 
   end; 
run; 
proc surveyselect data= ids  
         method = urs 
         n= &nids 
         seed = 1232   
         out = _idsamples (keep = bsample _id  numberhits  )  
         outall  noprint  ;        
      strata bsample ; 
      run;     
 
%do bsample = 0 %to &nboot; 
 
 %if %eval(&bsample) = 0 %then %do; 
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 proc printto print = &outdest; 
run; 
 
  /*logistic model for death given adherence*/ 
  proc logistic data = onesample descending; 
   model dth5 = &adhvar  
   adhpre0bin age_bin nonwhite IRK MI_bin NIHA_bin1 RBW_bin 
   CHF ACI AP IC ICIA DIG DIUR AntiArr AntiHyp OralHyp  
   CardioM AnyQQS AnySTDep AnyTWave STElev FVEB VCD  
   HiHeart HiDiasBP HiSySBP HiBili HiSerChol HiSerTrigly HiSerUric HiSerAlk  
   HiPlasUrea HiFastGluc HiOneGluc HiWhiteCell HiNeut HiHemat Cig Inact ; 
   output out = predicted_mean0 (keep=adher probY) p = probY ; 
  run; 
  data predicted_mean; 
   set predicted_mean0 ; 
   bsample = 0 ; 
   numberhits = 1 ; 
  run; 
   
  proc datasets library = work nolist; 
   delete predicted_mean0; 
  run; 
 
proc printto ; 
run; 
 %end; 
 
 %else %do; 
  data bootsample; 
   merge onesample _idsamples (where = (bsample = &bsample)); 
   by _id; 
  run;  
 
  ods listing select none ; 
  proc logistic data=bootsample descending; 
   model dth5 = &adhvar  
   adhpre0bin age_bin nonwhite IRK MI_bin NIHA_bin1 RBW_bin 
   CHF ACI AP IC ICIA DIG DIUR AntiArr AntiHyp OralHyp  
   CardioM AnyQQS AnySTDep AnyTWave STElev FVEB VCD  
   HiHeart HiDiasBP HiSySBP HiBili HiSerChol HiSerTrigly HiSerUric HiSerAlk  
   HiPlasUrea HiFastGluc HiOneGluc HiWhiteCell HiNeut HiHemat Cig Inact; 
   output out = predicted_mean1 (keep=bsample numberhits adher probY) p = 
probY ; 
   freq numberhits ; 
   by bsample ; 
  run; 
  ods listing ; 
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   data predicted_mean ; 
   set predicted_mean predicted_mean1; 
   by bsample ; 
  run; 
  
  proc datasets library = work nolist; 
   delete predicted_mean1 bootsample; 
  run; 
 %end; 
%end; 
 
proc printto print = &outdest; 
run; 
 
proc sort data = predicted_mean ; 
 by bsample adher; 
run; 
 
/*Risk Difference and Confidence Intervals*/ 
proc means data=predicted_mean mean noprint; 
 var probY ; 
 by bsample adher; 
 freq numberhits; 
 output out = results (keep = bsample adher mean) mean=mean; 
run; 
 
proc transpose data=results out = for_diff prefix = Risk_; 
 var mean; 
 id adher; 
 by bsample; 
run; 
data for_diff; 
 set for_diff; 
 mean = Risk_1 - Risk_0; 
 adher = 2; 
 keep bsample adher mean; 
run; 
proc means data = for_diff (where = (bsample >0)) noprint; 
 var mean; 
 by adher; 
 output out = diffstd (keep = adher std) std = std; 
run; 
data sample0; 
 set for_diff (where = (bsample = 0)); 
 keep mean; 
run; 
data final_2014Bbin; 
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 merge sample0 diffstd; 
 lb = mean - 1.96 * std ; 
 ub = mean + 1.96 * std ; 
 label lb="95% Lower bound" 
           ub="95% Upper bound" 
             std="Standard Error" 
      ; 
run; 
 
/*Print Results*/ 
proc printto print = &outdest; 
run; 
proc print data= final_2014Bbin label noobs ; 
title2 "95% Confidence Intervals using &nboot samples" ; 
title3 "Logistic Regression, Placebo Arm"; 
title4 "<80% Adherence vs >=80% Adherence"; 
 var mean std lb ub; 
run; 
proc datasets library=work nolist; 
 delete Ids Onesample  
  exp_plc plc plc0 plc1  
 predicted_mean results  
 diffstd for_diff sample0 _idsamples 
 ;  
quit; 
 
proc printto; 
run; 
 
%let timenow2=%sysfunc(time(), time.); 
%let datenow2=%sysfunc(date(), date9.); 
%put Part B is Complete; 
%put End time is &datenow2 / &timenow2 ; 
%put ;   
 
%mend partB_adjusted; 
 
/*****RUN MACROS***/ 
 
%let nboot = 50; 
 
%partB_unadjusted( outdest = "PartB.Unadj.final.rtf", inset = binary,  
 titlemain = 'Unadjusted, Missed Adherence Carried Forward', nboot = &nboot, lib=cdp); 
 
%partB_adjusted( outdest = "PartB.Adj.logistic.final.rtf", inset = binary,  
 titlemain = 'Adjusted, Missed Adherence Carried Forward',  nboot = &nboot, lib=cdp,adhvar = 
adhx15bin); 
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/*Run logistic regression with original 1980 adherence definition*/ 
%partB_adjusted( outdest = "PartA.Adj.logistic.final.rtf", inset = binary,  
 titlemain = 'Adjusted, Missed Adherence Carried Forward',  nboot = &nboot, lib=cdp,adhvar = 
old_adhx15bin); 
 
 
/************************************************************/ 
/**Program 4: New Analyses: Post-randomization Covariates **/ 
/**********************************************************/ 
/*Note: adherence carried forward 2 missed visits*********/ 
/**Regimes: Cumulative average >=80% vs *****************/ 
/**cumulative average <80%******************************/ 
/*%difference and 95%CI based on 500 bootstraps********/ 
/*IPW for adherence level at time t*******************/ 
/****************************************************/ 
 
libname cdp "</path/>"; 
 
%include “rcspline.sas”; 
 
%macro partC(outdest = , inset = ,  titlemain = , nboot= , lib=); 
title &titlemain; 
%let rawdata = &lib..&inset; 
%put &rawdata; 
 
/*Inverse probability weighting for censoring due to change in adherence*/ 
proc sort data=&rawdata out=onesample; 
by id visit; 
run; 
 
data onesample ; 
  set onesample end = _end_  ; 
  by ID; 
 retain _id ; 
  if _n_ = 1 then _id = 0; 
  if first.id then do; 
   _id = _id + 1 ;  
  end; 
  if _end_ then do ; 
     call symput("nids",trim(left(_id))); 
  end; 
 
/*Spline of time*/ 
%rcspline(visit,0,8,17); 
run; 
 
data ids ; 
   do bsample = 1 to &nboot; 
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       do _id = 1 to &nids ; 
           output ; 
       end; 
   end; 
run; 
proc surveyselect data= ids  
         method = urs 
         n= &nids 
         seed = 1232   
         out = _idsamples (keep = bsample _id  numberhits  )  
         outall  noprint  ;        
      strata bsample ; 
      run; 
 
%do bsample = 0 %to &nboot; 
 
 %if %eval(&bsample) = 0 %then %do; 
 
 
proc printto print = &outdest; 
run; 
    
    /*IPW for adherence at time t - point estimate*/ 
 
  /*model for adherence measured at time t*/ 
  /*Numerator: Pr(Adh_measured=1|A_0, Baseline covariates)*/ 
 
  proc logistic data = onesample (where =( adhbin0 ne . and adhpre0bin ne . and  adhr_t1 
ne . and visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
  
   NIHAFV_t1  ne . and HiSysBPFV_t1 ne . and   HiDiasBPFV_t1 ne . and   
HiWhiteCellFV_t1 ne . and   HiNeutFV_t1 ne . and   HiHematFV_t1 ne . and    
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   HiBiliFV_t1 ne . and   HiSerCholFV_t1 ne . and   HiSerTriglyFV_t1 ne . and   
HiSerUricFV_t1 ne . and   HiSerAlkFV_t1 ne . and   
   HiPlasUreaFV_t1  ne . and  HiFastGlucFV_t1  ne . and  HiOneGlucFV_t1  ne . and  
HiHeartFV_t1   ne . and  
   CHFFV_t1 ne . and   ACIFV_t1 ne . and   APFV_t1 ne . and   ICFV_t1 ne . and    
   ICIAFV_t1 ne . and   DIGFV_t1 ne . and   DIURFV_t1 ne . and   AntiArrFV_t1 ne . 
and    
   AntiHypFV_t1 ne . and   OralHypFV_t1 ne . and   CardioMFV_t1 ne . and   
AnyQQSFV_t1 ne . and   AnySTDepFV_t1 ne . and    
   AnyTWaveFV_t1 ne . and   STElevFV_t1 ne . and  FVEBFV_t1 ne . and   VCDFV_t1 
ne . and    
   CIGFV_t1 ne . and   INACTFV_t1 ne .)) descending; 
 
   model adh_measure = visit visit1 adhbin0 adhr_t1 
   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
  
   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 ; 
   output out = adhmeas_num0 (keep=id visit mesr_0a0) p = mesr_0a0; 
  run; 
 
  
  /*Denominator: Pr(Adh_measured=1|Baseline covariates, Time-varying covariates)*/ 
 
  proc logistic data = onesample (where =( adhbin0 ne . and adhpre0bin ne . and  adhr_t1 
ne . and visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
  
   NIHAFV_t1  ne . and HiSysBPFV_t1 ne . and   HiDiasBPFV_t1 ne . and   
HiWhiteCellFV_t1 ne . and   HiNeutFV_t1 ne . and   HiHematFV_t1 ne . and    
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   HiBiliFV_t1 ne . and   HiSerCholFV_t1 ne . and   HiSerTriglyFV_t1 ne . and   
HiSerUricFV_t1 ne . and   HiSerAlkFV_t1 ne . and   
   HiPlasUreaFV_t1  ne . and  HiFastGlucFV_t1  ne . and  HiOneGlucFV_t1  ne . and  
HiHeartFV_t1   ne . and  
   CHFFV_t1 ne . and   ACIFV_t1 ne . and   APFV_t1 ne . and   ICFV_t1 ne . and    
   ICIAFV_t1 ne . and   DIGFV_t1 ne . and   DIURFV_t1 ne . and   AntiArrFV_t1 ne . 
and    
   AntiHypFV_t1 ne . and   OralHypFV_t1 ne . and   CardioMFV_t1 ne . and   
AnyQQSFV_t1 ne . and   AnySTDepFV_t1 ne . and    
   AnyTWaveFV_t1 ne . and   STElevFV_t1 ne . and  FVEBFV_t1 ne . and   VCDFV_t1 
ne . and    
   CIGFV_t1 ne . and   INACTFV_t1 ne .)) descending ; 
 
   model adh_measure = visit visit1  adhbin0 adhr_t1 
   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
 
   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 
   
   NIHAFV_t1 HiSysBPFV_t1  HiDiasBPFV_t1  HiWhiteCellFV_t1  HiNeutFV_t1  
HiHematFV_t1   
   HiBiliFV_t1  HiSerCholFV_t1  HiSerTriglyFV_t1  HiSerUricFV_t1  HiSerAlkFV_t1  
   HiPlasUreaFV_t1  HiFastGlucFV_t1  HiOneGlucFV_t1  HiHeartFV_t1   
   CHFFV_t1  ACIFV_t1  APFV_t1  ICFV_t1  ICIAFV_t1  DIGFV_t1  DIURFV_t1  
AntiArrFV_t1   
   AntiHypFV_t1  OralHypFV_t1  CardioMFV_t1  AnyQQSFV_t1  AnySTDepFV_t1   
   AnyTWaveFV_t1  STElevFV_t1 FVEBFV_t1  VCDFV_t1   
   CIGFV_t1  INACTFV_t1 ; 
   output out = adhmeas_dnom0 (keep=id visit mesr_wa0) p = mesr_wa0; 
  run; 
 
  /*model for adherence at time t, given adherence measured*/ 
  
  /*Numerator: Pr(A_t=1|A_0, Baseline covariates)*/ 
 
  proc logistic data=onesample (where =( adhbin0 ne . and adhr_t ne . and  adhr_t1 ne . 
and adhpre0bin ne . and visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
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   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
   NIHAFV ne . and   HiSysBPFV ne . and   HiDiasBPFV ne . and   HiWhiteCellFV ne . 
and   HiNeutFV ne . and   HiHematFV ne . and    
   HiBiliFV  ne . and  HiSerCholFV ne . and   HiSerTriglyFV ne . and   HiSerUricFV ne . 
and   HiSerAlkFV ne . and   
   HiPlasUreaFV ne . and   HiFastGlucFV ne . and   HiOneGlucFV  ne . and  
HiHeartFV  ne . and   
   CHFFV  ne . and  ACIFV  ne . and  APFV  ne . and  ICFV  ne . and  ICIAFV  ne . and  
DIGFV  ne . and  DIURFV ne . and   AntiArrFV  ne . and   
   AntiHypFV ne . and   OralHypFV  ne . and  CardioMFV  ne . and  AnyQQSFV ne . 
and   AnySTDepFV ne . and   
   AnyTWaveFV  ne . and  STElevFV ne . and   FVEBFV ne . and   VCDFV ne . and   
   CIGFV ne . and   INACTFV ne .)) descending; 
 
   model adhr_t = visit visit1 adhbin0 adhr_t1 
   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
  
   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 ; 
   output out = censadh_num0 (keep=id visit punc_0a0) p = punc_0a0; 
  run; 
 
  /*Denominator: Pr(A_t=1|A_0, Baseline covariates, Time-varying covariates)*/ 
 
  proc logistic data=onesample (where =( adhbin0 ne . and adhr_t ne .  and  adhr_t1 ne .  
and adhpre0bin ne . and  visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
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   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
   NIHAFV ne . and   HiSysBPFV ne . and   HiDiasBPFV ne . and   HiWhiteCellFV ne . 
and   HiNeutFV ne . and   HiHematFV ne . and    
   HiBiliFV  ne . and  HiSerCholFV ne . and   HiSerTriglyFV ne . and   HiSerUricFV ne . 
and   HiSerAlkFV ne . and   
   HiPlasUreaFV ne . and   HiFastGlucFV ne . and   HiOneGlucFV  ne . and  
HiHeartFV  ne . and   
   CHFFV  ne . and  ACIFV  ne . and  APFV  ne . and  ICFV  ne . and  ICIAFV  ne . and  
DIGFV  ne . and  DIURFV ne . and   AntiArrFV  ne . and   
   AntiHypFV ne . and   OralHypFV  ne . and  CardioMFV  ne . and  AnyQQSFV ne . 
and   AnySTDepFV ne . and   
   AnyTWaveFV  ne . and  STElevFV ne . and   FVEBFV ne . and   VCDFV ne . and   
   CIGFV ne . and   INACTFV ne .)) descending; 
 
 
   model adhr_t =  visit visit1  adhbin0 adhr_t1 
   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
 
   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 
   
   NIHAFV HiSysBPFV HiDiasBPFV HiWhiteCellFV HiNeutFV HiHematFV  
   HiBiliFV HiSerCholFV HiSerTriglyFV HiSerUricFV HiSerAlkFV 
   HiPlasUreaFV HiFastGlucFV HiOneGlucFV HiHeartFV  
   CHFFV ACIFV APFV ICFV ICIAFV DIGFV DIURFV AntiArrFV  
   AntiHypFV OralHypFV CardioMFV AnyQQSFV AnySTDepFV 
   AnyTWaveFV STElevFV FVEBFV VCDFV 
   CIGFV INACTFV; 
   output out = censadh_dnom0 (keep = id  visit punc_wa0)  p = punc_wa0; 
  run; 
 
 
  proc sort data=adhmeas_num0; 
   by ID visit; 
  proc sort data=adhmeas_dnom0; 
   by ID visit; 
  proc sort data=censadh_num0; 
   by ID  visit; 
  proc sort data=censadh_dnom0; 
   by ID  visit; 
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  proc sort data=onesample; 
   by ID  visit; 
  data main_w6; 
          merge onesample censadh_num0 censadh_dnom0 adhmeas_num0 
adhmeas_dnom0 ; 
          by ID  visit; 
 
  /* variables ending with _0 refer to the numerator of the weights 
     Variables ending with _w refer to the denominator of the weights */ 
 
          if first.id then do;  
    k1_0=1; 
    k1_w=1;  
    m1_0=1; 
    m1_w=1; 
   end; 
   retain k1_0 k1_w m1_0 m1_w; 
   
   if adhr_t ne . then do; 
   
    if mesr_0a0 = . then mesr_0a0 =1;  
    if mesr_wa0 = . then mesr_wa0 =1; 
    m1_0=m1_0*mesr_0a0; 
    m1_w=m1_w*mesr_wa0; 
 
    if adhr_t = 0 then do; 
     if punc_0a0 = . then punc_0a0 =0; 
     if punc_wa0 = . then punc_wa0 =0; 
 
            k1_0=k1_0*(1-punc_0a0); 
            k1_w=k1_w*(1-punc_wa0); 
    end; 
    else if adhr_t = 1 then do; 
     if punc_0a0 = . then punc_0a0 =1; 
     if punc_wa0 = . then punc_wa0 =1; 
            k1_0=k1_0*(punc_0a0); 
            k1_w=k1_w*(punc_wa0); 
    end; 
 
   end; 
   else if adhr_t = . then do; 
    if mesr_0a0 = . then mesr_0a0 =0;  
    if mesr_wa0 = . then mesr_wa0 =0; 
    m1_0=m1_0*(1-mesr_0a0); 
    m1_w=m1_w*(1-mesr_wa0); 
 
    k1_0 = k1_0*1; 
    k1_w = k1_w*1; 
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   end; 
     
          stabw_a=(k1_0)/(k1_w); 
          nstabw_a=1/(k1_w); 
 
          stabw_m=(m1_0)/(m1_w); 
          nstabw_m=1/(m1_w); 
 
          stabw =stabw_a*stabw_m; 
          nstabw =nstabw_a*nstabw_m; 
 
  run; 
  proc printto print = &outdest; 
  run; 
  proc means data=main_w6  n mean std min max p95 p99 nmiss; 
   var nstabw stabw nstabw_a stabw_a nstabw_m stabw_m; 
   title 'weights, all'; 
  run; 
  proc printto print = &outdest; 
  run; 
  proc freq data=main_w6 nlevels; 
   where stabw ne .;  
   tables ID /noprint; 
   title 'weights, all'; 
  run; 
 
  data endfup; 
    set main_w6  end = _end_  ; 
   by ID; 
   retain _id ; 
    if _n_ = 1 then _id = 0; 
    if last.id then do; 
      _id = _id + 1 ;  
    output; 
     end; 
  run; 
 
  proc printto print = &outdest; 
  run; 
  proc means data=endfup  n mean std min max p95 p99 p1 nmiss; 
   var  nstabw stabw nstabw_a stabw_a nstabw_m stabw_m; 
   title 'weights, end of follow-up'; 
  run; 
   
  proc freq data=endfup nlevels; 
   where stabw ne .;  
   tables ID /noprint; 
   title 'weights, end of follow-up'; 
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  run; 
   
  /*for truncation*/ 
  proc means data=endfup  n mean std min max p95 p99 nmiss noprint; 
   var stabw; 
   title 'stabilized weights, end of follow-up'; 
   output out=pctl (keep = p99) p99 = p99 ; 
  run; 
  proc means data=endfup  p99 noprint; 
   var nstabw; 
   title 'stabilized weights, end of follow-up'; 
   output out=pctl_n (keep = p99) p99 = p99 ; 
  run;    
 
  data temp; 
   set pctl; 
   call symput ('cutoff', p99); 
  run; 
  data temp_n; 
   set pctl_n; 
   call symput ('cutoff_n', p99); 
  run; 
 
  data trunc;  
  set endfup; 
   stabw1 = stabw; 
   if stabw >  %sysevalf(&cutoff)  then do; 
    stabw1 = %sysevalf(&cutoff); 
   end; 
   nstabw1 = nstabw; 
   if nstabw >  %sysevalf(&cutoff_n)  then do; 
    nstabw1 = %sysevalf(&cutoff_n); 
   end; 
  run; 
  proc means data=trunc  n mean std min max p95 p99 nmiss; 
   var stabw stabw1 nstabw nstabw1; 
   title 'stabilized weights, end of follow-up'; 
  run; 
 
 
 
  /*Weighted regression model*/ 
  /*Pr(Y=1|Adherence at last visit, Baseline covariates)*/ 
  proc logistic data = trunc  descending ; 
  ods output ParameterEstimates = PE; 
          model dth5 =  adhx15bin  
          adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
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   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0  ; 
          weight stabw1; 
   title 'Main Weighted model'; 
  run; 
   
  proc sql noprint; 
   select ESTIMATE FORMAT =16.12 INTO: IBC_ESTIMATE separated by ' ' from pe; 
  quit; 
  proc sql noprint; 
   select variable INTO: model separated by ' ' from PE; 
  quit; 
 
  proc means sum noprint data = pe;  
   var df; 
   output out = nobs (drop = _type_ _freq_ where=(_stat_ ="N")); 
  run; 
  proc sql noprint; 
   select df into:nvar separated by ' ' from nobs;   
  quit; 
 
  data rq1 (keep = p0 p1 numberhits); 
   set trunc; 
   array var{&nvar} &model; 
   array coef{&nvar} (&ibc_estimate); 
 
   intercept = 1; 
   numberhits = 1; 
  
   xbeta0 = 0; 
   xbeta1 = 0; 
   do i = 1 to dim(var); 
    adhx15bin =0; 
    xbeta0 = xbeta0 + coef[i] *var[i]; 
   
    adhx15bin = 1; 
    xbeta1 = xbeta1 + coef[i]*var[i]; 
   end; 
 
   p0 = 1/(1+exp(-xbeta0)); 
   p1 = 1/(1+exp(-xbeta1)); 
  
   output; 
  run; 
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   proc means data = rq1 mean noprint; 
   var p0 p1; 
   freq numberhits; 
   output out = mean_1 (drop =_type_ _freq_) mean(p0 p1) = ; 
  run; 
   
  data mean_1; 
   set mean_1; 
   label p0 = "Cumulative Adherence < 80%" 
         p1 = "Cumulative Adherence >= 80%"; 
   bsample = &bsample; 
  run; 
 
  data means_all; 
   set mean_1; 
  run; 
   
 
  proc datasets library = work nolist; 
   delete censadh_num0  censadh_dnom0 temp pctl rq1 pe mean_1; 
  run; 
  %symdel cutoff; 
 
 
proc printto ; 
run; 
 
 %end; 
 
 %else %do; 
  title "Bootstrap number &bsample"; 
  
  proc sort data = onesample ; 
   by _id; 
  run; 
 
  data bootsample; 
   merge onesample _idsamples (where = (bsample = &bsample)); 
   by _id; 
  run; 
 
  proc sort data = bootsample  sortsize=5G ; 
   by id visit ; 
  run; 
 
    /*IPW for adherence at time t - bootstrap sample*/ 
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  /*model for adherence measured at time t*/ 
  /*Numerator: Pr(Adh_measured=1|A_0, Baseline covariates)*/ 
 
  proc logistic data = bootsample (where =( adhbin0 ne . and adhpre0bin ne . and  adhr_t1 
ne . and visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
  
   NIHAFV_t1  ne . and HiSysBPFV_t1 ne . and   HiDiasBPFV_t1 ne . and   
HiWhiteCellFV_t1 ne . and   HiNeutFV_t1 ne . and   HiHematFV_t1 ne . and    
   HiBiliFV_t1 ne . and   HiSerCholFV_t1 ne . and   HiSerTriglyFV_t1 ne . and   
HiSerUricFV_t1 ne . and   HiSerAlkFV_t1 ne . and   
   HiPlasUreaFV_t1  ne . and  HiFastGlucFV_t1  ne . and  HiOneGlucFV_t1  ne . and  
HiHeartFV_t1   ne . and  
   CHFFV_t1 ne . and   ACIFV_t1 ne . and   APFV_t1 ne . and   ICFV_t1 ne . and    
   ICIAFV_t1 ne . and   DIGFV_t1 ne . and   DIURFV_t1 ne . and   AntiArrFV_t1 ne . 
and    
   AntiHypFV_t1 ne . and   OralHypFV_t1 ne . and   CardioMFV_t1 ne . and   
AnyQQSFV_t1 ne . and   AnySTDepFV_t1 ne . and    
   AnyTWaveFV_t1 ne . and   STElevFV_t1 ne . and  FVEBFV_t1 ne . and   VCDFV_t1 
ne . and    
   CIGFV_t1 ne . and   INACTFV_t1 ne .)) descending; 
 
   model adh_measure = visit visit1 adhbin0 adhr_t1 
   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
  
   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 ; 
   freq numberhits ; 
   output out = adhmeasbootnum0 (keep=id visit mesr_0a0) p = mesr_0a0; 
  run; 
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  /*Denominator: Pr(Adh_measured=1|Baseline covariates, Time-varying covariates)*/ 
 
  proc logistic data = bootsample (where =( adhbin0 ne . and adhpre0bin ne .  and  
adhr_t1 ne . and visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
  
   NIHAFV_t1  ne . and HiSysBPFV_t1 ne . and   HiDiasBPFV_t1 ne . and   
HiWhiteCellFV_t1 ne . and   HiNeutFV_t1 ne . and   HiHematFV_t1 ne . and    
   HiBiliFV_t1 ne . and   HiSerCholFV_t1 ne . and   HiSerTriglyFV_t1 ne . and   
HiSerUricFV_t1 ne . and   HiSerAlkFV_t1 ne . and   
   HiPlasUreaFV_t1  ne . and  HiFastGlucFV_t1  ne . and  HiOneGlucFV_t1  ne . and  
HiHeartFV_t1   ne . and  
   CHFFV_t1 ne . and   ACIFV_t1 ne . and   APFV_t1 ne . and   ICFV_t1 ne . and    
   ICIAFV_t1 ne . and   DIGFV_t1 ne . and   DIURFV_t1 ne . and   AntiArrFV_t1 ne . 
and    
   AntiHypFV_t1 ne . and   OralHypFV_t1 ne . and   CardioMFV_t1 ne . and   
AnyQQSFV_t1 ne . and   AnySTDepFV_t1 ne . and    
   AnyTWaveFV_t1 ne . and   STElevFV_t1 ne . and  FVEBFV_t1 ne . and   VCDFV_t1 
ne . and    
   CIGFV_t1 ne . and   INACTFV_t1 ne .)) descending ; 
 
   model adh_measure = visit visit1  adhbin0 adhr_t1 
   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
 
   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 
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   NIHAFV_t1 HiSysBPFV_t1  HiDiasBPFV_t1  HiWhiteCellFV_t1  HiNeutFV_t1  
HiHematFV_t1   
   HiBiliFV_t1  HiSerCholFV_t1  HiSerTriglyFV_t1  HiSerUricFV_t1  HiSerAlkFV_t1  
   HiPlasUreaFV_t1  HiFastGlucFV_t1  HiOneGlucFV_t1  HiHeartFV_t1   
   CHFFV_t1  ACIFV_t1  APFV_t1  ICFV_t1  ICIAFV_t1  DIGFV_t1  DIURFV_t1  
AntiArrFV_t1   
   AntiHypFV_t1  OralHypFV_t1  CardioMFV_t1  AnyQQSFV_t1  AnySTDepFV_t1   
   AnyTWaveFV_t1  STElevFV_t1 FVEBFV_t1  VCDFV_t1   
   CIGFV_t1  INACTFV_t1 ; 
   freq numberhits ; 
   output out = adhmeasbootden0 (keep=id visit mesr_wa0) p = mesr_wa0; 
  run; 
 
  /*model for adherence at time t, given adherence measured*/ 
  
  /*Numerator: Pr(A_t=1|A_0, Baseline covariates)*/ 
 
  proc logistic data=bootsample (where =( adhbin0 ne . and adhr_t ne . and  adhr_t1 ne .  
and adhpre0bin ne . and visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
   NIHAFV ne . and   HiSysBPFV ne . and   HiDiasBPFV ne . and   HiWhiteCellFV ne . 
and   HiNeutFV ne . and   HiHematFV ne . and    
   HiBiliFV  ne . and  HiSerCholFV ne . and   HiSerTriglyFV ne . and   HiSerUricFV ne . 
and   HiSerAlkFV ne . and   
   HiPlasUreaFV ne . and   HiFastGlucFV ne . and   HiOneGlucFV  ne . and  
HiHeartFV  ne . and   
   CHFFV  ne . and  ACIFV  ne . and  APFV  ne . and  ICFV  ne . and  ICIAFV  ne . and  
DIGFV  ne . and  DIURFV ne . and   AntiArrFV  ne . and   
   AntiHypFV ne . and   OralHypFV  ne . and  CardioMFV  ne . and  AnyQQSFV ne . 
and   AnySTDepFV ne . and   
   AnyTWaveFV  ne . and  STElevFV ne . and   FVEBFV ne . and   VCDFV ne . and   
   CIGFV ne . and   INACTFV ne .)) descending; 
 
   model adhr_t = visit visit1 adhbin0 adhr_t1 
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   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
  
   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 ; 
   freq numberhits ; 
   output out = cnsadhbootnum0 (keep=id visit punc_0a0) p = punc_0a0; 
  run; 
 
  /*Denominator: Pr(A_t=1|A_0, Baseline covariates, Time-varying covariates)*/ 
 
  proc logistic data=bootsample (where =( adhbin0 ne . and adhr_t ne .  and  adhr_t1 ne . 
and adhpre0bin ne . and  visit >0 and  
   age_bin ne . and  nonwhite ne . and  IRK ne . and  MI_bin ne . and RBW_bin ne . 
and  
   NIHA_bin0 ne . and  HiSysBP0  ne . and  HiDiasBP0 ne . and   HiWhiteCell0 ne . 
and   HiNeut0 ne . and   HiHemat0   ne . and   
   HiBili0 ne . and   HiSerChol0  ne . and  HiSerTrigly0  ne . and  HiSerUric0  ne . and  
HiSerAlk0  ne . and  HiPlasUrea0  ne . and   
   HiFastGluc0  ne . and  HiOneGluc0  ne . and  HiHeart0 ne . and   CHF0 ne . and   
ACI0  ne . and  AP0 ne . and   
   IC0  ne . and  ICIA0 ne . and   DIG0  ne . and  DIUR0  ne . and  AntiArr0 ne . and   
AntiHyp0 ne . and   OralHyp0  ne . and   
   CardioM0 ne . and   AnyQQS0 ne . and   AnySTDep0  ne . and  AnyTWave0 ne . 
and   
   STElev0 ne . and   FVEB0 ne . and   VCD0 ne . and   CIG0 ne . and   INACT0 ne . 
and   
  
   NIHAFV ne . and   HiSysBPFV ne . and   HiDiasBPFV ne . and   HiWhiteCellFV ne . 
and   HiNeutFV ne . and   HiHematFV ne . and    
   HiBiliFV  ne . and  HiSerCholFV ne . and   HiSerTriglyFV ne . and   HiSerUricFV ne . 
and   HiSerAlkFV ne . and   
   HiPlasUreaFV ne . and   HiFastGlucFV ne . and   HiOneGlucFV  ne . and  
HiHeartFV  ne . and   
   CHFFV  ne . and  ACIFV  ne . and  APFV  ne . and  ICFV  ne . and  ICIAFV  ne . and  
DIGFV  ne . and  DIURFV ne . and   AntiArrFV  ne . and   
   AntiHypFV ne . and   OralHypFV  ne . and  CardioMFV  ne . and  AnyQQSFV ne . 
and   AnySTDepFV ne . and   
   AnyTWaveFV  ne . and  STElevFV ne . and   FVEBFV ne . and   VCDFV ne . and   
   CIGFV ne . and   INACTFV ne .)) descending; 
 
 
   model adhr_t =  visit visit1  adhbin0 adhr_t1 
   adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
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   NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
   HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
   IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
   CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
   STElev0 FVEB0 VCD0 CIG0 INACT0 
   
   NIHAFV HiSysBPFV HiDiasBPFV HiWhiteCellFV HiNeutFV HiHematFV  
   HiBiliFV HiSerCholFV HiSerTriglyFV HiSerUricFV HiSerAlkFV 
   HiPlasUreaFV HiFastGlucFV HiOneGlucFV HiHeartFV  
   CHFFV ACIFV APFV ICFV ICIAFV DIGFV DIURFV AntiArrFV  
   AntiHypFV OralHypFV CardioMFV AnyQQSFV AnySTDepFV 
   AnyTWaveFV STElevFV FVEBFV VCDFV 
   CIGFV INACTFV; 
   freq numberhits ; 
   output out = cnsadhbootden0 (keep = id  visit punc_wa0)  p = punc_wa0; 
  run; 
 
 
  proc sort data=adhmeasbootnum0; 
  by ID visit; 
  proc sort data=adhmeasbootden0; 
  by ID visit; 
  proc sort data=cnsadhbootnum0; 
  by ID visit; 
  proc sort data=cnsadhbootden0; 
  by ID visit; 
 
  proc sort data = bootsample  sortsize=5G ; 
   by id visit ; 
  run; 
 
  data weighted; 
          merge bootsample cnsadhbootnum0 cnsadhbootden0 adhmeasbootnum0 
adhmeasbootden0; 
          by ID visit; 
 
  /* variables ending with _0 refer to the numerator of the weights 
     Variables ending with _w refer to the denominator of the weights */ 
 
            if first.id then do;  
    k1_0=1; 
    k1_w=1;  
    m1_0=1; 
    m1_w=1; 
   end; 
   retain k1_0 k1_w m1_0 m1_w; 
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   if adhr_t ne . then do; 
   
    if mesr_0a0 = . then mesr_0a0 =1;  
    if mesr_wa0 = . then mesr_wa0 =1; 
    m1_0=m1_0*mesr_0a0; 
    m1_w=m1_w*mesr_wa0; 
 
    if adhr_t = 0 then do; 
     if punc_0a0 = . then punc_0a0 =0; 
     if punc_wa0 = . then punc_wa0 =0; 
 
            k1_0=k1_0*(1-punc_0a0); 
            k1_w=k1_w*(1-punc_wa0); 
    end; 
    else if adhr_t = 1 then do; 
     if punc_0a0 = . then punc_0a0 =1; 
     if punc_wa0 = . then punc_wa0 =1; 
            k1_0=k1_0*(punc_0a0); 
            k1_w=k1_w*(punc_wa0); 
    end; 
 
   end; 
   else if adhr_t = . then do; 
    if mesr_0a0 = . then mesr_0a0 =0;  
    if mesr_wa0 = . then mesr_wa0 =0; 
    m1_0=m1_0*(1-mesr_0a0); 
    m1_w=m1_w*(1-mesr_wa0); 
 
    k1_0 = k1_0*1; 
    k1_w = k1_w*1; 
   end; 
     
          stabw_a=(k1_0)/(k1_w); 
          nstabw_a=1/(k1_w); 
 
          stabw_m=(m1_0)/(m1_w); 
          nstabw_m=1/(m1_w); 
 
          stabw =stabw_a*stabw_m; 
          nstabw =nstabw_a*nstabw_m; 
 
  run; 
 
  data endfup_boot; 
    set weighted  end = _end_  ; 
   by ID; 
   retain _id ; 
    if _n_ = 1 then _id = 0; 
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    if last.id then do; 
      _id = _id + 1 ;  
    output; 
     end; 
  run; 
 
  proc means data=endfup_boot  p99 noprint; 
   var stabw; 
   title 'stabilized weights, end of follow-up'; 
   output out=pctl_boot (keep = p99) p99 = p99 ; 
  run; 
  proc means data=endfup_boot  p99 noprint; 
   var nstabw; 
   title 'unstabilized weights, end of follow-up'; 
   output out=pctl_boot_n (keep = p99) p99 = p99 ; 
  run; 
 
  data temp_boot; 
   set pctl_boot; 
   call symput ('cutoff', p99); 
  run; 
 
  data temp_boot_n; 
   set pctl_boot_n; 
   call symput ('cutoff_n', p99); 
  run; 
 
  data trunc_boot;  
   set endfup_boot; 
   stabw1 = stabw; 
   if stabw >  %sysevalf(&cutoff)  then do; 
    stabw1 = %sysevalf(&cutoff); 
   end; 
   nstabw1 = nstabw; 
   if nstabw >  %sysevalf(&cutoff_n)  then do; 
    nstabw1 = %sysevalf(&cutoff_n); 
   end; 
  run; 
 
  /*Weighted regression model*/ 
  /*Pr(Y=1|Cumulative Adherence to last visit, Baseline covariates)*/ 
  proc logistic data = trunc_boot  descending; 
  ods output ParameterEstimates = pe_boot; 
          model dth5 =  adhx15bin   
          adhpre0bin age_bin nonwhite IRK MI_bin RBW_bin  
 
       NIHA_bin0 HiSysBP0 HiDiasBP0 HiWhiteCell0 HiNeut0 HiHemat0   
   HiBili0 HiSerChol0 HiSerTrigly0 HiSerUric0 HiSerAlk0 HiPlasUrea0  
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       HiFastGluc0 HiOneGluc0 HiHeart0 CHF0 ACI0 AP0 
       IC0 ICIA0 DIG0 DIUR0 AntiArr0 AntiHyp0 OralHyp0  
       CardioM0 AnyQQS0 AnySTDep0 AnyTWave0 
       STElev0 FVEB0 VCD0 CIG0 INACT0  ;  
          weight stabw1; 
   freq numberhits; 
  run; 
 
  proc sql noprint; 
   select ESTIMATE FORMAT =16.12 INTO: IBC_ESTIMATE separated by ' ' from 
pe_boot; 
  quit; 
  proc sql noprint; 
   select variable INTO: model separated by ' ' from pe_boot; 
  quit; 
 
  proc means sum noprint data = pe_boot;  
   var df; 
   output out = nobs_boot (drop = _type_ _freq_ where=(_stat_ ="N")); 
  run; 
  proc sql noprint; 
   select df into:nvar separated by ' ' from nobs_boot;   
  quit; 
 
  data rq1_boot (keep = p0 p1 numberhits); 
   set trunc_boot; 
   array var{&nvar} &model; 
   array coef{&nvar} (&ibc_estimate); 
 
   intercept = 1; 
  
   xbeta0 = 0; 
   xbeta1 = 0; 
   do i = 1 to dim(var); 
    adhx15bin =0; 
    xbeta0 = xbeta0 + coef[i] *var[i]; 
   
    adhx15bin = 1; 
    xbeta1 = xbeta1 + coef[i]*var[i]; 
   end; 
 
   p0 = 1/(1+exp(-xbeta0)); 
   p1 = 1/(1+exp(-xbeta1)); 
  
   output; 
  run; 
 
  proc means data = rq1_boot mean noprint; 
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   var p0 p1; 
   freq numberhits; 
   output out = mean_boot (drop =_type_ _freq_) mean(p0 p1) = ; 
  run; 
   
  data mean_boot; 
   set mean_boot; 
   label p0 = "Cumulative Adherence < 80%" 
         p1 = "Cumulative Adherence >= 80%"; 
   bsample = &bsample; 
  run; 
 
  data means_all; 
   set means_all mean_boot; 
   by bsample; 
  run; 
   
  proc datasets library = work nolist; 
   delete mean_boot bootsample weighted cnsadhbootnum0 cnsadhbootden0  
endfup_boot trunc_boot temp_boot pctl_boot pe_boot rq1_boot; 
  run; 
  %symdel cutoff; 
 %end; 
%end; 
 
proc printto print = &outdest; 
run; 
 
title "Summary"; 
 
proc sort data=means_all; 
by bsample; 
run; 
 
/*Risk Difference and Confidence Intervals*/ 
data rds ; 
 set means_all; 
 risk_diff = p1-p0; 
 keep bsample risk_diff; 
run; 
 
proc means data = rds (where = (bsample > 0)) noprint ; 
 var risk_diff; 
 output out=diffstd (keep = std) std = std ; 
run; 
 
data sample0; 
 set rds (where=(bsample = 0)); 
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 keep risk_diff; 
run; 
 
data final_2014C; 
 merge sample0 diffstd;  
 lb = risk_diff - 1.96 * std ; 
 ub = risk_diff + 1.96 * std ; 
 label lb="95% Lower bound" 
       ub="95% Upper bound" 
          std="Standard Error" 
      ; 
run; 
 
proc printto print = &outdest; 
run; 
proc print data= final_2014C label noobs ; 
title &titlemain; 
title2 'Adjusted Risk Difference, Logistic regression'; 
title3 "95% Confidence Intervals using &nboot samples" ; 
title4 "<80% Adherence vs >=80% Adherence"; 
 var risk_diff std lb ub; 
run; 
 
proc datasets library=work nolist; 
 delete Diffstd Ids Main_w6 Onesample  
 results sample0 weighted _idsamples means_all rds 
 ;  
quit; 
 
 
proc printto; 
run; 
%let timenow2=%sysfunc(time(), time.); 
%let datenow2=%sysfunc(date(), date9.); 
%put Part C is complete; 
%put End time is &datenow2 / &timenow2 ; 
%put Program is complete; 
%put ;   
 
%mend partC; 
 
/**RUN MACROS**/ 
 
%let nboot = 50; 
%partC( outdest = "PartC.cumA.final.rtf", inset = censwt_ag,  
 titlemain = 'Adherence at time t: IPW Adjusted, Missed Adherence Carried Forward', nboot = 
&nboot, lib=cdp); 
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